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Abstract 
 
Immune senescence is associated with a predisposition to infections, poor vaccination 
responses and early mortality in older individuals. Furthermore, evidence that chronic 
cytomegalovirus (CMV) infection is a key driver of immune senescence is becoming 
increasingly recognised. This thesis aimed to investigate the hypothesis that large CD8+ T 
cell expansions (TCEs) caused by chronic CMV infection during ageing may be 
instrumental in this association.  
 
Data presented here shows CMV-specific CD8+ TCEs that accumulate during ageing are 
predominately of the CD45RA+ memory phenotype. However, these cells exhibit low Ki-
67 positivity and low Bcl-2 levels directly ex-vivo, in addition to poor proliferation and 
low telomerase activity in response to activation. This indicates they are not 
accumulating through increased proliferation or resistance to cell-death, and may 
represent a population close to senescence. These CMV-specific CD8+CD45RA+ memory 
T cells were also found to display a lower functional avidity for peptide, with higher 
activation threshold compared with CMV-specific CD8+CD45RO+ T cells. Furthermore, IL-
15 was shown to cause CMV-specific CD8+CD45RO+ memory T cells to proliferate and re-
express CD45RA in-vitro; adding to existing evidence indicating a role for IL-15 in the 
homeostatic, rather than antigenic, driven generation of CD8+CD45RA+ memory T cells 
from a CD45RO+ memory T cell pool.  
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The possible impact of these CMV-specific TCEs during ageing is highlighted by the 
finding that old CMV positive individuals had significantly shorter T cell telomere lengths 
than old CMV negative individuals. Therefore, the accumulation of TCEs is likely to 
impact the CD8 compartment of healthy individuals in two ways; by restricting immune 
space and also lowering the overall telomere length of the compartment through the 
accumulation of highly differentiated CD8+ TCEs. Both of these have been shown to 
increase susceptibility to infection. This study therefore provides further evidence for 
the detrimental effects of CMV infection and its role in driving immune senescence. 
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1 Introduction  
 
Medical advances during the 20th century have contributed to the extension of life-
expectancy by a staggering 30 years in western countries, with developing countries 
showing the most rapid gains (Kirkwood, 2008, Christensen et al., 2009). However, 
predictions that 40% of the population in Europe and America will be over 60 years of 
age by 2050 (Lutz et al., 1997) raises concerns of how public healthcare systems will 
cope with an increasingly aged population (Christensen et al., 2009). The incidence of 
age associated illnesses is predicted to become increasingly common, putting pressure 
on healthcare systems and resources (Adhikari et al., 2010). Longer life expectancy also 
presents a new challenge to the immune system, as it must continue to protect for 
many more years than our ancestors required. A lifetime of antigenic burden may 
complicate a variety of clinical conditions in the upper limits of life expectancy 
(Franceschi et al., 2007, Soderberg-Naucler, 2006). Now more than ever, it is important 
to identify these age-related changes and determine their influence on the quality and 
duration of life.  
 
1.1 Ageing 
Ageing is characterised by the declining ability to respond to stress, increased 
homeostatic imbalance, and increased risk of age associated diseases, with the 
inevitable consequence being death. However, the exact mechanisms of ageing remain 
insufficiently understood. 
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1.1.1 Theories of ageing 
Generally, theories of ageing fall into one of two categories: programmed or stochastic 
theories. Programmed theories propose ageing is due to changes in gene expression, 
which control maintenance, repair and defence responses, and is advantageous to the 
species as a whole, rather than the individual, by having a finite lifespan (Ljubuncic and 
Reznick, 2009). Stochastic theories propose the lifelong accumulation of a wide variety 
of molecular and cellular damage causes ageing (Kirkwood, 2008), which are 
summarised in table 1.1. However, this categorisation of theories has been questioned 
(Rattan, 2006), and ageing is now generally regarded to result from multiple causes.  
 
DNA damage RNA damage Protein damage Membrane damage 
Copying/repair errors Transcription errors Misfolding Oxidation 
Telomere shortening Aberrant slicing Synthesis error  
Mitochondrial mutations  Post-translational error  
Viral gene disruption  Aberrant aggregation  
Epigenetic modifications  Impaired catabolism  
Table 1-1. Examples of cellular damage that may contribute to ageing (Adapted from(Kirkwood, 2008). 
 
The evolutionary aspects of ageing have also been hotly debated. Darwin’s theory of 
natural selection is based on the concept that random and heritable variations of 
biological traits will lead to the reproduction of those who are preferentially fit to 
survive in the environment. However, as Peter Medawar formalised in his mutation 
accumulation theory - the force of natural selection weakens with increasing age 
through ‘real hazards of mortality’ (predation, disease, accidents); therefore if a ‘genetic 
disaster’ occurs later in life, its effects may be completely unimportant (Medawar 1946).  
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1.1.2 Measuring cellular ageing – Telomere length 
Research into cellular senescence has long attracted both popular and scientific interest. 
The dominant view of the early 20th century was that cells could grow indefinitely, 
highlighted in Alexis Carrel’s publication ‘on the permanent life of tissues outside the 
organism’ (Carrel, 1912). It was not until 1962, that Leonard Hayflick challenged the 
dogma by showing that normal cells had a limited capacity for replication - since termed 
‘the Hayflick limit’ (Hayflick, 1965), and also referred to as replicative senescence. The 
sensing mechanism that limits this lifespan is the telomere.  Telomeres are composed of 
the simple sequence TTAGGG, which is repeated many hundreds to thousands of times 
at the chromosome ends (Hodes et al., 2002). 50-100 base pairs of this telomeric DNA 
are lost per cell division due to the inability of DNA polymerase to fully replicate the 
ends of chromosomes. With increasing divisions, a decrease in telomere length results; 
eventually leading to DNA instability and apoptosis, or cell-arrest through p53 (Rufer et 
al., 1999). Indeed, a hallmark of senescent cells is the diminished ability to respond to 
cellular stress and overall physical and oxidative stress (Effros et al., 2005). Telomere 
length can therefore be indicative of the residual replicative capacity of the cell, making 
it an important biomarker in the context of senescence. Most importantly, mounting 
evidence suggests short telomeres in lymphocytes are a risk factor for mortality in 
cardiovascular disease, Hepatitis C infection, and age-related diseases such as 
Alzheimer’s disease (Samani et al., 2001, Calado and Young, 2009, Brouilette et al., 
2007, Brouilette et al., 2003). One study has also correlated short telomeres with an 
eight fold increase in susceptibility to death by infection (Cawthon et al., 2003). 
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1.1.3 Telomerase 
Telomere attrition can be suppressed by the enzyme telomerase, a ribonucleoprotein 
complex that adds back the telomeric repeat sequence directly to the single stranded 
telomeric overhang (Akbar and Vukmanovic-Stejic, 2007). Lymphocytes are among a 
small number of somatic cells that can up-regulate telomerase, which compensates for 
telomere attrition (Hiyama et al., 1995, Weng et al., 1996). This suggests an important 
role in the preservation of immune memory (Hodes et al., 2002, Beverley, 2010). 
However, repeated stimulation can eventually lead to loss of telomerase activity in 
lymphocytes (Plunkett et al., 2007, Henson et al., 2009, Lobetti-Bodoni et al., 2010, 
Hodes et al., 2002). Telomerase therefore represents a possible target for the reversion 
of age-related damage, which has already been demonstrated in mouse studies 
(Jaskelioff et al., 2011).  Dysfunctions of telomerase can also lead to malignancy, with 
current estimates suggesting 85% of tumour cells are the result of telomerase up-
regulation (Cesare and Reddel, 2010). The significance of telomerase was recognized by 
awarding the 2009 Nobel Prize of Physiology and Medicine to its discoverers: Elizabeth 
Blackburn, Carol Greider and Jack Szostak.  
 
1.1.4 Ageing and infectious disease susceptibility 
Age-associated susceptibility to a variety of pathogens including pneumonia, meningitis, 
sepsis, urinary tract infections, influenza, and Respiratory Syncytial Virus have been 
documented (Gorina et al., 2008, Fry et al., 2005, Akbar et al., 2004, Nikolich-Zugich, 
2008). Viral reactivation is also more common in old individuals; the best example being 
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Varicella-Zoster Virus (VZV) (LaGuardia and Gilden, 2001), but there are also reports of 
Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivations (Scott et al. 
1994;(McVoy and Adler, 1989). Furthermore, novel pathogens in particular, are known 
to cause greater disease severity in the old; Severe Acute Respiratory Syndrome (SARS) 
was rarely fatal in the young, but caused >50% mortality in the old (Donnelly et al., 
2003). Also, West Nile Virus, an emerging virus in the US, showed 80% of adult 
infections under 50 experienced an asymptomatic infection, with <1% developing 
severe disease, whereas lethality was 10 fold higher in the over 50’s, and a staggering 
40-50 times higher in the over 70’s (Chowers et al., 2001, Mostashari et al., 2001, 
O'Leary et al., 2004). Individuals with premature ageing syndromes such as Dyskeritosis 
congenita, who mimic many age-related changes to the immune system seen in the old, 
are also more susceptible to infections (Sedgwick & Boder, 1991).  
1.1.5 Ageing of the immune system – Immune senescence 
The extent of immunological memory to a previous pathogenic challenge is remarkable, 
and can persist for a lifetime without re-challenge. This is exemplified by the fact that 
90% of those given the smallpox vaccine up to 75 years ago, still maintain immunity 
(Hammarlund et al., 2003). However the immune system undergoes significant changes 
during ageing, including a major reduction in T cell generation through thymic 
involution, and senescence of the memory pool through repeated homeostatic 
proliferation. Poor vaccination responses are also commonplace in the old, highlighted 
by the fact that seasonal influenza vaccine has an efficacy of just 30-40% in the over 65’s 
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(Kovaiou et al., 2007, McElhaney and Dutz, 2008, Seder et al., 2008, Weinberger et al., 
2008). Such age-associated impairments of the immune system, collectively called 
immune senescence, are therefore thought to contribute to the increased incidence in 
age-associated susceptibility to infection.  
 
1.2 T cells  
Before discussing the impact of ageing on T cells (section 1.4), an overview of T cells will 
be given. This section outlines: what T cells are and how they are generated; how T cells 
are activated; the generation of effector and memory T cells; the maintenance of T cell 
numbers; and what constitutes a quality T cell response.   
 
1.2.1 T cell generation  
T cells are generated from bone marrow derived haematopoietic progenitors, but 
undergo selection and maturation in the thymus (Kindt et al., 2007). Haematopoietic 
progenitors enter the thymus from the blood (Schwarz and Bhandoola, 2006), and 
undergo extensive cell division within the thymus, to generate a large population of 
immature thymocytes (Kindt et al., 2007). Immature thymocytes each make a distinct T 
cell receptor (TCR), by a process of random gene rearrangement (Kruisbeek, 1993). TCR 
recognizes antigen only when presented by major histocompatibility complex (MHC) 
molecules, on antigen presenting cells (APCs)(Kindt et al., 2007). Thymocytes undergo a 
selection procedure by interaction with APCs in the thymus. Positive selection selects 
for T cells capable of interacting with self MHC presented by thymic stromal cells 
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(Kruisbeek, 1993). Only those thymocytes interacting with adequate affinity for self 
antigen and MHC receive a survival signal and are positively selected, whereas those 
with insufficient affinity die by apoptosis (Starr et al., 2003). The two main subsets of T 
cell are the CD4+ and CD8+ T cell, which recognize antigen presented by MHC class II and 
MHC class I respectively. The fate of a thymocyte as a CD4+ or CD8+ T cell is dependent 
on whether they are presented self peptide by MHC II or MHC I respectively, during 
positive selection (Starr et al., 2003). Thymocytes which survive positive selection then 
migrate towards the thymic medulla, at which point they are again presented with self 
antigen in complex with MHC by APCs including dendritic cells and macrophages. 
Thymocytes that interact too strongly at this point undergo apoptosis by a process of 
negative selection. The vast majority of thymocytes will die at this stage (Starr et al., 
2003). Therefore, only interactions with intermediate reactivity survive selection, and 
are exported into the periphery as recent thymic emigrants, which mature post 
thymically to form naïve T cells (Shortman et al., 1990). This results in a naive T cell 
repertoire that is sufficiently diverse and reactive towards a vast array of foreign 
antigens, but is also non-reactive to self antigens (Nikolich-Zugich et al., 2004).    
 
1.2.2 TCR structure 
The TCR is a heterodimer composed of two different protein chains: 95% of T cells 
display the αβ heterodimer and 5% the γδ heterodimer (Kindt et al., 2007). Each chain 
of the TCR is a member of the immunoglobulin superfamily; consisting one N-terminal 
immunoglobulin (Ig) variable (V) domain (binding MHC and presented antigen, pMHC) 
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and one Ig constant (C) domain (a trans-membrane spanning region and a short 
cytoplasmic tail at the C terminal end involved with intracellular cell signalling events) 
(Rudolph et al., 2006). αβ TCR diversification mainly occurs in the thymus, by stochastic 
recombination of non-contiguous gene segments, with further diversity enhanced by 
imprecise joining of nicked segments, addition of non-germline nucleotides by DNA-
repair machinery, and pairing of different α and β segments (Nikolich-Zugich, 2008). 
Binding of the variable domain to pMHC is largely dependent on the complementarity 
determining regions (CDRs). There are 3 CDRs on each vB protein chain, with CDR3 
showing the greatest diversification (Kindt et al., 2007). Diversification results in the T 
cell repertoire i.e. a pool of T cells specific for a vast array of antigens. Once activated, a 
naïve T cell will proliferate and differentiate into effector or memory T cells, which 
generate immune responses against cells infected by pathogen or altered self 
(cancerous) cells - referred to as cell-mediated immunity. 
1.2.3 T cell activation 
The activation of naive CD4+ and CD8+ T cells are generally similar, and are initiated by 
co-ordinated signalling from two main sources: the interaction of TCR with processed 
antigen presented by MHC on the APC, and co-stimulatory molecule signalling (Smith-
Garvin et al., 2009). It is also the role of various accessory and adhesion molecules to 
stabilise and sustain this interaction, and for cytokines to direct the responses during 
and following activation (Kindt et al., 2007).  
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1.2.3.1 Antigen presenting cells 
As all cells express either MHC class I or II, strictly speaking they are all antigen 
presenting cells (APCs). However, by definition, those cells displaying MHC class I only 
are referred to as target cells (for CD8+ T cells) and those displaying MHC class II (to CD4+ 
T cells) are APCs (Kindt et al., 2007). Although a variety of cells may act as APCs, three 
types are classified as professional APCs: dendritic cells (DCs), macrophages, and B cells. 
Non-professional APCs are cells induced to express MHC class II and co-stimulatory 
molecules transiently during an inflammatory response, and include fibroblasts in the 
skin, glial cells in the brain, pancreatic β cells, and various epithelial and endothelial cells 
(Nickoloff and Turka, 1994). DCs are among the most effective APCs, as they 
constitutively express high levels of MHC class II and co-stimulatory molecules. DCs can 
further be divided on the basis of their anatomical location, phenotype and function as 
depicted in table 1.2. 
 
 Plasmacytoid DCs Myeloid DCs Langerhans cells Interstitial DCs 
Location Blood Blood Epidermis Dermis and other 
tissues 
Phenotype CD11c
–
CD1a
+
 
CD1c
–
CD123
high
 
CD304
+
 
CD11c
+
CD1a
+
 
CD1c
+
CD123
low
 
CD304
–
 
CD11c
+
CD1a
+
 
CD207
+
 
CD11c
+
CD1a
–
 
CD68
+
  
coagulation 
factor XIII A 
chain 
T cell priming Yes Yes Yes Yes 
B cell activation Yes Yes Weak Yes 
IFN-α production High Yes Yes Yes 
Table 1-2. Subsets of human dendritic cells (adapted from(Lambotin et al., 2010). 
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DCs will initially exist as immature DCs; unable to activate T cells as they lack the 
requisite molecules such as CD40, CD54, and CD86 (Banchereau and Steinman, 1998). 
However, these cells are efficient at capturing antigen, and can take up particles or 
microbes by a variety of methods, including: phagocytosis, pinocytosis, c-type lectin 
receptors and pattern recognition receptors (PPRs) such as toll-like receptors (TLRs) 
(Banchereau and Steinman, 1998, Lambotin et al., 2010). Antigen capture triggers full 
maturation and mobility of the DC to T cell rich areas of the lymph nodes, during which 
time antigen is processed and displayed together with MHC, on the surface of the DC 
(Banchereau and Steinman, 1998). DCs migrate to lymphoid tissues such as the spleen 
and lymph nodes, where they complete their maturation and release chemokines to 
attract circulating T cells and B cells (Adema et al., 1997).  
 
1.2.3.2 T cell interaction with APC 
The interaction between the TCR complex on the surface of the T cell and antigen 
presented with MHC on the APC is a highly specific one. However, other molecules 
strengthen this interaction, including the co-receptors CD4 and CD8 that bind to 
conserved regions on MHC class II and class I respectively. These co-receptors prolong 
engagement and recruit essential molecules inside the cell which are involved in 
signalling (Rudolph et al., 2006). The TCR also associates with CD3 on the surface of the 
T cell, forming a TCR-CD3 complex. The CD3 accessory molecule participates in signal 
transduction following interaction of the TCR with antigen, but does not itself influence 
antigen binding (Smith-Garvin et al., 2009). 
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1.2.3.3 Co-stimulation 
Signalling solely through the TCR results in a non-responsive state known as anergy, 
therefore co-stimulation is required for productive activation (Smith-Garvin et al., 2009). 
Co-stimulation may be provided by various molecules, but two families of receptors, the 
CD28 receptor family and the tumour necrosis factor (TNF) receptor family, are key 
players in providing co-stimulation. Various studies have shown the importance of 
CD28, which binds CD80 and CD86 on APC’s, in promoting T cell proliferation, survival, 
metabolism and cytokine production (reviewed in(Acuto and Michel, 2003). The TNF 
receptor family includes CD27, CD40, 4-1BB and OX-40. CD27 for example, binds CD70 
on APCs, and is important in the generation, survival, maintenance, and quality of a T 
cell response (Duttagupta et al., 2009). 
 
1.2.3.4 T cell signalling events following activation 
The first step of intracellular signalling following TCR ligation is the activation of src (lck 
and fyn) protein tyrosine kinases (PTKs), which leads to the phosphorlyation of 
immunoreceptor tyrosine-based activation motifs (ITAMs) on the cytoplasmic tails of 
CD3 (van der Merwe and Dushek, 2011). This triggers the recruitment of ZAP-70 and 
subsequent cascade of phosphorylation events (Smith-Garvin et al., 2009). Among such 
events are the activation of phospholipase C γ-1 (PLCγ-1) dependent pathways, 
including Ca2+ and Diacylglycerol (DAG) induced responses, cytoskeletal rearrangement 
and integrin activation pathways (van der Merwe and Dushek, 2011). Co-stimulatory 
molecules such as CD28 also act to augment these responses (Acuto and Michel, 2003). 
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1.2.4 Generation of effector and memory T cells 
Upon successful activation, the T cell will undergo rounds of repeated division 2-3 times 
per day for 4-5 days, enhanced by an increase in IL-2 levels, generating a progeny of T 
cell effector clones. Naive CD8+ T cells become cytotoxic effector cells, targeting 
intracellular pathogens and altered self cells; whereas CD4+ T cells largely provide 
effector cytokine help to CD8+ T cell and B cell responses (Kindt et al., 2007). On 
resolution of the infection, the vast majority of the expanded population of effector T 
cell clones are removed, and a population of memory CD4+ and CD8+ T cells are formed, 
providing protection in the event of re-challenge.  
1.2.5 Redressing the balance after resolution of infection 
Following the successful clearance of a pathogen, up to 95% of the expanded T cell 
clones are removed, as they no longer benefit the host and may produce large amounts 
of potentially detrimental cytokines (Krammer et al., 2007). At the same time, 
immunological memory must be formed in the event antigen is re-encountered. A T 
cell’s fate will be determined both by the survival signals it receives (through TCR, co-
stimulatory molecules, adhesion molecules and cytokines) and the apoptotic signals it 
receives (Adams and Cory, 1998). Caspases are the executioners of apoptosis, a family of 
proteases having a major role in regulating most mechanisms of apoptotic cell death, 
including extrinsic cell-death-receptor-dependent apoptosis and intrinsic mitochondria-
dependent apoptosis (Krammer et al., 2007). These two pathways have different origins 
of initiation, but can converge downstream of activation at the point of caspase release. 
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1.2.5.1 The extrinsic apoptotic pathway 
The extrinsic apoptotic pathway is initiated by ligation of the cell-death receptors 
containing ‘death domains’ on the surface of cells. These include TNF receptor, CD95 
(FasL or apo-1), TNF related apoptosis inducing ligand receptor (TRAIL) 1 and TRAIL 2, 
and death receptor 3 (DR3) or DR6 (Ashkenazi and Dixit, 1998). Pro-apoptotic signals are 
delivered by these receptors through a death inducing signalling complex (DISC) 
formation on the plasma membrane e.g. CD95 triggering by CD95L, results in the 
formation of the CD95 DISC. This initiates downstream caspase activation leading to 
apoptosis of the T cell. 
 
1.2.5.2 The intrinsic apoptotic pathway 
The intrinsic apoptotic pathway differs from the extrinsic apoptotic pathway in that it is 
regulated by the balance of pro- and anti-apoptotic signals predominately from the B 
cell lymphoma 2 (Bcl-2) family (Adams and Cory, 1998, Aggarwal and Gupta, 1998, Chao 
and Korsmeyer, 1998). A number of BCl-2 family members have been discovered and 
are summarised in table 1.3. The intrinsic apoptotic pathway involves mitochondrial 
permeabilisation, causing the release of mitochondrial contents including cytochrome C. 
Together with apoptotic-protease activating factor 1 (APAF-1), this initiates  
apoptosome formation and caspase release, leading to the destruction of the cell 
through apoptosis (Adams and Cory, 1998, Chao and Korsmeyer, 1998). 
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Pro-apoptotic Anti-apoptotic 
Bax (Oltvai et al., 1993) Bcl-2 (Chao and Korsmeyer, 1998) 
Bak (Chittenden et al., 1995) Bcl-XL (Boise et al., 1993) 
Bad (Yang et al., 1995) Mcl-1 (Zhou et al., 1997) 
Bcl-XS (Boise et al., 1993) Bcl-w (Gibson et al., 1996) 
Bik (Boyd et al., 1995) A1 (Lin et al., 1996) 
Bid (Wang et al., 1996)  
Table 1-3. Members of the BCl-2 family involved in apoptosis (with references). 
 
1.2.6 Differentiation pathways of effector and memory T cells 
It remains unclear whether effector or memory T cells arise independently from each 
other or if they are the same cells at various stages of differentiation. The two main 
models proposed for the differentiation of T cells are the linear and divergent pathways 
(figure 1.1). As their name’s suggest, the linear pathway proposes a direct lineage from 
naive to effector, then to memory, T cells (Opferman et al., 1999, Sallusto et al., 1999) 
whereas the divergent pathway proposes effector and memory cells are generated as 
daughter cells from one cell (Chang et al., 2007, Manjunath et al., 2001). Evidence exists 
to support both models, and are reviewed elsewhere (Kalia et al., 2010), however a few 
lines of evidence will be mentioned here. Support of a linear differentiation pathway 
comes from studies using lymphocytic choriomeningitis virus (LCMV) infection, which 
shows memory CD8+ T cells develop from a greatly expanded population of effector 
CD8+ T cells (Kaech et al., 2002, Murali-Krishna et al., 1998). Additionally, adoptive 
transfer experiments have shown memory CD4+ T cells can be generated from antigen 
activated effector CD4+ T cells in-vivo (Garcia et al., 1999). Support for a divergent 
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pathway comes from elegant experiments by Change et al., in which they showed 
activated naive T cells exhibit unequal partitioning of proteins that mediate cell 
signalling and cell fate, leading to asymmetrical division of the two daughter cells, which 
are differentially fated phenotypically and functionally to become effector or memory T 
cells (Chang et al., 2007).  
 
 
 
 
 
Figure 1-1. Models of T cell differentiation pathways. 
Two models proposing the differentiation pathway of T cells are shown. The linear pathway (top) 
proposes a direct lineage from naive to effector then to memory T cells, whereas the divergent pathway 
(bottom) proposes effector and memory cells are generated as daughter cells at the same time from one 
single cell.  
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1.2.7 The identification of T cells using pMHC multimeric complexes 
HLA-peptide multimeric complexes allow for the direct ex-vivo visualization of antigen-
specific T cells by flow cytometry (Klenerman et al., 2002, Ogg and McMichael, 1998, 
Altman and Davis, 2003). Specific peptide is engineered and folded in the presence of 
MHC to construct single pMHC monomers. These pMHC monomers are therefore 
recognized by T cells specific for that peptide. The TCR-pMHC interaction is rather weak 
however, therefore single pMHC monomers are biotinylated (using Bir A enzyme) then 
conjugated (using streptavidin) together as four, five or more multimeric units to 
generate tetramers, pentamers or streptamers respectively. These provide multiple 
TCR-pMHC interactions which increases the chance of binding, and therefore of staining, 
the T cell of interest (figure 1.2a). Although, it is currently believed three (or even two) 
pMHC monomer complexes are sufficient for staining (Wooldridge et al., 2009). 
Multimers are usually fluorescently labeled during streptavidin conjugation to facilitate 
T cell identification by flow cytometry  (Altman and Davis, 2003). 
 
1.2.7.1 Affinity vs. Avidity 
The terms affinity and avidity are often used interchangeably, however they are distinct 
(Stone et al., 2009). Affinity is defined as the strength of the interaction between one 
ligand and its receptor e.g. TCR affinity for peptide presented by MHC (pMHC). TCR 
affinity for peptide is determined during T cell generation (section 1.2.2). Avidity is 
defined as the sum strength of multiple interactions e.g. TCR binding to pMHC is 
strengthened by additional interactions between the T cell and APC (Smith-Garvin et al., 
2009). These include: co-receptor binding e.g. CD4 and CD8 bind conserved region of 
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MHC; co-stimulatory molecules e.g. CD27 and CD28 on T cells interact with CD70 and 
CD80/CD86 on APCs; adhesion molecules e.g. LFA-1 on T cell bind cellular adhesion 
molecules on APCs (Smith-Garvin et al., 2009, Stone et al., 2009) 
 
1.2.7.2 Identifying high avidity T cells using mutated tetramers  
 
T cells recognising the same antigen presented by MHC can vary in their sensitivity by 
several orders of magnitude (Alexander-Miller, 2000, Alexander-Miller et al., 1996, 
Walker et al., 2010). Furthermore, it has been shown that high-avidity CD8+ T cells are 
the most efficient at eliminating viruses (Alexander-Miller et al., 1996, Almeida et al., 
2007, Derby et al., 2001). Although, one study has shown that low-avidity CD8+ T cells 
may be more beneficial in chronic infections (Harari et al., 2007), necessitating further 
investigation into the role of T cell avidity in immune control during acute and chronic 
viral infections. High avidity T cell populations may be identified experimentally by 
stimulating T cells with titrating amounts of peptide, and identifying cells responding at 
the lowest concentrations as the high avidity T cells (Almeida et al., 2007, Harari et al., 
2007, Villacres et al., 2003). In the present study, specially engineered ‘CD8null’ 
tetramers were used that contain a mutation in the α3 domain (D227K/T228A) of the 
conserved MHC binding site (Walker et al., 2010, Melenhorst et al., 2008). This mutation 
weakens CD8 co-receptor binding to MHC class I that normally stabilises the peptide-
TCR interaction. Therefore, CD8+ T cells binding mutated tetramer are less reliant upon 
CD8, and have higher avidity for peptide. A high avidity population can therefore be 
identified and compared with the normal population which binds regular, un-mutated 
tetramer (figure 1.2). 
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(A) 
 
(B) 
 
Figure 1-2.  Antigen-specific CD8
+
 T cell staining using normal or mutated (CD8null) tetramers. 
(A) Normal tetramers are composed of four MHC class I monomers engineered to present a specific 
peptide recognised by a specific CD8
+
 T cell. As with regular MHC class I molecules, these contain the α-3 
binding domain which interacts with CD8 co-receptor for stabilisation. In this example, the TCR has low 
affinity to pMHC. When monomers are conjugated to a fluorescently labelled streptavidin molecule via 
biotin, tetramers are formed (tetramerisation). This creates multiple interactions which are strong and 
most CD8
+
 T cells specific for that antigen are stained with the aid of CD8. (B) Mutated (CD8null) 
tetramers are composed of the same antigen-specific MHC class I monomers, but contain an α-3 binding 
domain mutation (D227K/T228A) which results in an inability to bind CD8. Therefore, as shown in this 
example, only T cells with high affinity TCRs will bind the tetramer without CD8 help. Either the normal or 
CD8null tetramer binding populations can then be identified by flow-cytometry. 
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1.3 T cell subpopulations 
T cells are commonly classified into subpopulations, based on their phenotypic and 
functional characteristics. These give an insight into the role of the T cell, or its relative 
point at various stages of differentiation, which reflect changes in expression of genes 
controlling cell cycle, survival, effector functions and migration.  
1.3.1 Defining T cell subpopulations 
T cells subpopulations are based on various criteria, so it is important to understand 
which markers are commonly used for classification and why. 
1.3.1.1 CD45R isoform expression 
CD45R, also called the common leukocyte antigen, was the first and prototypic 
receptor-like protein tyrosine phosphatase to be identified (Thomas, 1989). It consists of 
an intracellular domain, a transmembrane region and an extracellular domain, which 
exists in different isoforms; CD45RA being the largest and CD45RO the smallest isoforms 
(Hermiston et al., 2003). CD45R is expressed on all haematopoietic cells and covers up 
to 10% of the cell surface, making it one of the most abundant cell surface glycoproteins 
(Thomas, 1989). Its ligand has yet to be identified, but the main intracellular targets of 
CD45 phosphatase activity are the Src-family kinases (predominately p56Lck and p59Fyn in 
the T cell) which initiate signal transduction upon TCR engagement (McNeill et al., 
2007). Experiments using monoclonal antibodies revealed expression of the higher 
molecular weight isoform, CD45RA, was indicative of naïve T cells, and the subsequent 
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shift in expression to the lower molecular weight isoform, CD45RO, following activation 
was indicative of an antigen experienced T cell (Akbar et al., 1988).  
1.3.1.2 CD27 and CD28 co-stimulatory molecule expression 
CD27 and CD28 were described previously as important co-stimulatory molecules in T 
cell activation (section 1.2.3.3). However, these molecules are also useful markers for 
defining T cell subpopulations; as their expression is down-regulated in response to 
repeated stimulation, and therefore indicative of T cells at various stages of 
differentiation (Appay et al., 2002, Azuma et al., 1993, Hamann et al., 1997). This is 
exemplified by the fact that long term culture of T cells result in the entire population 
eventually becoming CD28- (Effros et al., 1994). Interestingly, CD4+ T cells differentiate 
and lose the expression of CD27 first and then CD28, whereas CD8+ T cells show CD28 
then CD27 down-regulation (Appay et al., 2002, Khan et al., 2002b). This may reflect 
preferential use of either co-stimulatory pathway.  
1.3.1.3 Homing and adhesion molecule expression 
Lymphocytes continually circulate in the blood and lymph in surveillance of foreign 
antigen. Different subpopulations of T cells will also migrate differentially to various 
tissues. Naive T cells for example, are unable to mount an immune response until 
activation, and therefore do not require homing to inflammatory sites. Instead they 
need to interact with DC’s in secondary lymphoid tissues. The route of trafficking by a T 
cell is determined by the homing (or trafficking) receptors on its surface.  
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Some homing receptors recognise specific vascular addressins expressed by the high 
endothelial venules’ (HEV’s) of different secondary lymphoid tissues, thus promoting 
migration into the secondary lymphoid tissue. Others homing receptors interact with 
vascular addressins on endothelium at sites of inflammation, therefore promoting 
peripheral migration.  There are multiple receptors involved in the homing of T cells 
(Woodland and Kohlmeier, 2009), but some commonly used for classification include 
CD62L (l-selectin) and CCR7. CCR7 is a chemotactic receptor, belonging to the G-protein 
coupled receptor family, which binds CCL19 and CCL21, directing migration to the 
lymphoid tissues (Woodland and Kohlmeier, 2009). CD62L is an adhesion molecule, 
which, in addition to CCR7, is required for the migration of T cells to the lymph nodes 
(Butcher and Picker, 1996). Naive T cells therefore express CCR7 and CD62L. 
 
1.3.2 Central memory (TCM) and effector memory (TEM) cells 
By dividing the antigen experienced CD45RO+ memory CD4+ or CD8+ T cells further by 
CCR7 expression, two main subpopulations were found to have distinct functional 
properties (Sallusto et al., 1999). T cells lacking CCR7, rapidly respond to antigen by 
producing effector cytokines, including IFN-γ, IL-4, IL-5, and perforin. These cells were 
termed effector memory T cells (TEM) as they migrate to inflamed tissues, using the 
alternate receptors CCR1, CCR3 and CCR5. T cells expressing CCR7 were termed central 
memory T cells (TCM), as they lacked immediate effector function and had low activation 
threshold, but could home to the lymph nodes for efficient DC communication 
(Lanzavecchia and Sallusto, 2005, Wherry et al., 2003). Furthermore, CD62L expression 
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is found to largely overlap with CCR7 expression (Sallusto et al., 1999) and is therefore 
sometimes used in place of CCR7. By using radioactive isotope labelling of proliferating 
cells in-vivo, the turnover rate of CD4+ naïve, TEM, and TCM cells were determined as 1 
year, 15 days and 48 days respectively (Macallan et al., 2004). This highlights that TEM in 
particular, are short lived effectors that may require continual replenishment.  
1.3.3 CD45RA+ Memory (TEMRA) cells 
The switch from a naive CD45RA+ to a memory CD45RO+ T cell is reversible, and a 
population of the memory pool may comprise these CD45RA+ memory T cells. These can 
be identified by tetramers, confirming their specificity for antigen (Appay and Rowland-
Jones, 2004, van Leeuwen et al., 2002, Faint et al., 2001). They are delineated from 
naive T cells by their lack of expression of CD27 and CCR7; in which case they are termed 
TEMRA cells (Hamann et al., 1999b, Sallusto et al., 2004, van Leeuwen et al., 2002). 
Compared to naïve CD45RA expressing T cells, TEMRA cells show signs of repeated 
stimulation i.e. low expression of the co-stimulatory molecules CD27 and CD28, 
indicative of repeated cell division (Wills et al., 2002), and express various effector-like 
markers (van Leeuwen et al., 2002, Wills et al., 2002).  
 
It was initially proposed that TEMRA cells were terminally differentiated (Champagne et 
al., 2001). However, evidence now suggests that TEMRA cells may instead represent a 
stable population within the T cell memory pool. In-vitro studies have shown that 
stimulated CMV-specific and EBV-specific CD8+ TEMRA cells can undergo significant clonal 
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expansion, up-regulate CD45RO expression, secrete perforin and IFN-γ, and show direct 
ex-vivo cytotoxicity (van Leeuwen et al., 2002, Faint et al., 2001, Wills et al., 2002). 
Although lacking CD27 and CD28 expression, stimulated CMV-specific TEMRA cells can 
increase expression of CD137 (4-1BB), CD278 (ICOS) and homing receptors CCR5 and 
CXCR3 (Waller et al., 2007). The significance of this is apparent when CD137L treated 
TEMRA cells are given CD137L blocking antibody and a subsequent drop in proliferation 
(40-60%) is observed compared to controls (CD137L treated, no blocking antibody), an 
effect not observed with CD80, CD86 or CD275 (Waller et al., 2007). This suggests highly 
differentiated TEMRA cells could be using other co-stimulatory signalling pathways 
besides the classical CD27/CD28 co-stimulatory pathways. 
1.3.4 Subpopulation consensus issues 
The simultaneous measurement of a variety of markers enables the distinction of a 
multitude of T cell subpopulations. However, there is yet to be a consensus on which 
subpopulation classification system is best to use (Appay et al., 2008). This can cause 
confusion and difficulty when comparing results between research groups. In this thesis, 
subpopulations of T cells will be defined by the markers CD45RA and CD27, as based on 
work performed in our lab and others (Dunne et al., 2005, Hamann et al., 1997, Libri et 
al., 2011, van Lier et al., 2003). In our experience, delineating on the basis of CD27 
expression gives a clearer dissection of the four subpopulations, compared with CCR7. 
CD27 is also more relevant to the present study, in terms of ageing and differentiation, 
rather than CCR7, which is indicative of homing properties. Furthermore, CD27 re-
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expression does not occur on CD27 negative memory T cell populations (Hintzen et al., 
1993) whereas CCR7 re-expression following antigenic stimulation has been reported 
(Schwendemann et al., 2005, van Leeuwen et al., 2005). However, there is considerable 
homology between CD27 and CCR7 or CD62L expression (Sallusto et al., 2004, Sallusto 
et al., 1999, Appay et al., 2008, Fierro et al., 2008), meaning a fair comparison is 
possible, as summarised in table 1.4. 
 
 
 
Table 1-4. Phenotypic markers defining T cell subpopulations. 
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1.4 The impact of ageing on T cells 
Immune senescence can impact the innate immune response (discussed later in section 
1.5), however it is the defects in T cell immunity that are the most marked and best 
documented (Nikolich-Zugich, 2008). These defects can occur at a single-cell or cell 
population level and will be discussed here.  
1.4.1 Decreased naive T cell production during ageing 
The progressive involution of the thymus during ageing leads to decreasing production 
of naive T cells. Involution begins approximately one year after birth, and by middle-age 
most parenchymal tissue is replaced by fat, although functional thymic tissue remains at 
least into the sixth decade of life (Linton and Dorshkind, 2004). Although the exact 
mechanism for thymic involution remains poorly understood, the cause may be a loss or 
disruption of interaction between developing thymocytes and the supportive thymic 
stoma (Lynch et al., 2009). With involution of the thymus comes a decrease in recent 
thymic emigrants (RTE), which may put pressure on homeostatic mechanisms needed to 
sustain a diverse naive T cell repertoire through ageing (Nikolich-Zugich, 2008). 
1.4.2 Increased naive T cell turnover during ageing 
Compared with memory T cells, naive T cells rarely undergo division, instead being 
homeostatically maintained by weak TCR triggering and cytokines (Boyman et al., 2009). 
However, experiments with aged rhesus macaques have shown naive T cells have 
significantly higher rates of turnover, with no subsequent increase in numbers (Cicin-
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Sain et al., 2010). Furthermore, in humans, CD4+ T cell homeostatic proliferation was 
seen to double in the over 70’s (Naylor et al., 2005). This suggests naive T cells may be 
under added pressure to survive during old age, and risk being lost through senescence. 
1.4.3 Expansion of memory T cells with ageing 
The older the individual becomes the more pathogens they are likely to have 
encountered, and hence the more memory T cells they have generated. However, there 
are large clonal expansions of T cells specific for a restricted number of epitopes, 
especially within the CD8+ T cell compartment, reported in ageing mice and humans 
(Callahan et al., 1993, Posnett et al., 1994, Ku et al., 1997, Schwab et al., 1997). Current 
evidence suggests these non-malignant expansions are the result of chronic pathogen 
stimulation by viruses, including Cytomegalovirus (further discussed in section 1.6). 
1.4.4 Age-related restriction of the TCR repertoire 
The compounding effect of decreased naive T cell numbers and accumulation of 
memory T cells during ageing is thought to shrink the overall diversity of the T cell pool 
by old age (Nikolich-Zugich et al., 2004, Naylor et al., 2005, Ahmed et al., 2009). 
Observations of TCR diversity during ageing suggests it remains constant in youth, but 
later in life TCR vβ usage becomes uneven and reduction of CDR3 diversity occurs 
(Vargas et al., 2001, Schwab et al., 1997). This could have consequences, as a diverse T 
cell repertoire is essential for mounting immune responses to new pathogens. Indeed, 
increased susceptibility to new infections is a hallmark of age-related immune decline 
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(section 1.1.4). Although direct evidence for this is lacking in humans, experiments in 
animal models show a restricted TCR diversity can result in impaired immunity to viruses 
(Messaoudi et al., 2004, Yager et al., 2008, Cicin-Sain et al., 2010). 
1.4.5 Inverted CD4:CD8 ratio 
The normal CD4:CD8 ratio in adults is usually around 2:1, in cord blood for comparison it 
is higher at around 3:1 (Brzezinska, 2005). Interestingly, inversion of the CD4/CD8 ratio 
alone was predictive of survival rate in a UK sample of old people (Huppert et al., 2003) 
and predictive of individuals with poor T cell proliferative responses to mitogens (Peres 
et al., 2003). Inverted CD4:CD8 have also been reported in some older individuals in care 
homes (Cretel et al., 2010) and those experiencing high levels of job stress (Bosch et al., 
2009), an association which became stronger with increased age.  
1.4.6 Down-regulation of CD27 and CD28 expression 
CD27 and CD28 are co-stimulatory molecules found on the surface on T cells (section 
1.3.1.2). Virtually all T cells in umbilical cord blood express CD27 and CD28 (Azuma et al., 
1992, Brzezinska, 2005). However, the fraction of CD4+ and CD8+ T cells expressing CD27 
and/or CD28 significantly decreases during ageing (Boucher et al., 1998, Nijhuis et al., 
1994, Fagnoni et al., 1996, Fletcher et al., 2005, Wikby et al., 2005, Kovaiou et al., 2005, 
Posnett et al., 1994). These CD27-CD28- T cells represent a population which have 
undergone repeated stimulation, as they have shorter telomere lengths relative to 
CD27+CD28+ T cells (Monteiro et al., 1996, Fletcher et al., 2005, Soares et al., 2004) and 
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show defective telomerase activity (Plunkett et al., 2007). CD27/CD28 expression also 
gradually decreases during long-term in-vitro T cell culturing (Brzezinska, 2005, Effros et 
al., 1994), which seems to confirm those findings in-vivo.  
 
1.4.7 T cell defects at a cellular level 
T cells in old individuals have been associated with a variety of functional defects. One 
of the first to be documented was low IL-2 production upon activation (Gillis et al., 1981, 
Chen et al., 1986), but has since been extended to include low activation-induced IFN-γ 
production (Murasko and Goonewardene, 1990), impaired activation (Schindowski et 
al., 2002), and signalling defects through lipid rafts (Larbi et al., 2010). Studies in mice 
have also shown ageing results in declining activation of a range of substrates including 
tyrosine phosphorylation of CD3 ζ-chains and various kinase activities (Miller et al., 
1997). 
 
1.4.8 T cell senescence vs. exhaustion  
Repeated proliferation and/or stimulation of T cells throughout life can result in T cell 
senescence or exhaustion. However, although these terms are often used 
interchangeably, there is evidence to suggest they may be distinct processes (Akbar and 
Henson, 2011). Generally, either process can be divided into 3 phases; each phase on 
course to a different pathway (figure 1.3). 
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Figure 1-3. The 3 phases of senescence versus exhaustion (adapted from(Akbar and Henson, 2011) 
 
Cellular senescence can be induced (phase 1) either by telomere erosion or DNA 
damage, caused by reactive oxygen species (ROS), chromatin perturbation and 
activation of stress pathways in response to growth factor deprivation (Campisi and 
d'Adda di Fagagna, 2007, d'Adda di Fagagna, 2008, Passos and Von Zglinicki, 2006). 
These telomere-dependent, and telomere-independent, inducers of senescence lead to 
phase 2: the DNA damage response (DDR), which involves the recruitment of DNA repair 
proteins (Akbar and Henson, 2011, Campisi and d'Adda di Fagagna, 2007). This causes 
temporary growth arrest, however, if the DNA damage cannot be repaired, cell cycling 
ceases and a permanent state of senescence (phase 3) is reached (Campisi and d'Adda 
di Fagagna, 2007, d'Adda di Fagagna, 2008). A well characterised marker of T cell 
senescence is CD57 a.k.a HNK-1, a terminally sulfated glycan carbohydrate epitope 
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(glycoepitope) that was first described in 1981 on human natural killer (HNK) cells (Abo 
and Balch, 1981). CD57 is associated with high susceptibility to activation-induced cell 
death and an inability to undergo cell division (Focosi et al., 2010), a proliferative defect 
which cannot be overcome by cytokine help (Kern et al., 1996). Another marker of 
senescence is killer-cell lectin-like receptor G-1 (KLRG-1). KLRG-1+ cells are unable to 
undergo clonal expansion following activation (Voehringer et al., 2002), due in part to 
KLRG-1 inducing defective Akt phosphorylation and proliferation (Henson et al., 2009).  
 
T cell exhaustion is defined by the progressive loss of function and is induced (phase 1) 
by high antigenic load, such as during chronic viral infection or cancer (Akbar and 
Henson, 2011). Under conditions of high antigenic load, T cells are driven further to 
differentiation and begin to express inhibitory receptors (phase 2). Signalling through 
these receptors can lead to decreased cytotoxic capacity, decreased cytokine 
production and eventually growth arrest (phase 3). A well characterised inhibitory 
receptor is programmed death receptor 1 (PD-1); a member of the CD28 receptor family 
that has been shown to be highly expressed on CD8+ T cells during chronic infection 
(Barber et al., 2006, Blackburn et al., 2009). Importantly, blocking PD-1 has been shown 
to restore T cell function in mice and humans (Barber et al., 2006, Lages et al., 2010, 
Nakamoto et al., 2009, Trautmann et al., 2006). Other inhibitory receptors shown to 
induce T cell exhaustion include cytotoxic T lymphocyte antigen 4 (CTLA4), T cell 
immunoglobulin domain and mucin domain protein 3 (TIM3), and lymphocyte activation 
gene 3 (LAG3) (Blackburn et al., 2009, Sakuishi et al., 2010, Wherry et al., 2007).   
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1.4.9 The immune risk phenotype (IRP) 
The age-related changes to T cells described thus far are therefore important 
biomarkers indicative of immune ageing. How these biomarkers are associated with 
age-related susceptibility to infections and poor vaccination responses have therefore 
been investigated. One such investigation is the ongoing Swedish OCTO and NONA 
longitudinal studies (Wikby et al., 2005, Wikby et al., 2002, Wikby et al., 2006), which 
measure various immunological parameters in the very old (80+ and 90+ years of age 
respectively) to determine their impact on life expectancy. Upon conclusion of the 
study, a set of parameters defining an immune risk phenotype (IRP) were proposed, and 
those individuals within the IRP had decreased survival rates of up to 4 years compared 
to those outside the IRP. Furthermore, follow up studies have shown groups of long 
lived individuals over 100 years of age are frequently outside the IRP (Strindhall et al., 
2007, Derhovanessian et al., 2010). Many of the significant associations identified in the 
studies were found to relate to T cells (table 1.5). The significant association with 
cytomegalovirus seropositivity will be discussed further in section 1.6. 
 
Immune Risk Phenotype 
CD4:CD8 ratio <1 
Poor T cell proliferative responses 
CD28↓ 
CD57↑ 
KLR-G1↑ 
IL-2↓ 
IFN-γ↓ 
CMV
pos
 
Table 1-5. Parameters of the IRP (adapted from(Pawelec et al., 2004) 
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1.5 The impact of ageing on other components of the immune system 
 
1.5.1 The innate immunity and immune senescence 
Innate immunity comprises four types of defence: the anatomical, physiological, 
phagocytic and inflammatory barriers. Anatomical barriers include the skin and mucous 
membranes. Physiological barriers include temperature e.g. Fever (inhibits pathogen 
growth), pH (e.g. stomach acid), lysozymes (cleave bacterial cell walls) and interferon 
(induces antiviral state in surrounding uninfected cells). Phagocytic barriers including 
blood monocytes, neutrophils and tissue macrophages, which internalize, digest and kill 
whole microorganisms. Finally there are inflammatory barriers: tissue damage causes 
local leakage of vascular fluid, containing serum proteins with antimicrobial activity, and 
inflammatory mediators which recruit phagocytic cells into the area.  
 
In comparison to the lymphoid progenitors, there is no decrease in the numbers of 
myeloid progenitors during ageing which give rise to many of the cells involved in innate 
immunity (Beerman et al., 2010). In fact, there are reports suggesting increased 
numbers and hyper-activity of these cells in the old (Gomez et al., 2008, Kovacs et al., 
2009, Shaw et al., 2010). Instead, ‘innate immune senescence’ usually reflects 
dysregulation. For example, decreased TNF-α production by dermal macrophages 
impairs T cell migration during immune responses to Candida in old skin, whereas ex-
vivo, macrophages function properly (Agius et al., 2009). This demonstrated 
dysregulation of macrophages in the tissue environment, rather than impaired function.  
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1.5.2 B cells and immune senescence 
B cells are generated and mature within the bone marrow. A mature B cell leaves the 
bone marrow expressing membrane-bound immunoglobulin (mIg) with a single 
antigenic specificity. The mIg associates with the disulphide linked heterodimer Ig-α/Ig-β 
which is involved in cell signalling, to collectively form the B cell receptor or BCR (Kindt 
et al., 2007). When a naïve B cell encounters antigen specific for its BCR, it divides 
rapidly, differentiating by a process of affinity maturation for antigen, class switching, 
and formation of effector (plasma) and memory B cells. Plasma cells produce and 
secrete antibody in large amounts which attach to pathogens initiating their destruction 
or facilitating their removal by phagocytes. Plasma B cells die after a few days, however 
memory B cells have much longer lifespan and continue to express the bound BCR and 
patrol the organism in the event of re-challenge.  
 
Although total B cell numbers do not decline with age (Weksler and Szabo, 2000), the 
memory B cell compartment increases with age and shows decreased CD27 co-
stimulatory molecule expression (Colonna-Romano et al., 2003), in a similar manner to T 
cells. Furthermore, B cells from older individuals are stimulated 70% less efficiently than 
B cells from young individuals (Aydar et al., 2002). However, It is believed that many of 
these age-related impairments in B cell activation result from a lack of T cell help, and 
the change in the cytokine environment with ageing (Weiskopf et al., 2009).  
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1.6 Cytomegalovirus  
Cytomegalovirus (CMV) is associated with driving T cells to greater differentiation 
(Akbar and Fletcher, 2005, Appay et al., 2002, Fletcher et al., 2005, Khan et al., 2002b, 
Pawelec et al., 2004). CMV seropositivity was also found to be a significant factor in the 
immune risk phenotype (IRP), a cluster of immune parameters associated with 
decreased survival in the very old (section 1.4.9). This section describes CMV and 
evidence linking CMV with immune senescence.  
1.6.1 Discovery of CMV 
As far back as 1881, descriptions of large “protozoan like” cells in the kidneys of still-
born babies were reported (Ribbert, 1904). With the advent of advanced cell culture 
techniques, the virus causing these cytomegalic cells with intranuclear inclusions was 
isolated, and hence named Cytomegalovirus (Craig et al., 1957).  
1.6.2 Seroprevalence of CMV 
CMV is shed in bodily fluids, resulting in infection of others through close contact 
(Hanshaw et al., 1968). Seroprevalence is approximately 50-90%, with the majority of 
the population being infected by adulthood; highlighted by a one per cent cumulative 
rise in chance of infection per year of age (Griffiths, 1997). The rate of infection is also 
highly influenced by geographical location and socio-economic status (Ho, 2008). The 
success of the virus is highlighted by the incidence of CMV seropositivity being so 
ubiquitous it reaches even the most isolated tribal communities (Black et al., 1974).   
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1.6.3 CMV pathology 
Upon acute infection of a healthy host, symptoms are rare, but may include 
mononucleosis (Taylor, 2003). The virus then establishes a life-long chronic yet sub-
clinical infection, entering a state of latency, when infectious virions are undetectable 
(Sinclair, 2008). In immune-compromised individuals however, CMV is a major cause of 
morbidity and mortality, with various pathological manifestations. In AIDS patients for 
example, CMV disease commonly presents as retinitis or enteritis (Harari et al., 2004). In 
organ transplant recipients, CMV is the most common viral infection: causing fever, 
hepatosplenomegaly, myalgias, leukopenia and thrombocytopenia with or without 
specific organ dysfunction (Emery, 2001). This can indirectly affect the host’s immune 
response, leading to acute rejection, graft loss, and onset of other opportunistic 
infections (Strippoli et al., 2006). Primary CMV infection is also the leading cause of birth 
defects and developmental disabilities (Hyde et al., 2010). 
1.6.4 Latency 
CMV belongs to a family of viruses of the genus herpesviridae, from the greek herpein, 
meaning “to creep” - in reference to the latent, recurring infection typical of this group 
of viruses. CMV is part of the subfamily betaherpesvirinae, which establishes latency 
predominately in monocytes, as compared with the alphaherpesvirinae herpes-simplex 
virus (HSV) and varicella-zoster virus (VZV) or the gammaherpesvirinae EBV, which 
establish latency predominately in neuronal cells and B cells respectively (Sinclair, 2008).  
However, many other cell types are permissive for CMV infection in-vivo; including 
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epithelial cells, endothelial cells, granulocytes and lymphocytes (Emery, 2001, Sinclair 
and Sissons, 2006, Revello and Gerna, 2010), creating a potentially large reservoir of 
latent virus. Evidence suggests latent CMV virus in monocytes may become reactivated 
during differentiation into macrophages (Soderberg-Naucler et al., 1997, Soderberg-
Naucler et al., 1998). CMV may also disseminate throughout the body as a result of 
adhesion molecule interaction between leukocytes and infected endothelial cells, 
creating fusion points for virion transmission (Revello and Gerna, 2010). 
1.6.5 Is CMV reactivating in healthy individuals? 
CMV related pathology in otherwise healthy individuals has been reported (McVoy and 
Adler, 1989), although reports are seldom, indicating CMV infection is kept under 
control. Analysis for the presence of CMV DNA in the monocytes of old volunteers 
however revealed 56% had detectable CMV DNA, with significantly higher percentages 
of CMV-pp65 specific CD8+ T cells than those without detectable CMV DNA (Leng et al., 
2011). CMV IgM titers were also found to be negative for all subjects, indicating that 
recent primary CMV infection was unlikely and reactivation therefore the cause. CMV 
may also be reactivating at other sites of the body, including the kidneys, as CMV can be 
detected in the urine of older CMV positive individuals (Stowe et al., 2007). 
Furthermore, ‘abortive reactivations’ occur frequently for herpesviruses such as EBV 
and CMV (Kurz et al., 1999, Laichalk and Thorley-Lawson, 2005). In this process, viruses 
start gene replication within the cell but abort before generation of infectious virus. 
Frequent abortive reactivation result in repetitive immune stimulation (Virgin et al., 
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2009) and may account for an expansion of clones without detection of CMV in the 
blood or appearance of CMV associated symptoms.  
1.6.6 Immune responses to CMV  
CMV elicits a strong immune response in-vivo, triggering early B cell production of CMV-
specific neutralising antibodies targeting surface glycoprotein B (gB/UL55) (Emery, 
2000). Immunisation with CMV-specific gB induces neutralising antibody responses 
which can protect animals from an otherwise lethal CMV infection (Schleiss, 2008). 
Evidence also suggests Natural killer (NK) cells are important in immune responses to 
CMV. Neonatal mice are rendered susceptible to lethal infection if NK cells ablated 
(Brown et al., 2001, Polic et al., 1998). In humans, CMV-related disease during organ 
transplantation is correlated with poor NK cell protection (Gandhi and Khanna, 2004, 
Quinnan et al., 1982). However, it is the cell-mediated branch of the immune response, 
in particular CD8+ T cells, which control CMV replication most efficiently (Moss and 
Khan, 2004, Gandhi and Khanna, 2004, Harari et al., 2004). CD8+ T cells can target a 
broad range of CMV peptides, but the major targets are the pp65 matrix protein (UL83) 
and the immediate-early (IE) genes (Sylwester et al., 2005, Emery, 2000, Kern et al., 
2000, Khan et al., 2002a).  
1.6.7 CMV immune evasion strategies  
CMV is a DNA virus with a large genome encoding over 200 genes (Chee et al., 1990, 
Emery, 2001). It has co-existed with eukaryotic cells for millions of years (Maffei et al., 
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2008) and this is exemplified by the vast array of immune evasion strategies it has 
developed (Wiertz et al., 1997, Emery, 2001). Many of these disrupt antigen processing 
and presentation within CMV infected cells, thereby avoiding recognition by patrolling 
immune cells. Some CMV genes devoted to immune evasion and their mechanisms of 
action are summarised in table 1.6.  
 
HCMV gene Immune evasion strategy 
US2/US11 Destroy newly synthesized MHC class I molecules 
US3 Retains MHC class I molecule in endoplasmic reticulum 
US6 Blocks peptide transport by transporter associated with antigen (TAP) 
US28 Acts as promiscuous chemokine receptor 
UL18 MHC class I homolog. Acts as a decoy for natural killer (NK) cells 
UL83 (pp65) Phosphorlyates immediate early  (IE) protein leading to IE presentation being 
suppressed, due to lack of processing by proteasome 
Table 1-6. HCMV genes involved in immune evasion 
Abbreviations: unique short (US) and unique long (UL). 
1.6.8 CMV and the immune risk phenotype 
One hundred per cent of those in the immune risk phenotype (IRP) group in the NONA 
study were CMV positive versus eighty four per cent in the non-IRP group (Wikby et al., 
2002). The role of CMV as a causal factor in the IRP may be due to the accumulation of 
CMV-specific CD8+ T cell expansions (TCEs) which the virus elicits (see 1.6.10). These 
could contribute to the skewing of the CD4:CD8 ratio, a parameter in IRP and itself a 
predictor of early mortality in the old (Huppert et al., 2003). Furthermore, there is a 
decrease in naïve CD8 T cells in the old, but it is the increase of effector memory T cells 
that cause the inflated CD8 numbers (Pawelec et al., 2006a). A decrease in the 
expression of the co-stimulatory molecules CD27 and CD28, and increased CD57 
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expression, on T cells are also biomarkers of the IRP, and incidentally also linked to CMV 
driven differentiation and senescence in T cells. This will be discussed in more detail in 
the following sections.  
1.6.9 CMV-specific T cell differentiation 
MHC class I tetramers have been particularly useful in studying virus-specific CD8+ T cell 
populations during the progress of infection, and different virus specific CD8+ T cells 
display varying degrees of differentiation. For example, Influenza-A-specific memory 
CD8+ T cells show an early differentiation phenotype; reflecting the acute nature and 
clearance of an Influenza infection (Appay et al., 2002). CMV-specific CD8+ T cells 
however, show the most differentiated phenotype of all virus-specific CD8+ T cells, 
exhibiting low CD27 and CD28, indicative of repeated activation (Appay et al., 2002, 
Klenerman and Hill, 2005, Koch et al., 2007, van Lier et al., 2003, Wills et al., 2002).  
 
Many factors associated with a particular virus may influence the state of differentiation 
of the CD8+ T cells targeting it, including antigenic load and presentation, viral 
persistence and location, and the influence of viral immune escape mechanisms (Appay 
and Rowland-Jones, 2004). Indeed, CMV devotes multiple genes to immune evasion, as 
discussed earlier. The obvious reason for such a differentiated phenotype is that CMV-
specific T cells are encountering antigen more frequently. This may be due to the 
cellular tropism of the virus e.g. HSV resides in neuronal cells and may therefore not be 
seen as frequently by T cells as is CMV is, which is present in various cell types, including 
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epithelial and endothelial cells (Revello and Gerna, 2010, Sinclair, 2008). CMV effects 
are not limited to CD8+ T cells, as CD8+ T cells also require the help of CMV-specific CD4+ 
T cells, which are also found in high numbers in healthy CMV seropositive individuals 
and similarly show a highly differentiated phenotype (Koch et al., 2006, Fletcher et al., 
2005).  
1.6.10 CMV-specific CD8+ T cell clonal expansions  
Large CMV-specific T cell expansions (TCEs) are found within CMV positive individuals, 
and persist for a lifetime (Harari et al., 2004). These TCEs seem highly restrictive, using 
only one or two vβ gene segments (Khan et al., 2002b, Wallace et al., 2011, Karrer et al., 
2003). They are found in both the CD4+ and CD8+ T cell compartments, accounting for up 
to 50% of the entire repertoire in older CMV positive individuals (Harari et al., 2004, 
Looney et al., 1999, Wikby et al., 2002). Furthermore, these TCEs are predominately 
CD28− and CD57+ T cells indicating they have undergone repeated stimulation and are 
close to senescence (Khan et al., 2002b, Weekes et al., 1999, Wills et al., 1999). 
 
1.6.11 Are CMV-specific T cell expansions useful? 
It could be argued that expanded CMV-specific T cell clones have protective qualities, as 
severe CMV disease is rarely seen in the immune-competent host (Effros et al., 2005). 
However, rare reports of CMV disease in healthy individuals have been documented 
(Crowley et al., 2002, Eddleston et al., 1997, Wreghitt et al., 2003). It has also been 
suggested that highly differentiated T cells may have a suppressive function, as donor 
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specific CD8+CD28− T cells are often found in the blood of people with successful, stable, 
transplants, and are absent in those with acute rejection (Colovai et al., 2003, Liu et al., 
1998). However, a suppressive role may also explain their association with relatively 
poor responses of the old to influenza vaccination (Effros et al., 2005, Song et al., 2010). 
Furthermore, older individuals have higher numbers of CD8+ T cells specific for CMV, but 
these have been shown to have significantly decreased secretion of IFN-γ and IL-10 
when compared to those in the young (Ouyang et al., 2004, Khan et al., 2004). This 
questions the benefit of having an expanded CMV-specific T cell population. 
1.6.12 The Impact of T cell expansions 
Age-related susceptibility to infection and increased incidences in reactivation of latent 
microorganisms have been documented in the old (section 1.1.4). T cells specific for 
viruses that are infrequently occurring e.g. vaccinia or influenza, or those less accessible 
to lymphocytes e.g. latent HSV may be at risk of being lost from the T cell pool through 
age-dependent changes (section 1.4). One theory is TCEs may cause the squeezing out 
of other T cell specificities through competition for space and growth factors (Akbar et 
al., 2004, Ouyang et al., 2004). A number of reports support this ‘immune space theory’. 
In mice, those with TCEs have poor responses to HSV challenge, with greater disease 
severity than those without TCEs (Messaoudi et al., 2004). In rhesus monkeys, those 
with TCEs had poor vaccine responses to Vaccinia, compared to those without TCEs 
(Cicin-Sain et al., 2010). 
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1.6.13 CMV, inflammation and the Inflamm-ageing hypothesis 
The inflamm-ageing hypothesis proposes that immune senescence is associated with 
chronic inflammation, driven by chronic antigenic load (Franceschi et al., 2000, De 
Martinis et al., 2005). CMV is therefore an obvious candidate in this hypothesis, and 
evidence to support the involvement of CMV in exacerbating inflammation is abundant 
(Freeman, 2009, Schmaltz et al., 2005, Simanek et al., 2011, Soderberg-Naucler, 2006, 
Wikby et al., 2006). Active CMV replication has also been found at sites of inflammation, 
including atherosclerotic plaques, vascular lesions of coronary transplant vasculopathy, 
and during inflammatory bowel disease (IBS), arthritis, Sjögren’s Syndrome, Hashimoto’s 
thyroiditis, and systemic lupus erythematosus  (Freeman, 2009, Soderberg-Naucler, 
2006). One of the most frequently reported associations is between CMV and increased 
risk of mortality from cardiovascular disease (Simanek et al., 2011, Roberts et al., 2010, 
Blankenberg et al., 2001). Although, whether CMV causes inflammation or is simply a 
bystander to inflammation is difficult to determine. To illustrate this point, the 
reactivation of latent CMV within monocytes can be initiated by the differentiation of 
monocytes to macrophages as a result of inflammatory mediators including TNF-α and 
IFN-γ (Sinclair, 2008, Soderberg-Naucler, 2006).  
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1.7 Aims 
Evidence suggests CMV may accelerate immune senescence, and it is hypothesised the 
accumulation of CMV-specific CD8+ T cell expansions (TCEs) during ageing may be 
instrumental in this association. The purpose of this thesis was to address this 
hypothesis. The specific aims of this project were to: 
 
1. Phenotypically characterise CD8+ and CMV-specific CD8+ TCEs according to age. 
2. Investigate the impact of CMV infection on the rate of telomere length attrition 
during ageing. 
3. Investigate how CMV-specific CD8+ TCEs may be generated. 
4. Investigate the functional quality of CMV-specific TCEs with ageing. 
 
 
 
 
 
 
 
 
 
 
 
  
61 
 
2 General Materials and Methods 
 
2.1 Donors  
 
2.1.1 Donors and Blood sample collection 
Whole blood (between 10-80ml) was collected in standard heparinised tubes from 
healthy volunteers. Where data is stratified by age, young is defined as donors between 
18-35 years and old donors between 65-95 years. All samples were obtained according 
to the ethical committee of the Royal Free and University College Medical School. 
Donors did not have any co-morbidity and were not on any immunosuppressive drugs, 
they also retained physical mobility and lifestyle independence. 
2.1.2 PBMC isolation 
Whole blood was collected in standard heparinised tubes and diluted 1:1 with Hanks 
Balanced Salt Solution (HBSS, Life Technologies, Paisley, UK). 20ml of Ficoll (Amersham 
Biosciences. Uppsala, Sweden) was added to a 50ml tube and 25 ml of the whole 
blood/HBSS mix was gently layered on top of the Ficoll surface. These tubes were then 
centrifuged for 20 minutes at 800xg without any break. Subsequently, the white PMBC 
layer formed was then extracted carefully with a pasteurette and placed into a new 50 
ml tube. This was filled to the 50ml mark with HBSS and centrifuged for 10 minutes at 
650xg with the break at position 2. Supernatant was decanted and cell pellet washed 
again with 50mls of HBSS for 10min at 350xg. Supernatant was then discarded and 
PBMC pellet re-suspend in complete medium (RPMI, 100 IU Penicillin, 100 μg/ml 
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streptomycin, 2mM L-glutamine, and 10% foetal calf serum (FCS) [Life Technologies]) 
and centrifuged for 5 minutes at 650xg. Finally the supernatant was discarded and an 
appropriate volume of complete medium added for counting. 
2.1.3 Determination of donor CMV status 
The CMV status of donors was obtained by stimulation of freshly isolated PBMCs 
(section 2.1.2) with a CMV viral lysate preparation (Fletcher et al., 2005). CMV viral 
lysate was prepared by infecting human embroyonic lung fibroblasts with the Towne 
strain of CMV at multiplicity of infection of 2. After 5 days, infected cells were lysed by 
freeze-thaw cycles. Upon production of the viral lysate, and when a new batch was 
prepared, a titrating stimulation was performed to determine peak IFN-γ production 
and therefore the volume of lysate used for stimulation.  
 
For the stimulation, three sterile polypropylene tubes each containing 1x106 PBMCs 
were prepared. To these were added either a Staphylococcal Enterotoxin B (SEB) lysate 
(SEB; Sigma-Aldrich, Dorset, UK) for a positive control, a CMV lysate, or an un-stimulated 
control as a guide for delineating positive and negative populations. All tubes were then 
placed at 37°C for 2hrs at which point Brefeldin A was added and samples left for a 
further 12 hrs. Brefeldin A is a fungal metabolite that enhances the staining of 
intracellular cytokines by interfering with the vesicular transport of cytokines from the 
rough ER to the golgi complex. This prevents their secretion in antigen activated T cells 
and instead makes their identification possible. The cells were then surface stained with 
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anti-CD4, and then intracellularly stained with anti-IFN-γ, as described in section 2.2.3. 
Uninfected cell lysates did not induce any IFN-γ secretion and there was significant 
concordance between an IFN-γ+ response and seropositivity obtained from routine 
hospital IgG titres (Fletcher et al., 2005). 
 
2.1.4 Viable Cell Count 
Cell suspensions were diluted 1:1 with 0.4% trypan blue (Sigma) and 8μl was inserted 
beneath the cover slip on an improved Neubauer chamber (Weber Scientific, UK 
Materials) and total cell counts estimated from the mean of 3 grid sample counts. Dead 
cells were stained blue and were therefore excluded from the counts. 
2.1.5 Cryopreservation of PBMCs.  
Cells were frozen at 107/ml/cryo-vial. After centrifuging cells for 5 mins @650xg and 
removing all medium, 0.5ml of FCS was added to cell pellet, which was re-suspended 
and then added to a 1ml cryo-vial and placed in the fridge for 10 minutes. 0.5ml of 
freezing mix (20% dimehtylsulphoxide [DMSO] in FCS) was added to the 0.5ml cryo-vial 
containing cells, mixed gently and left in fridge for 20 minutes. Cells were stored inside a 
passive freezer (MR. FROSTY by Nalgene) containing isopropyl alcohol and then placed 
at –80oC overnight. Finally, the cryo-vials were transferred to liquid nitrogen for long-
term storage. Frozen PBMCs were thawed quickly by exposing to warm medium then 
being diluted with warm medium and centrifuged immediately for 5 mins @650xg. 
 
  
64 
 
2.2 Flow Cytometric Analysis 
The details and concentrations of the antibodies used in the following sections are 
summarised in table 2.1: 
 
 
Antigen Source Clone Isotype Concentration 
CD8-FITC BD SK1 mIgG1 10 
CD8-PerCP BD SK1 mIgG1 10 
CD27-FITC BD M-T271 mIgG1 10 
CD27-PE BD M-T271 mIgG1 10 
CD27-APC eBiosciences O323 mIgG1 5 
Ki67-FITC BD B56 mIgG1 10 
Bcl-2-FITC BD B56 mIgG1 12 
HLA-A2-PE AbD Serotec BB7.2 mIgG1 10 
HLA-B7-FITC AbD Serotec BB7.1 mIgG1 10 
IFNγ-FITC Cedarlane B27 mIgG2b 1 
CD45RA-APC Invitrogen MEM-56 mIgG2b 5 
CD45RA-PE-Cy7 BD L48 mIgG1 3 
CD45RO-APC Invitrogen MEM-56 mIgG2b 5 
CD4-Biotin Immunotech 13B8.2 mIgG1 1 
Table 2-1. Details and concentrations of antibodies used 
Concentrations shown are amount added (μl) per 100μl of 10
6
 resuspended cells  
 
2.2.1 Surface staining PBMCs 
Following PBMC isolation (section 2.1.2), cell phenotype was analysed by flow-
cytometry using a combination of antibodies. Staining was conducted for 30mins at 4°C 
and washed in PBS (650xg for 5min). Samples were then fixed with 2% 
paraformaldehyde and acquired on either the BD FACs Calibur or BD LSR/LSRII using cell 
quest or DIVA software respectively. 
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2.2.2 Tetramer staining 
Tetramer staining was conducted on Human leukocyte Antigen (HLA) matched donor 
PBMCs with either HLA-A*02 or HLA-B*07 positive individuals using tetramers loaded 
with CMVpp65 NLVPMVATV or TPRVTGGGAM peptide respectively (a gift from 
P.Klenerman, Oxford University). PBMCs were isolated (as discussed in section 2.1.2) 
and cells suspended in approx. 106 cells per 100μl. 1μl of tetramer was added per tube 
and incubated at 37°C for 20mins, then washed in PBS (650xg for 5min). Cells were then 
surface stained with CD8-PerCP and any other antibodies indicated and/or 
intracellularly stained in accordance with protocols in sections 2.2.1or 2.2.3 respectively.  
2.2.3 Intracellular staining 
Intracellular staining for the detection of IFN-γ was performed using the caltag fixation 
and permeabilisation kit (Caltag Laboratories, Paisley, UK). Approximately 106 cells were 
suspended in 100μl of PBSA (PBS containing 1% bovine serum albumin, BSA) in a FACS 
tube. Cells were surface stained with anti-CD4 antibody at 4 C in the dark for 30mins. 
Cells were then washed in PBSA by centrifuge at 650xg for 5min, wash discarded and 
cells resuspended in 100μl solution A and incubated at room temperature for 15 mins. 
Cells were then washed in PBSA by centrifuge at 650xg for 5min, wash discarded and 
cells resuspended in 100μl solution B containing 1μl IFN-γ APC and incubated at room 
temperature for 15 mins. This was followed by one final wash in PBSA by centrifuge at 
650xg for 5min, and finally resuspended in 300μl 2% PF for FACs analysis. 
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2.2.4 Intranuclear staining 
Ki-67, γ-H2AX and Bcl-2 staining was performed using the intranuclear Miltenyi FoxP3 
Buffer Staining kit (Miltenyi Biotec, Surrey, UK). Approximately 106 cells were suspended 
in 100μl of a suitable medium in a FACS tube. If the donor was a CMV positive HLA 
match tetramer staining was first conducted (section 2.2.2). If they were not, or 
following tetramer staining cells were then surface stained with anti-CD8, anti-CD27 and 
anti-CD45RA at 4 C in the dark for 30mins. Cells are then washed in 1ml cold PBS by 
centrifuge at 650xg for 5min and resuspended in 1ml Fix/Perm solution (mix 
concentrate and diluent 1:3) and incubated at 4 C in the dark for 30mins. Cells are then 
washed in 1ml PBS by centrifuge at 650xg for 5min, wash discarded and 3ml Perm buffer 
added (dilute 1 in 10 in distilled water). The tubes were vortexed centrifuged at 650xg 
for 5min to pellet cells. This wash was repeated with 1ml Perm buffer/tube and excess 
liquid from the tubes blotted using tissue. Antibodies for Ki67-FITC, γ-H2AX-FITC or BCl2-
FITC were then added to the relevant tubes together with isotype controls and 
incubated at 4 C, in the dark for 30mins. Following incubation, cells are washed in 1ml 
Perm buffer twice and finally resuspended in 300μl 2% PF for FACs analysis. Positive 
populations are identified by gating on relevant isotype controls (table 2.1). 
 
2.3 Isolation and sorting of populations from PBMCs 
 
2.3.1 Negative selection of CD8+ T cells using MACS isolation kit. 
Magnetic Cell Sorting (MACS, Miltenyi Biotec, Surrey, UK) allows the purification of cell 
subsets from complex cell mixtures. MACS Buffer (1 x PBS containing 0.5% BSA (5g/litre, 
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stored in cold room) and 2mM EDTA (4ml of 0.5M stock) was first prepared then filtered 
and degassed (in 50ml aliquots) before use and kept at 4 C or on ice. Degassing took 
approximately 10 minutes from room temp or 30 minutes from 4 C. PBMCs were 
extracted from whole blood (as described in 2.1.2) then washed in MACS buffer by 
centrifuge @1800rpm for 5mins. Subsequently, the supernatant was decanted 
completely and the cell pellet resuspended in 40 l buffer per 107 cells. 10 l biotin-
Antibody cocktail was added per 107 cells then mixed and incubated for 10mins at 4 C. 
30 l buffer per 107 cells and 20 l anti-biotin beads per 107 cells were then added, mixed 
well and incubated for 15mins at 4 C. Cells were then washed with 1ml MACS buffer 
and supernatant decanted completely. Cell pellet was then resuspended in 500 l MACS 
buffer per 108 cells (500 l if less cells). Appropriate column size was selected (MS 
selected for max number of labelled cells being 107 or LS for maximum number of 
labelled cells being 108) and placed in the magnetic field of the MACS separator. The 
column was prepared by washing with either 3ml (LS) or 500 l (MS) of buffer. The cell 
suspension was applied onto the column and effluent collected, these were the 
unlabelled cells, representing the enriched CD4+ or CD8+ T cell fraction. Finally, the 
column was washed with 3 x 3ml (LS) or 3 x 500 l (MS) and the total effluent collected. 
An aliquot was removed at this point to check cell purity. Cells retained on the column 
can be used as APC. In this event the column was removed from the magnet and placed 
in a suitable collection tube, followed by pipetting either 5ml (LS) or 1ml (MS) of buffer 
onto the column and immediately flushing out the cells by firmly applying the plunger 
supplied with the column. 
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2.4 Measurement of telomere length and telomerase activity 
 
2.4.1 Telomere length via Flow-FISH 
PBMCs were stained using CD4-biotin (Immunotech) and streptavidin-Cy3 (Cedarlane 
Laboratories) or combinations of CD8-FITC, CD45RO-FITC (BD Biosciences), CD8-Q565, 
CD45RA-Q605 (invitrogen) then fixed with BS3 (Pierce). Cells were washed once in 
hybridization buffer (70% formamide, 20 mM Tris, 150 mM NaCl, and 1% BSA) and then 
incubated at 82°C for 10 min with 0.75 µg/ml Cy5-conjugated telomeric (CCCTAA) 
peptide nucleic acid probe (Applied Biosystems). After rapid cooling on ice, the samples 
were hybridized for 1 h at room temperature in the dark, washed twice each in 
posthybridization buffer (70% formamide, 10 mM Tris, 150 mM NaCl, 0.1% BSA, and 
0.1% Tween 20) and PBSA, and analyzed by flow cytometry.  
 
Samples were analyzed with and without probe to control for differences in background 
fluorescence between samples. To ensure consistency of the results between 
experiments, two cryopreserved PBMC samples with known telomere fluorescence were 
used as standards. Results were obtained as median fluorescence intensity values, which 
could then be converted to telomere length in kilobases using a standard curve. The 
standard curve was constructed using 30 samples of varying telomere length analyzed 
both by flow-FISH and telomeric restriction fragment (TRF) analysis.  
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2.4.2 Measuring telomere length in CMVpp65-specific cells 
To measure telomere length of CMVpp65-specific CD8+ T cells, a modified form of the 
Flow-FISH technique (section 2.4.1) was used; phenotyping was performed using 
CMVpp65-specific biotin labelled pentamer (Proimmune) according to manufacturers 
guidelines, then a second layer staining with streptavidin-Q800 (Invitrogen) in 
combination with CD45RA-Q605, CD8-FITC or CD45RO-FITC. Cells were then fixed with 
BS3 (Pierce) and the protocol detailed in section 2.4.1, post BS3 staining, was then 
continued. 
2.4.3 Measuring telomerase activity – the TRAP assay 
Sorted cell populations (2 x 105 cells) were activated with either OKT3 (0.5μg/ml) or 
CMV peptide (2pg/ml) plus irradiated autologous APCs for 4 days. Following activation 
an aliquot of 104 cells were stained for Ki67 positivity. The remaining cells were 
centrifuged (650xg for 5min) to pellet, any medium aspirated and snap-frozen (using 
liquid nitrogen). Telomerase activity was determined using the telomeric repeat 
amplification protocol (TRAP; TRAPeze telomerase detection kit; Serologicals) as 
previously described (Plunkett et al., 2007). Briefly, cell extracts were obtained by 
treating pellets with lysis buffer. Subsequently, PCR was performed with samples 
adjusted to 500 Ki67+ T cells per reaction (Reed et al., 2004). Telomeric elongation was 
performed using a *γ-P32] ATP-end-labelled telomerase substrate (TS) primer. These 
samples were then amplified by PCR amplification, using 25 to 28 cycles of 30s at 94°C 
and 30s at 59°C. The PCR products were run on a 12% polyacrylamide gel (Sigma-
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Aldrich) that was then exposed to an autoradiography film (Hyperfilm MP, Amersham). 
Telomerase activity was calculated as a ratio between the optical density of the 
telomeric repeat bands and one of the internal standard band.  
2.5 Functional analysis 
 
2.5.1 CD8+ T cell subpopulation multiparametric flow cytometry 
Multiparametric flow cytometry on total CD8+ T cells was conducted at the Brighton and 
Sussex Medical School (BSMS) in collaboration with Professor Kern. The expression of 
the functional markers CD40L, IFN-γ, IL-2 and TNF-α by CD8+ CD45RA/CD27 T cell 
subpopulations was assessed following stimulation of total PBMCs with OKT3 (0.5μg/ml) 
in the presence of brefeldin A for 16 hours. Boolean gating analysis was used to 
determine polyfunctionality of each CD8+ T cell subpopulation (Harari et al., 2007). 
 
2.5.2 Activation responses of CD45RA vs. CD45RO CMV-specific CD8+ T cells 
A CD8+ fraction was collected by negative MACs selection (detailed in section 2.3.1). The 
non-CD8 fraction was retained for use as APCs; half of which were pulsed with medium 
containing CMVpp65 NLVPMVATV (NLV) peptide (Proimmune) for 1hr at 37C and the 
other half of cells with medium only, before both populations were then irradiated. 
Meanwhile the CD8+ subset was stained with CD45RA-APC (Caltag) and CD45RO-FITC 
(Dako) and sorted to give CD45RA and CD45RO subpopulations of greater than 95% 
purity using a BD FACS Aria. 200,000 cells of each population were then placed in sterile 
FACs tubes and irradiated APCs added back at cell ratios of 2:1, 1:1, 1:2, and 1:4. 
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Additionally APCs not pulsed with NLV were added at 1:1, and an un-stimulated control 
(cells plus medium only) was also included. After 2hr incubation at 37°C, BFA was added 
and cells incubated for a further 4hrs. Following stimulation, PBMCs were then stained 
intracellularly with IFNγ Pe-Cy7 (BD Biosciences) as described previously in section 2.3.3. 
2.5.3 Polyfunctionality of normal vs. high avidity CMV-specific CD8+ T cells 
Polyfunctional response of CMVpp65-specific CD8+ T cells was performed by staining 
whole PBMCs first with either normal or mutated (null) tetramer and CD107a for 2hrs at 
37°C. This was followed by the addition of pp65 peptide at concentrations of 0, 0.001, 
0.01, 0.1 and 1ug/ml in the presence of Monensin and Brefeldin A for a further 4 hours 
at 37°C. Following stimulation, PBMCs were then stained intracellularly with IFNγ Pe-Cy7 
and TNF-α APC (BD Biosciences) as described in section 2.2.3.  
2.6 IL-15 experiments 
 
2.6.1 CD45RA re-expression experiments 
PBMCs were isolated (section 2.1.2) then a CD8 positive fraction was collected by 
magnetic bead separation (MACS) as previously described (2.2.1). One of two reversion 
experiments was then conducted to investigate CD45RA re-expression: 1) using four 
CD8+ T cell subpopulation determined by CD45RA and CD27 and 2) using two CMV-
specific CD8+ T cell subpopulations determined by CD45RA and CD45RO. For the first 
experiment CD8+ T cells were stained with CD45RA-APC (Caltag) and CD27-FITC (BD 
biosciences) and sorted using a BD FACs Aria to yield the four CD8+ T cell 
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subpopulations: CD45RA+CD27+; CD45RA+CD27-; CD45RA-CD27+, and CD45RA-CD27-. For 
the second experiment CD8+ T cells were stained with CD45RA-APC (Caltag) and sorted 
using a BD FACs Aria to yield a CD45RA negative fraction. Each subpopulation was 
individually cultured with IL-15 (10U) in a 96 well round bottom plate at a concentration 
of 100,000 cells per well for up to 21 days. On days 0, 1, 4, 9, 14 and 21 (depending on 
cell numbers) post IL-15 addition, one well of cells was harvested and viable cell 
numbers counted to determine cell expansion. Cells were then stained as outlined (2.2.1 
and 2.2.2) for total CD8+ T cell subpopulations (CD45RA and CD27) or CMV-specific CD8+ 
T cell subpopulations (CD45RA and CD45RO). 
2.6.2 Measuring IL-15 mRNA following treatment with CMV lysate or IFN-α 
The mRNA level of IL-15 was measured in total PBMCs before (directly ex-vivo) and after 
4hrs, 24hrs, 48hrs, and 72hrs of culture in the presence of the lysate from CMV-infected 
cells (1:10 of stock solution of 0.64mg/ml). Additionally, mRNA levels of IL-15 were also 
measured in total PBMCs before (directly ex-vivo) and after 4, 24 and 48 hours of culture 
in the presence of different concentration of IFN-α (Alpha 2a, 11100-1 from PBL 
Interferon source) ranging from 100U/ml to 1000 U/ml. Total RNA was purified with 
RNeasy columns (Qiagen). Reverse transcription was performed with random primers 
using the MuLVRT reverse transcriptase (Invitrogen) to generate cDNA. The mRNA level 
of IL-15 was then determined using cDNA by real-time quantitative PCR (RT-qPCR) on an 
ABI PRISM 7500, with TaqMan Gene Expression Master Mix according to manufacturer 
protocol (Applied Biosystems), with the TaqMan primers for IL-15 primers 
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(Hs99999039_m1). The housekeeping 18S mRNA was amplified from the same cDNA 
reaction mixture using the TaqMan primers for human 18S (Hs03928985_g1*). Each 
sample was run in triplicate and target mRNA level was expressed as a ratio to the level 
of 18S to control for differing levels of cDNA in each sample.  
2.7 Statistical Analysis 
 
Graph Pad Prism v5 was used to construct all graphs, dot plots and bar charts. The 
D'Agostino-Pearson omnibus K2 normality test was used to determine if data fitted a 
Gaussian (normal) distribution. Statistical significance was evaluated using the Student’s 
t test if data followed a normal distribution and if data was also paired it was assessed 
using a Student’s paired t test. Unpaired non-parametric data was evaluated using a 
Mann-Whitney U test, with a Wilcoxon matched paired test used if data points 
represented paired observations. All t tests performed were as two-tailed unless 
otherwise stated. All p-values ≤0.05 were regarded as significant. 
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3 Phenotyping CD8+ and CMV-specific CD8+ T cells according 
to age 
 
3.1 Introduction 
Longitudinal studies measuring various immunological parameters in the very old have 
revealed a group of biomarkers defining an immune risk phenotype (IRP) that is 
associated with a decreased survival rate in the very old (section 1.4.9). Cytomegalovirus 
(CMV) seropositivity was one of the significant factors identified. It has been proposed 
that this could be due to CMV infected individuals having large and persistent CMV-
specific T cell expansions (TCEs), which may contribute to the inversion of the CD4/CD8 
ratio and acceleration of T cell differentiation. CMV has therefore been identified as a 
key factor in driving immune senescence of the T cell pool (discussed in section 1.6).  
 
3.2 Aims 
The aim of this chapter was two-fold; to investigate how CMV influences the natural 
age-related changes seen within the CD8 compartment, and secondly, to uncover how 
CMV-specific TCEs may accumulate. This was achieved by phenotyping CD8+ T cells and 
CMV-specific CD8+ T cells directly ex-vivo from a cohort of healthy donors over a wide 
age range. Phenotyping determined the differentiation status of CD8+ T cells by the 
expression of CD45RA and CD27; giving the four distinct CD8+ T cell subpopulations (as 
described in section 1.3). The frequency of these subpopulations, their relative rate of 
proliferation and relative susceptibility to apoptosis was investigated in all donors and 
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stratified on the basis of age and CMV status, to uncover any statistically significant 
associations.  
 
3.3 Results 
 
3.3.1 Selecting suitable donors and steps for phenotypic analysis 
Figure 3.1 outlines the selection process for donors. Further information can be found in 
the materials and methods section in chapter 2. Briefly, healthy donor volunteers were 
first recruited according to an exclusion criterion: all subjects were mobile, did not have 
any cognitive impairment, were not suffering from acute or chronic illness, and were not 
on medication known to affect the immune system. Fresh PBMCs from these healthy 
individuals were isolated and stimulated overnight with CMV lysate to identify those 
that were CMV positive (figure 3.2A). Those who were CMV positive were further 
screened to determine their suitability for CMV-specific CD8+ T cell analysis using 
tetramers. The tetramers chosen for use in this thesis were specific for the pp65 matrix 
protein of CMV. CMVpp65 was chosen as it is readily targeted by the immune system 
and is considered the most immunodominant of the CMV epitopes (Kern et al., 2002, 
Moss and Khan, 2004, Wills et al., 1996). Individuals who were HLA-A*02 or HLA-B*07 
positive (the most common European alleles) were therefore selected as suitable for 
staining with the NLVPMVATV (NLV) or TPRVTGGGAM (TPR) CMVpp65-specific 
tetramers respectively (figure 3.2B).  
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Figure 3-1. Donor selection process 
Healthy donor volunteers are recruited and those not meeting the healthy criteria excluded. An initial 
blood sample is taken and fresh PBMCs isolated and stimulated overnight with CMV lysate, to determine 
CMV status. Those that are CMV positive are further screened for HLA-A*02 or HLA-B*07 match, using 
antibodies specific for these two antigens, in combination with CD8. HLA-A*02 or HLA-B*07 matched 
donors are therefore suitable for subsequent analysis using NLVPMVATV (NLV) or TPRVTGGGAM (TPR) 
CMVpp65-specific tetramers respectively. 
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(A) 
 
 (B) 
 
 
 
Figure 3-2. CMV positive screening and selection for tetramer analysis  
(A) CMV positivity was determined by stimulating total PBMCs with either CMV lysate, an S.E.B positive 
control and un-stimulated (U.S) negative control. Following stimulation PBMCs were stained with CD4 and 
IFN-γ antibodies. A CMV positive donor (top) shows IFN-γ
+
 cell numbers above background (U.S) 
compared with a CMV negative individual (bottom). Both donors show IFN-γ
+
 cells to S.E.B. (B) individuals 
suitable for tetramer analysis were HLA-A*02 or HLA-B*07 matches and subsequently used for staining 
with NLV or TPR tetramers respectively. 
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3.3.2 Investigating the differentiation status of CD8+ T cells 
A larger number of highly differentiated CD8+ T cells have been reported in older 
humans (Effros et al., 2005, Akbar and Fletcher, 2005) and CMV-specific CD8+ T cells 
show a high degree of differentiation compared with most other virus-specific CD8+ T 
cells (Appay et al., 2002). Therefore the impact of age and CMV serostatus was 
investigated on the CD8+ T cell subpopulations in our healthy donors.  
 
3.3.2.1 Differentiation of CD8+ T cells by CD45RA and CD27 expression 
Donor PBMCs were stained with antibodies to CD8, CD45RA and CD27 to identify the 
four CD8+ T cell subpopulations as discussed in section 1.3: 
 
CD45RA+CD27+  =  Naive (TN)  
CD45RA-CD27+  =  Central Memory (TCM)  
CD45RA-CD27-  =  Effector Memory (TEM)  
CD45RA+CD27-  =  Effector Memory CD45RA re-expressing (TEMRA)  
 
A representative example of how these subpopulations were identified is shown in 
figure 3.3. Briefly, CD8+ T cell subpopulations were identified first by plotting size 
(forward scatter, FSC) versus granularity (side scatter, SSC) to identify the live 
lymphocyte population (L) from monocytes (M), highly granular cells (G) and cellular 
debris (D). Upon gating on live lymphocytes a CD8high subset was then identified, 
separating it from CD4+ T cells, B cells and natural killer (NK) cells (Trimble et al., 2000). 
Finally the CD8+ T cell compartment was dissected via CD45RA and CD27 expression to 
identify the four CD8+ T cell subpopulations of interest. 
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Figure 3-3. Gating method to identify CD8
+
 T cell subpopulations from PBMCs 
See text for details. Arrows displayed within the FACs plot analysis on the four subpopulations (right) 
denote possible differentiation pathways. Abbreviations: live lymphocytes (L); Granulocytes (G); 
Monocytes (M); Dead cells (D); Naive (TN); Central Memory (TCM); Effector Memory (TEM); and Effector 
Memory CD45RA re-expressing (TEMRA). 
 
3.3.2.2 CD8+ T cell subpopulation profiles by age group 
Representative examples of healthy donor CD8+ T cell subpopulation profiles in the 
three defined age groups: young (<35 years old); middle (35 to 65 years old) and old 
(>65 years old) are shown in figure 3.4. CD8+ T cells in young individuals showed a 
predominately early differentiated profile i.e. CD45RA+CD27+ phenotype, compared 
with old individuals which showed a predominately late differentiated profile i.e. 
CD45RA+CD27- phenotype. 
 
 
Figure 3-4. Representative density plots of CD8
+
 T cell subpopulation profiles by age group 
Density plots of healthy donor CD8 differentiation profiles as based on CD45RA and CD27 expression. 
Numbers in quadrants represent the percentage of the relevant subpopulation within total CD8
+
 T cell 
compartment. Young individuals are defined as under 35 and old individuals as over 65years of age. 
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3.3.2.3 Age-related differentiation of CD8+ T cells 
The frequency of each subpopulation, as a percentage of the total CD8 compartment, 
was recorded for all donors (figures 3.5–3.8). In total, 125 healthy donors aged between 
22 to 95 were analysed, with a CMV seropositivity rate of 73%. This CMV seroprevalence 
rate is consistent with reports (Cannon et al., 2010).  
 
A line of best fit was generated by linear regression analysis and the correlation 
assessed by Pearson and Spearman rank (GraphPad Prism) for each CD8+ T cell 
subpopulation. The CD45RA+CD27+ (Naive, TN) subpopulation (figure 3.5A) was found to 
significantly decrease with age (p<0.0001, R2=0.588) whereas there was no significant 
age-related change observed with the CD45RA-CD27+ (Central Memory, TCM) 
subpopulation (figure 3.6A). However, the late differentiated CD45RA-CD27- (Effector 
Memory, TEM) and CD45RA
+CD27- (Effector Memory CD45RA re-expressing, TEMRA) 
subpopulations (figures 3.7A & 3.8A respectively) significantly increased with age 
(p=0.0014, R2=0.798 and p<0.0001, R2=0.350 respectively).  
 
3.3.2.4 CMV accelerates age-related differentiation of CD8+ T cells 
To investigate the influence of age and CMV seropositivity as statistically independent 
factors upon CD8+ T cell subpopulations, data was further analysed in two ways: firstly 
by dividing the data into either the young or old age group and on the basis of CMV 
serostatus, and secondly by performing multiple linear regression analysis.  
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When dividing data into young (<35) or old (>65) age groups and on the basis of CMV 
serostatus, CMV+ young individuals had significantly less CD8+ TN cells than CMV
- young 
individuals (p=0.0007, figure 3.5B). Both CMV+ groups also had significantly more CD8+ 
TEMRA cells compared with the CMV
- groups (young p=0.001 and old p=0.002, figure 
3.8B).  
 
Multiple linear regression analysis was performed by SPSS software and revealed a 
highly significant relationship between the decrease in CD8+ TN cells and increase in 
CD8+ TEMRA cells with either age or CMV serostatus as independent factors (p<0.0001, 
figures 3.5C and 3.8C). There was also significant increases in CD8+ TEM cells with age or 
CMV serostatus (p=0.04 and p=0.007 respectively, figure 3.7C) and a significant 
decrease in CD8+ TCM cells with CMV serostatus (p=0.01, figure 3.6C), but not with age.  
 
Overall, results showed both age and CMV serostatus significantly impacts the CD8+ T 
cell compartment. However, the most significant changes were a decrease in CD8+ TN 
cells and an increase in the highly differentiated CD8+ TEMRA cells. 
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TN 
 
(A) 
 
(B) 
 
(C) 
 
 
 
 
 
unstandardized  
coefficient 
P-value 
95.0% CI 
lower limit upper limit 
Age -0.59 <0.0001 -0.7 -0.49 
CMV status -15.62 <0.0001 -21.46 -9.77 
 
 
 
Figure 3-5. Distribution of naive (CD45RA
+
CD27
+
) CD8
+
 T cells and the impact of age and CMV 
serostatus.  
(A) Pooled data showing the distribution of Naive (CD45RA
+
CD27
+
) CD8
+
 T cells defined as a percentage of 
the total CD8
+
 T cell compartment within all donors (125) as stratified by age. One dot represents one 
donor and line of best fit shown. (B) The same data shown by age group and CMV status, donors shown: 
CMV-(Y)=19; CMV+(Y)=15; CMV-(O)=7; CMV-(Y)=60 (C) Table showing the un-standardized coefficient, 
significance and 95% confidence interval from the output of SPSS software for Naive CD8
+
 T cells. Unit of 
age is equal to 1 year. *<0.05;**<0.005;***<0.0005. 
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TCM 
 
(A) 
 
(B) 
 
(C) 
 
 
 
unstandardized  
coefficient 
P-value 
95.0% CI 
lower limit upper limit 
Age -0.03 0.52 -0.12 0.06 
CMV status -6.18 0.01 -10.86 -1.49 
 
 
 
Figure 3-6. Distribution of central memory (CD45RA
-
CD27
+
) CD8
+
 T cells and the impact of age and CMV 
serostatus.  
(A) Pooled data showing the distribution of central memory (CD45RA
+
CD27
+
) CD8+ T cells defined as a 
percentage of the total CD8
+
 T cell compartment within all donors (125) as stratified by age. One dot 
represents one donor and line of best fit shown. (B) The same data shown by age group and CMV status. 
Donors shown: CMV-(Y)=19; CMV+(Y)=15; CMV-(O)=7; CMV-(Y)=60 (C) Table showing the un-standardized 
coefficient, significance and 95% confidence interval from the output of SPSS software for central memory 
CD8
+
 T cells. Unit of age is equal to 1 year. *<0.05;**<0.005;***<0.0005. 
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TEM 
 
(A) 
 
(B) 
 
(C) 
 
 
unstandardized  
coefficient 
P-value 
95.0% CI 
lower limit upper limit 
Age 0.125 0.04 0.005 0.24 
CMV status 9.05 0.007 2.58 15.53 
 
 
 
Figure 3-7. Distribution of effector memory (CD45RA
-
CD27
-
) CD8
+
 T cells and the impact of age and CMV 
serostatus.  
(A) Pooled data showing the distribution of effector memory (CD45RA
-
CD27
-
) CD8
+
 T cells defined as a 
percentage of the total CD8
+
 T cell compartment within all donors (125) as stratified by age. One dot 
represents one donor and line of best fit shown. (B) The same data shown by age group and CMV status. 
Donors shown: CMV-(Y)=19; CMV+(Y)=15; CMV-(O)=7; CMV-(Y)=60 (C) Table showing the un-standardized 
coefficient, significance and 95% confidence interval from the output of SPSS software for effector 
memory CD8
+
 T cells. Unit of age is equal to 1 year. *<0.05;**<0.005;***<0.0005. 
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TEMRA 
 
 (A) 
 
(B) 
 
(C) 
 
 
unstandardized  
coefficient 
P-value 
95.0% CI 
lower limit upper limit 
Age 0.385 <0.0001 0.27 0.5 
CMV status 14.77 <0.0001 8.43 21.11 
 
 
 
Figure 3-8. Distribution of effector memory CD45RA re-expressing (CD45RA
+
CD27
-
) CD8
+
 T cells and the 
impact of age and CMV serostatus.  
(A) Pooled data showing the distribution of effector memory CD45RA re-expressing (CD45RA
+
CD27
-
) CD8+ 
T cells defined as a percentage of the total CD8
+
 T cell compartment within all donors (125) as stratified by 
age. One dot represents one donor and line of best fit shown. (B) The same data shown by age group and 
CMV status. Donors shown: CMV-(Y)=19; CMV+(Y)=15; CMV-(O)=7; CMV-(Y)=60.  (C) Table showing the 
un-standardized coefficient, significance and 95% confidence interval from the output of SPSS software 
for effector memory CD45RA re-expressing CD8
+
 T cells. Unit of age is equal to 1 year. 
*<0.05;**<0.005;***<0.0005.. 
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3.3.3 CMV-specific CD8+ T cell expansion during ageing 
In the last section, a significant increase in CD8+ TEMRA cells with both age and CMV was 
revealed. However, it is unclear if it is the CMV-specific CD8+ TEMRA cells that largely 
account for the expansion of this subpopulation within CMV positive individuals. 
Therefore, the size and phenotype of the CMV-specific CD8+ T cell population was 
investigated. 
3.3.3.1 CMV-specific CD8+ T cells expands during ageing 
The CMVpp65-specific CD8+ T cell population has been reported to expand during 
ageing (Khan et al., 2002b, Koch et al., 2007). To verify this in our healthy cohort, all 
CMV positive donors suitable for analysis by tetramer staining were first identified (as 
discussed in 3.3.1). In total, 70 donors were suitable and the CMVpp65-specific 
compartment calculated as a percentage of their total CD8+ T cell compartment. Figure 
3.9A shows representative examples of the CMVpp65-specific CD8+ T cell population 
found within old versus young CMV positive individuals. Older CMV positive individuals 
were found to contain larger CMVpp65-specific CD8+ T cell expansions, being up to 28% 
of total CD8s, compared with younger CMV positive individuals. This was highlighted 
when data was pooled, and a significant positive correlation between donor age and 
size of the CMVpp65-specific compartment was revealed in total donors (p=0.002, 
R2=0.157, figure 3.9B), HLA-A*02+ donors targeting the NLV-specific epitope of 
CMVpp65 (p=0.028, R2=0.134, figure 3.9B) or HLA-B*07+ donors targeting the TPR-
specific epitope of CMVpp65 (p=0.019, R2=0.227, figure 3.9B).  
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(A)                                                                           
 
 
(B) 
 
 
(C)                                                                                       (D) 
 
 
Figure 3-9. The CMVpp65-specific CD8
+
 T cell population expands with age 
(A) Representative example of the CMVpp65-specific population identified by tetramer (NLV shown). 
Pooled data showing the size of the CMVpp65-specific population as a percentage of total CD8
+
 T cells is 
shown for total (B) from 70 donors and separately as NLV-specific population only (C) from 36 donors or 
TPR-specific population only (C) from 24 donors as stratified by age. One dot represents one donor and 
significant correlations are represented by asterisks; *<0.05;**<0.005;***<0.0005.. 
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3.3.3.2 CMV-specific CD8+ TEMRA cells dominate in older individuals 
The CMVpp65-specific population was analysed for the expression of CD45RA and CD27 
(figure 3.10). Older individuals frequently showed more highly differentiated CD8+ 
CMVpp65-specific T cell populations compared with younger individuals (figure 3.10A). 
When data was pooled, CD8+ CMVpp65-specific TEMRA cells occupied a significantly 
higher percentage of the CMV-specific compartment in the old age group compared 
with the young age group (p=0.004, figure 3.10B). Conversely, CD8+ CMVpp65-specific 
TCM and TEM cells occupied a significantly lower percentage of the population in the old 
age group compared with the young age group (p=0.002 and 0.025 respectively).  
 
To investigate further whether this represented significant expansions of the CD8+ CMV-
specific TEMRA cells in the old, the relative size of each CMV-specific CD8
+ T cell 
subpopulation was calculated as a percentage of total CD8+ T cell subpopulation, and of 
total CD8+ T cells, and compared by age group (figure 3.11 & 3.12 respectively). Both 
CMV-specific TEMRA and TN cells occupied a significantly larger proportion of total TEMRA 
and TN cells in older individuals compared with younger individuals (p=0.009 and 
p=0.0005 respectively) with no significant increase in TCM or TEM cells (figure 3.11). 
Furthermore, relative to total CD8+ T cells, both CMV-specific TEMRA and TN cells were 
significantly higher in older individuals compared with younger individuals (p=0.0006 
and p=0.008 respectively) with no significant increase in TCM or TEM cells (figure 3.12). 
Overall, results showed CD8+ CMVpp65-specific TEMRA cells dominated the CMVpp65-
specific CD8+ T cell compartment in older individuals. 
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(A) 
 
 
 
(B) 
 
 
 
 
 
 
Figure 3-10. Differentiation status of CMVpp65-specific CD8
+
 T cells in young and old donors.  
(A) Representative density plots of healthy donor CMV-specific CD8
+
 T cell differentiation on the basis of 
CD45RA and CD27 expression in young versus old age groups. Donor numbers shown are 12 young and 14 
old. Numbers in quadrants represent percentage of the subpopulation within the total CMV-specific CD8
+
 
T cell compartment. (B) Pooled data showing the distribution of subpopulations defined as a percentage 
of the total CMVpp65-specific CD8
+
 T cell compartment by age group. One dot represents one donor. 
Significant correlations represented by asterisks; *<0.05;**<0.005;***<0.0005. 
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Figure 3-11. Relative size of each CMVpp65-specific CD8
+
 T subpopulation as a percentage of total CD8+ 
T cell subpopulation in young and old donors. 
Pooled data showing the distribution of each CMV-specific T cell subpopulation as a percentage of the 
total CD8
+
 T cell subpopulation compartment by age group. Donor numbers shown are 12 young and 14 
old. One dot represents one donor. Significant correlations represented by asterisks; 
*<0.05;**<0.005;***<0.0005. 
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Figure 3-12. Relative size of CMVpp65-specific CD8
+
 T subpopulations as a percentage of total CD8+ T 
cells in young and old donors. 
Pooled data showing the distribution of subpopulations defined as a percentage of the total CD8
+
 T cell 
compartment by age group. Donor numbers shown are 12 young and 14 old. One dot represents one 
donor. Significant correlations represented by asterisks; *<0.05;**<0.005;***<0.0005. 
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3.3.4 Investigating the rate of proliferation by CD8+ TEMRA cells 
The simplest explanation for the expansion of CD8+ TEMRA cells would be an increase in 
their rate of proliferation relative to the other CD8+ T cell subpopulations. Therefore the 
proliferative rates of CD8+ and CMV-specific CD8+ T cell subpopulations were 
investigated. 
3.3.4.1 Using Ki-67 expression as a marker for proliferation 
Ki-67 protein is present during all active phases of the cell cycle (G1, S, G2 and mitosis) 
but is absent during cell resting (G0) and its expression is believed to be an absolute 
requirement for the progression to cell division (Scholzen and Gerdes, 2000). This makes 
the detection of Ki-67 antigen an excellent indicator of recent proliferative activity, and 
has been used extensively for such purposes (Kirik et al., 2009, Endl et al., 1997, 
Urruticoechea et al., 2005, Velu et al., 2009, Scholzen and Gerdes, 2000, Miles et al., 
2007, Roos et al., 2000, Wallace et al., 2010). 
 
If CD8+ TEMRA cells, and in particular CMVpp65-specific CD8
+ TEMRA cells, are proliferating 
at a high rate, this may be reflected by increased levels of Ki-67 protein present within 
this TEMRA cells, relative to the other CD8
+ T cell subpopulations. Intracellular staining for 
Ki-67 was therefore performed on donor PBMCs directly ex-vivo, without stimulation, in 
order to provide a ‘snap-shot’ indicative of the proliferative activity of each CD8+ T cell 
subpopulation in-vivo. 
 
  
93 
 
3.3.4.2 CD8+ TEMRA cells show low Ki-67 
Both the CD8+ and CMVpp65-specific CD8+ T cell subpopulations were analysed for the 
expression of Ki-67, as shown in the representative FACs plot analysis in figure 3.13. Ki-
67 positivity was analysed in total CD8+ and CMVpp65-specific CD8+ T cell 
subpopulations within 55 and 12 donors respectively (figures 3.14 & 3.15). When 
comparing overall Ki-67 positivity of the total CD8+ T cell compartment in individuals on 
the basis of their age and CMV serostatus (figure 3.14A) there was no significant 
difference between CMV positive and CMV negative individuals in either age group. 
However, there were increased Ki-67 levels in CD8+ T cells in the old CMV positive 
compared with young CMV positive age group. Additionally, no significant difference 
was observed for Ki-67 levels in total CD8+ T cells and total CMVpp65-specific CD8+ T 
cells within the same individuals, from a group of 12 donors (figure 3.14B). When 
comparing at the subpopulation level, Ki-67 levels were highest in the TCM and TEM 
subpopulations but relatively low in TEMRA cells in both the CD8
+ (figure 3.15A) and 
CMVpp65-specific CD8+ T cell subpopulations (figure 3.15B). Finally, further stratification 
of the Ki-67 data for each subpopulation by age and CMV status failed to reveal any 
significant associations (not shown).  
 
Overall, results showed CD8+ CMVpp65-specific T cells had low levels of Ki-67 positivity 
directly ex-vivo. Furthermore, CMV-specific CD8+ TEMRA cells did not show increased Ki-
67 levels over other subpopulations.  
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Figure 3-13. Representative example of Ki67 staining directly ex-vivo in one individual 
Representative FACs plot analysis of Ki-67 positivity in CD8
+
 (top) and CMVpp65-specific CD8
+
 (bottom) T 
cell subpopulations within the same individual. Numbers represent percentage positivity as indicated in 
quadrant. Gating is determined by using manufacturer supplied Ki-67 FITC IgG1 isotype control as shown. 
Example shown is representative of 12 donors.                 
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 (A)                                                   
 
 
 
 
(B) 
 
 
 
 
 
 
Figure 3-14.  Ki-67 within total CD8
+
 and CMVpp65-specific CD8
+
 T cells 
(A) Ki-67 positivity of total CD8
+
 T cells by age group and CMV serostatus. Donor numbers shown: CMV-
(Y)=8; CMV+(Y)=11;CMV-(O)=5;CMV+(O)=22. (B) Ki-67 positivity of total CD8
+
 versus total CMVpp65-
specific CD8
+
 T cells within 12 of the same individuals. One dot represents one donor. 
*<0.05;**<0.005;***<0.0005. 
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(A)                                                   
 
 
 
(B) 
 
 
 
 
Figure 3-15. Ki-67 within CD8
+
 and CMVpp65-specific CD8
+
 T cell subpopulations  
(A) Pooled data showing Ki-67 positivity of CD8
+
 T cell subpopulations. 55 donors tested. (B) Pooled data 
showing Ki-67 positivity within each CMVpp65-specific CD8
+
 T cell subpopulation. 12 donors tested. One 
dot represents one donor. *<0.05;**<0.005;***<0.0005. 
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3.3.5 Apoptosis resistance of CD8+ and CMVpp65-specific CD8+ T cells  
In the last section CD8+ TEMRA cells showed low levels of Ki-67 protein, indicating they are 
not undergoing or have not recently undergone proliferation. However, this 
subpopulation could instead be accumulating through a resistance to apoptosis. 
Apoptosis is a useful way of purging the clonally expanded memory CD8+ T cells 
following the clearance of an infection (Krammer et al., 2007), as discussed in section 
1.2.4. However, the reason why CMV-specific TCEs are not deleted but instead remain a 
stable population is not fully understood. The next step therefore was to compare the 
relative susceptibility to apoptosis exhibited by each subpopulation directly ex-vivo to 
uncover if CD8+ TEMRA cells, in particular confer a resistance to apoptosis. 
3.3.5.1 Bcl-2 expression as an indicator of susceptibility to apoptosis 
Bcl-2 is an anti-apoptotic protein which has been shown to induce pro-survival 
properties within T cells (Adams and Cory, 1998). Abnormally high levels of Bcl-2 within 
cells is associated with malignancy and a resistance to apoptosis (Cotter, 2009) whereas 
low level Bcl-2 expression is associated with cell death and a pro-apoptotic state (Chao 
and Korsmeyer, 1998). There are other indicators of cell death, associated with pro-
apoptotic or anti-apoptotic properties (as discussed in section 1.2.4), however the 
expression of Bcl-2 was chosen for analysis here as it is crucial for the survival of 
activated T cells (Scheel-Toellner et al., 2008) and has been used extensively elsewhere 
as a marker for T cell susceptibility to cell death (Aggarwal and Gupta, 1998, Doisne et 
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al., 2004, Libri et al., 2011, Miles et al., 2007, Salmon et al., 1994, Scheel-Toellner et al., 
2008, Schluns et al., 2000, Wallace et al., 2010). 
 
3.3.5.2 CD8+ TEMRA cells show little resistance to apoptosis 
Intracellular staining for Bcl-2 protein was performed on donor PBMCs directly ex-vivo. 
Both the CD8+ and CMVpp65-specific CD8+ T cell subpopulations were analysed for the 
expression of Bcl-2, as shown in the representative FACs plot analysis in figure 3.15. Bcl-
2 levels were analysed in total CD8+ and CMVpp65-specific CD8+ T cell subpopulations 
within 34 and 13 donors respectively (figures 3.16 & 3.17). When comparing Bcl-2 levels 
of the total CD8+ T cell compartment in individuals on the basis of their age group and 
CMV serostatus (figure 3.16A) no significant differences were uncovered. However, 
CMVpp65-specific CD8+ T cells did have significantly lower Bcl-2 levels than global CD8+ 
T cells when compared within the same individuals (p<0.0001; Figures 3.16B). Bcl-2 
expression was then compared in CD8+ (figure 3.17A) and CMVpp65-specific CD8+ 
(figure 3.17B) T cell subpopulations. Bcl-2 levels in CD8+ T cells decreased significantly 
from high to low in TN>TCM>TEM>TEMRA subpopulations respectively. In CMVpp65-specific 
CD8+ T cells, the TEM and TEMRA cells showed the lowest levels of BCl-2. 
 
Overall, the results showed that CD8+ and CMVpp65-specific CD8+ TEMRA cells are 
relatively susceptible to apoptosis compared to the other subpopulations, as based on 
Bcl-2 anti-apoptotic protein expression. Furthermore, CMV-specific CD8+ T cells showed 
significantly lower Bcl-2 expression than total CD8+ T cells within the same individuals. 
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Therefore, anti-apoptotic properties of CMV-specific CD8+ T cells, in particular the TEMRA 
cell subpopulation, are unlikely to be the cause for their persistence and expansion 
within the CD8 compartment.  
 
 
 
 
 
 
 
 
Figure 3-16. Bcl-2 staining directly ex-vivo 
Representative FACs plot analysis of Bcl-2 staining of CD8
+
 and CMVpp65-specific CD8
+
 T cell 
subpopulations within the same individual. BCl-2 levels are recorded following the adjustment of MFI to 
control sample MFI levels, in order to ensure consistency between acquisitions. Control sample MFI was 
determined by identifying a positive population gated against an IgG1 Isotype control. Numbers represent 
MFI in relevant histogram. Example shown is representative of 13 donors. 
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(A) 
  
 
 
 
(B) 
 
 
 
 
 
Figure 3-17. Bcl-2 levels in CD8
+
 and CMV-specific CD8
+
 T cells 
(A) Bcl-2 levels of total CD8
+
 T cells by age group and CMV serostatus. Donor numbers shown: CMV-(Y)=9; 
CMV+(Y)=12;CMV-(O)=5;CMV+(O)=9. (B) Bcl-2 levels of total CD8
+
 versus total CMVpp65-specific CD8
+
 T 
cells within 13 of the same individuals. One dot represents one donor. *<0.05;**<0.005;***<0.0005. 
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(A) 
  
 
 
(B) 
 
 
 
 
 
 
Figure 3-18.  Bcl-2 expression in CD8
+
 and CD8
+
 CMVpp65-specific T cell subpopulations  
(A) Pooled data showing Bcl-2 expression in CD8
+
 T cell subpopulations. 34 Donors analysed. (B) Pooled 
data showing Bcl-2 expression in CMVpp65-specific CD8
+
 T cell subpopulation. 13 donors analysed. One 
dot represents one donor. *<0.05;**<0.005;***<0.0005. 
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3.4 Discussion 
Data presented in this chapter highlights the impact of CMV infection upon global CD8 
populations within healthy individuals. CMV infection was found to exaggerate the 
natural age-related decrease in naive CD8+ T cells and increase in CD8+ TEMRA cells. This 
has recently been confirmed elsewhere (Chidrawar et al., 2009). Most importantly, 
results showed that as the CMV-specific CD8+ T cell pool expands with age, it becomes 
increasingly dominated by CMV-specific CD8+ TEMRA cells.  Therefore the aim of this 
chapter, to investigate how CMV-specific TCEs appear, became focused around this 
accumulating CMV-specific TEMRA subpopulation.  
 
To induce and maintain such a large population of CMV-specific T cells, chronic 
stimulation by antigen is thought to be necessary, suggesting CMV could be reactivating 
continuously (van Leeuwen et al., 2002).  However, Ki-67 analysis indicated CMV-specific 
CD8+ T cells, and CMV-specific CD8+ TEMRA cells in particular, show low level proliferation, 
not an increase, as would be expected and commensurate with their accumulation. Ki-
67 is indicative of current or recent proliferation by cells based on the presence of Ki-67 
protein, so therefore has its limitations. Another way to investigate proliferation would 
be by using the Carboxyfluorescein succinimidyl ester (CFSE) assay, which directly 
identifies dividing cells and can be used in combination with flow cytometry (Parish, 
1999). However, results presented here are consistent with observations that during 
active CMV infection, CMV-specific CD8+ T cells exhibit high Ki-67 positivity, whereas in 
convalescence Ki-67 levels are found to be comparable to global CD8+ T cells, despite 
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the CMV-specific population persisting (Miles et al., 2007). The authors also found it was 
during convalescence that the CMV-specific CD45RA+ memory population appeared. 
Furthermore, others investigating CMV-specific CD8+ T cell turnover during 
convalescence, using in-vivo labelling with deuterated glucose, shown CMVpp65-specific 
CD8+ T cells have lower uptake of deuterated glucose than background CD8s (Wallace et 
al., 2010), indicative of reduced proliferation despite the population being observed to 
persist within donors over the time-points sampled. One possibility therefore is that 
following an initial burst of proliferation, effector CMV-specific CD8+ T cells that are 
CD45RO+ during primary infection cease dividing and undergo a switch back to the 
CD45RA+ phenotype. 
 
Once generated, are the CMV-specific CD8+ TCEs therefore persisting through a 
resistance to apoptosis? The argument for the requirement of antigen to maintain 
memory cells is contradicted by findings that virus-specific CD8+ T cells can persist 
indefinitely after being adoptively transferred to a virus-free host (Hou et al., 1994, Lau 
et al., 1994). CMV-specific TCEs and in particular CMV-specific CD8+ TEMRA cells may 
therefore persist through a resistance to apoptosis rather than induction by CMV 
antigen. This was tested by investigating the expression of anti-apoptotic molecule Bcl-
2. There were no significant differences in Bcl-2 levels in CD8+ T cells found on the basis 
of age and CMV in our cohort, despite reports on the contrary that Bcl-2 levels of CD8+ T 
cells are lower in older individuals (Aggarwal and Gupta, 1998). It has been shown 
previously that EBV-specific CD8+ TEMRA cells show a resistance to apoptosis through 
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increased Bcl-2 expression upon resolution of infectious mononucleosis (Dunne et al., 
2002). However, the relative levels of apoptosis resistance exhibited by CMV-specific 
CD8+ T cells in this study were significantly lower compared with the global CD8 
compartment. Furthermore, CD8+ TEMRA cells exhibited the lowest Bcl-2 levels of all 
CMV-specific CD8+ T cell subpopulations. These findings therefore do not support an 
increased resistance to apoptosis as a cause for their accumulation. However, the 
expression of other anti-apoptotic molecules besides Bcl-2 or a decrease in expression 
of pro-apoptotic molecules must be investigated to rule this out completely.  
 
One issue that arises when analyzing CD45RA/CD27 subpopulations of CMV-specific 
CD8+ T cells is whether the CD45RA+CD27+ ‘TN’ phenotype is actually a true naïve 
subpopulation. For example, the mean percentage of CD45RA+CD27+ TN cells within the 
CMVpp65-specific compartment was found to be approximately 20% (figure 3.10B), 
which would be high for an un-primed naïve CMVpp65-specific T cell population. 
Secondly, the high Bcl-2 levels seen in total CD45RA+CD27+ CD8+ T cells were not 
matched by CD45RA+CD27+ CMVpp65-specific CD8+ T cells. Furthermore, this population 
has lower CD27 expression compared with total CD45RA+CD27+ CD8+ T cells (not shown) 
in addition to low CCR7 and high LFA-1 expression (Faint et al., 2001). Taken together, 
this suggests CD45RA+CD27+ CMVpp65-specific CD8+ T cells are a primed memory 
population undergoing CD45RA re-expression. To a degree, this fits with observations 
during primary acute CMV infections that CMV-specific CD45RO+ memory CD8+ T cells 
dominate whereas in convalescence a significant CD45RA+ memory population appears 
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(Kuijpers et al., 2003, van de Berg et al., 2008, Wills et al., 2002). Indeed, results 
presented in this chapter showed CMV-specific ‘TN’ cells were found to increase in 
numbers commensurate with TEMRA cells, which may indicate these are a transitionary 
‘pseudo naive’ CD45RA re-expressing memory population.  
 
However, CMVpp65-specific CD8+ TEMRA cells were not sufficiently large enough to solely 
account for total CD8+ TEMRA cells, although the proportion of CMV-specific TEMRA and TN 
cells out of total CD8+ TEMRA and TN cells were significantly larger in older individuals. This 
means the shrinking TN population in older individuals likely contain a significant 
population of primed memory cells, including those specific for CMV. Furthermore, the 
finding that CMV seropositivity alone increases TEMRA cell numbers with age but CMV-
specific TEMRA cells in the old still occupy a significantly higher percentage of total TEMRA 
cells further highlights that CMV-specific TEMRA cells come to dominate in older 
individuals. Still, CD8+ TEMRA cells specific for other CMV proteins and other viral proteins 
are likely to contribute to the global increase in the CD8+ TEMRA population. For example,, 
CMV IE-1-specific CD8+ T cells can occupy up to 40% of the CD8 compartment and can 
show a high degree of CD45RA expression (Khan et al., 2010, Khan et al., 2002a).  
 
In conclusion, this chapter has confirmed a relationship between CMV, ageing and the 
changes within the CD8 compartment. The most prominent finding is that CD8+ TEMRA 
cells accumulate with age despite showing low levels of Ki-67 and Bcl-2. This suggests 
that CD8+ TEMRA cells may instead be generated from other CD8
+ memory T cells which 
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have ceased to proliferate. This non-proliferative state can result from the exhaustion or 
senescence of the memory T cells that represent different pathways for T cell fate 
(section 1.4.8). This will therefore be explored further in the coming chapters, which will 
focus on how senescent CD8+ TEMRA cells are at the telomeric level. Furthermore, it will 
be investigated whether CMV positivity can impact negatively on the overall telomere 
length of an individual, as a result of the accumulation of these highly differentiated 
CD8+ T cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
107 
 
4 CMV infection and telomere length attrition during ageing 
 
4.1 Introduction  
Telomeres are instrumental in determining the lifespan of cells and can trigger a state of 
senescence when critically short (sections 1.1.2 & 1.4.8). Telomere length is therefore 
indicative of how close T cells are to senescence. Indeed, the telomere length of a T cell 
is predictive of its replicative capacity in-vitro (Plunkett et al., 2005). Naïve T cells have 
longer telomeres than memory T cells, and older individuals have shorter telomere 
lengths compared to the young (Akbar et al., 2004). However, there is a large variation 
between individuals of the same age (Rufer et al., 1999). This could be due to a variety 
of factors, including inter-individual genetic differences, cumulative oxidative damage, 
and chronic inflammatory environments (Valdes et al., 2005, Epel et al., 2004).   
 
The impact of antigenic burden throughout life may also be a factor that determines 
telomere length variation. However, this has not been extensively investigated. 
Repeated stimulation can eventually lead to loss of telomerase activity in highly 
differentiated CD8+CD27-CD28- memory T cells, which is linked to decreased Akt 
phosphorlyaltion (Plunkett et al., 2007, Henson et al., 2009). Chronic virus-specific CD8+ 
T cells also shown progressive telomere shortening (Plunkett et al., 2001), suggesting 
these memory cells are limited in their capacity to be maintained through proliferation.  
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4.2 Aims  
In the previous chapter, CMV serostatus was shown to have a significant impact on the 
CD8 compartment of healthy individuals, by accelerating the loss of TN and 
accumulation of highly differentiated CD8+ and CMV-specific CD8+ TEMRA cells. This may 
disrupt the ‘immune space’ by competitively squeezing out other T cells (Akbar and 
Fletcher, 2005, Franceschi et al., 2000, Nikolich-Zugich et al., 2004, Pawelec et al., 2005, 
Vasto et al., 2007). Furthermore, this may serve to simultaneously lower the overall 
telomere length of the T cell compartment, as a result of the accumulation of highly 
differentiated cells with shorter telomeres. This is important, as short telomeres have 
been associated with an increased risk of susceptibility to death by infection and various 
other conditions (as discussed in 1.1.2).   
 
The aim of this chapter therefore, was to determine whether CMV infection and CMV-
specific TCEs can impact telomere lengths in healthy individuals. Telomere lengths of 
lymphocyte subsets within our healthy cohort were measured to determine the 
significance of CMV serostatus on natural age-related telomere length attrition. The 
telomere lengths of CD8+ and CMV-specific CD8+ TEMRA cells were also investigated in 
relation to the other subpopulations, to determine the effect their accumulation has on 
the overall telomere length of individuals. Furthermore, defining the telomere length of 
these CD8+ TEMRA cells may help explain why they persist within the CD8 compartment, 
despite having a low proliferative and anti-apoptotic phenotype. 
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4.3 Results 
 
4.3.1 Measuring telomere lengths 
Telomere lengths can be measured using a variety of methods (reviewed in(Baird, 
2005). The technique used throughout this thesis is called flow cytometric fluorescence 
in-situ hybridization (flow-FISH) which was adapted in our lab from an original protocol 
by the Rufer group (Rufer et al., 1998, Faint et al., 2001, Reed et al., 2004). Flow-FISH 
uses peptide nucleic acid (PNA) probes, which specifically bind the hexameric repeats of 
telomeres during a hybridisation step. When these PNA probes are fluorescently 
labelled they therefore equate intensity of the signal with telomere length. When this 
procedure is coupled with flow cytometry, flow-FISH has the advantage over other 
techniques in its ability to analyse telomere lengths within single cell populations.  
 
Figure 4.1 outlines the analysis of telomere length using the flow-FISH technique. 
Further details can be found in materials and methods (section 2.4). A standard curve 
was generated previously in our lab by plotting the telomere length MFI against actual 
telomere length, as determined by telomeric restriction fragment (TRF) analysis, for 
healthy individuals over a wide age range (Fletcher et al., 2005, Reed et al., 2004). 
Therefore, telomere MFI readings, once converted using this standard curve, equated to 
estimations of real telomere lengths.  
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Figure 4-1. The Flow-FISH procedure 
The flow-FISH procedure is shown for CD4
+
 T cell telomere length analysis as an example. The process is 
broken down into 3 steps: 1. sample preparation - isolated PBMCs are cell surface stained with CD4 then 
fixed with BS3. They are then hybridised with the telomere probe using a heat step process. Confocal 
microscopy image shows CD4
+
 T cells (red) hybridised with a quantitative telomere PNA probe (blue), the 
intensity of which is equal to telomere length; 2. Acquisition and analysis – first the telomere MFI is 
adjusted to the control i.e. sample with known telomere length MFI. Once properly adjusted and 
compensated the other samples are acquired in triplicate. The mean MFI of the triplicates is calculated i.e. 
100 following FACs analysis. 3. Conversion - finally the mean MFI values are converted using a standard 
curve to estimate real telomere length, in this case MFI of 100 equates to 5.5kb telomere length.  
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4.3.2 CMV accelerates age-associated telomere attrition in T cells 
As discussed in section 1.6, evidence suggests it is the CD8 compartment that is most 
affected by CMV infection largely due to the CMV-specific CD8+ TCEs it induces. The first 
step therefore was to investigate the natural age-related attrition of telomeres within 
CD8+ T cells compared with the other lymphocyte subsets and to analyse any significant 
impact CMV may have on the rate of telomere attrition. Flow-FISH was therefore 
conducted on healthy donor PBMCs on the four cell subsets: total lymphocytes, CD4+ T 
cells, CD8+ T cells, and the remaining CD4-CD8- lymphocytes (predominately B cells).  
4.3.2.1 Telomere lengths in total lymphocytes 
The pooled data for telomere lengths in total lymphocytes is shown in figure 4.2. In total 
110 donors were analysed, 47% of which were CMV positive. The rate of total 
lymphocyte telomere attrition was found to be significantly correlated with age in both 
CMV positive (p<0.0001, r2 =0.615) and CMV negative individuals (p<0.0001, r2 =0.416) 
as depicted in figure 4.2A. However, the base pair per year (bpy) loss in CMV positive 
individuals was greater, equating to 61bpy compared with CMV negative individuals at 
46bpy. When data is further separated into old or young age groups and on the basis of 
CMV positivity (figure 4.2B); significantly shorter telomeres were found in CMV positive 
old individuals versus CMV negative old individuals (p=0.005). However, there was no 
significant difference between young CMV positive versus young CMV negative 
individuals. 
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4.3.2.2 Telomere lengths in CD4-CD8- lymphocytes 
The pooled data for telomere lengths of CD4-CD8- lymphocytes is shown in figure 4.3. In 
total 58 donors were analysed, of which 62% were CMV positive. The rate of CD4-CD8- 
telomere attrition was found to be significantly correlated with age in both CMV positive 
(p=0.0002, r2 =0.505) and CMV negative individuals (p=0.0015, r2 =0.260) as depicted in 
figure 4.3A. The base pair per year loss in CMV positive and CMV negative individuals 
was similar however at 46bpy and 43bpy respectively. When data is further separated into 
old or young age groups and on the basis of CMV positivity (figure 4.3B) no significant 
association was uncovered. 
4.3.2.3 Telomere lengths in CD4+T cells 
The pooled data for telomere lengths of CD4+ T cells is shown in figure 4.4. In total 110 
donors were analysed, 47% of which were CMV positive. The rate of CD4+ T cell 
telomere attrition was found to be significantly correlated with age in both CMV positive 
(p<0.0001, r2 =0.582) and CMV negative individuals (p<0.0001, r2 =0.410) as shown in 
figure 4.4A. The base pair per year loss in CMV positive individuals was greater, equating 
to 63bpy versus 48bpy in CMV negative individuals. Furthermore, when divided by age 
group and CMV positivity (figure 4.4B) CD4+ T cell telomeres were significantly shorter in 
CMV positive old versus CMV negative old individuals (p=0.011). There was no 
significant difference in telomere lengths between young CMV positive versus young 
CMV negative individuals  
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4.3.2.4 Telomere lengths in CD8+T cells 
The pooled data for telomere lengths of CD8+ T cells is shown in figure 4.5. In total 69 
donors were analysed, of which 57% were CMV positive. Telomere attrition was found 
to be most pronounced in CD8+ T cells relative to the other subsets analysed. Base pair 
loss was significantly correlated with age among the populations studied with both CMV 
positive (p<0.0001, r2=0.784) and CMV negative individuals (p<0.0001, r2=0.587) 
showing significant attrition with age (figure 4.5A). However, the base pair per year loss 
in CMV positive individuals was the most marked of all populations, equating to 94bpy 
versus 77bpy in CMV negative individuals. When the data was further divided into old or 
young categories and on the basis of CMV positivity (figure 4.5B) CD8+ T cells exhibit 
significantly shorter telomeres in CMV positive old versus CMV negative old (p=0.0004).  
 
Overall, results demonstrated the most significant telomere attrition was seen in the 
CD8+ T cell compartment. Furthermore, CMV positive individuals were associated with 
an accelerated rate of telomere shortening. The large CMV-specific TCEs which occupy 
the CD8 compartment in CMV seropositive individuals may lower the overall telomere 
length of the CD8 compartment as a whole, thus providing an explanation for this result. 
This could also account for the lack of significance in telomere length in the young age 
group on the basis of CMV positivity, as CMV-specific TCEs are smaller in CMV positive 
young versus CMV positive old individuals. Therefore, to investigate the impact of CMV 
on telomere lengths further it was necessary to look at telomere lengths within CD8+ 
and CMV-specific CD8+ T cell subpopulations. 
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Figure 4-2. The impact of age and CMV serostatus on telomere lengths in total lymphocytes  
(A) Telomere lengths of total lymphocytes in 110 donors stratified by age and CMV status: open circles 
represent CMV negative individuals with the correlation shown by a solid line; closed circles represent 
CMV positive individuals with the correlation shown by a dashed line. The gradient is representative of 
base pair loss per year (bpy). (B) Donor telomere lengths stratified according to CMV status and age 
group; young (<35) and old (>65). Donor numbers: CMV-(Y)=29; CMV+(Y)=24; CMV-(O)=17; CMV+(O)=26. 
Significant differences only displayed by p values. 
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Figure 4-3. The impact of age and CMV serostatus on telomere lengths in CD4
-
CD8
-
 lymphocytes 
(A) Telomere lengths of CD4
-
CD8
-
 lymphocytes in 58 donors stratified by age and CMV status: open circles 
represent CMV negative individuals with the correlation shown by a solid line; closed circles represent 
CMV positive individuals with the correlation shown by a dashed line. The gradient is representative of 
base pair loss per year (bpy). (B) Donor telomere lengths stratified according to CMV status and age 
group; young (<35) and old (>65). Donor numbers: CMV-(Y)=19; CMV+(Y)=10; CMV-(O)=10; CMV+(O)=7. 
Significant differences only displayed by p values. 
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Figure 4-4. The impact of age and CMV serostatus on telomere lengths in CD4
+
 T cells 
(A) Telomere lengths of CD4
+
 T cells in 110 donors stratified by age and CMV status: open circles represent 
CMV negative individuals with the correlation shown by a solid line; closed circles represent CMV positive 
individuals with the correlation shown by a dashed line. The gradient is representative of base pair loss 
per year (bpy). (B) Donor telomere lengths stratified according to CMV status and age group; young (<35) 
and old (>65). Donor numbers: CMV-(Y)=30; CMV+(Y)=18; CMV-(O)=16; CMV+(O)=32. Significant 
differences only displayed by p values. 
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Figure 4-5. The impact of age and CMV serostatus on telomere lengths in CD4
+
 T cells 
(A) Telomere lengths of CD8+ T cells in 69 donors stratified by age and CMV status: open circles represent 
CMV negative individuals with the correlation shown by a solid line; closed circles represent CMV positive 
individuals with the correlation shown by a dashed line. The gradient is representative of base pair loss 
per year (bpy). (B) Donor telomere lengths stratified according to CMV status and age group; young (<35) 
and old (>65). Donor numbers: CMV-(Y)=23; CMV+(Y)=12; CMV-(O)=10; CMV+(O)=11. Significant 
differences only displayed by p values. 
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4.3.3 Using Quantum dot technology in the Flow-FISH assay  
Investigating telomere lengths in CD8+ T cell subpopulations and CMV-specific CD8+ T 
cell populations can be difficult using flow-FISH as the range of flurochromes that can be 
used to define populations are limited due to the denaturing effect of the telomere 
probe hybridization step (requiring a temperature of 82°C for 10mins). To overcome this 
problem it is often necessary to sort populations beforehand, requiring more blood, 
obtained fresh on the day, followed by the expensive and time consuming step of cell 
sorting. However, if more heat stable flurochromes are available it should be possible to 
expand the panel for use in flow-FISH and obviate the need for cell sorting and larger 
numbers of cells being required for analysis. To address this, I investigated the 
availability of more robust (heat-stable) antibody labels. Quantum dot (Qdot) labelled 
antibodies (from Invitrogen) have a novel design giving them improved structural 
stability over original flurochromes. I subsequently chose to test these in the flow-FISH 
assay. 
4.3.3.1 Qdots show superior heat stability during flow-FISH 
The first step was to test a selection of Qdots against original fluorochromes for thermal 
stability during the hybridisation step. Fluorescence intensities were recorded before 
and after treatment of the fluorochromes FITC, PE, PerCP, APC and Cy3 compared with 
those of Qdots 605, 705 and 800 after treatment as depicted in the histograms of figure 
4.6. Qdots were found to withstand the heat treatment very well compared with the 
traditional fluorochromes, sustaining original pre-treatment fluorescence levels.  
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Figure 4-6. Histograms depicting original fluorochromes versus Qdots 
Comparative analysis of flurochromes FITC, PE, PerCP, APC and Cy3 versus Qdots Q605, 705 and 800 pre-
heating (shaded histogram) and after hybridisation step (open histogram). Representative example of 3 
experiments. 
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Qdots could retain flurorescence after the heat hybridisation step, however, it is not just 
a drop in fluorescence intensity that may result from heat-treatment during the 
hybridisation step, but also a loss in percentage of identifiable population. To illustrate 
this point, we need to look at the identification of positively stained populations during 
FACs plot analysis (figure 4.7A). Here, it is shown that some fluorochomes, for example 
PerCP, denature significantly during hybridisation and result in no PerCP positive 
population being identifiable after treatment. Other fluorochromes, however, for 
example APC, partially survive the heat hybridisation step but this results in a 
considerable portion of the population identified by APC being lost upon analysis i.e. 
15% vs. 28% as illustrated in the FACs plots example. This can be particularly 
problematic in the analysis of telomere lengths in small cell numbers e.g. virus-specific 
CD8+ T cell populations. No such loss of population occurs when using Qdots however, 
as illustrated by identification with Q800 in the example. 
 
The percentage of population retained was therefore calculated in this way for each 
fluorochome versus Qdot label before and after heat treatment and data consolidated 
and summarised in the bar chart of figure 4.7B. Here, the mean of the three 
experiments as a percentage of the original MFI retained (relative to 100% pre-
treatment) is compared in the panel. As can be seen, Qdots show superior heat stability 
which results in the original population identified pre-treatment still being retained 
post-treatment.  
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Figure 4-7.  The use of Quantum dot technology in the flow-FISH protocol  
(A) Comparison of FACs plot analysis used to determine positive populations using PerCP, APC or Qdot 
800. (B) Bar charts represent 3 individual experiments showing mean and SD of percentage of original 
signal retained. 
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Qdots were shown to have superior signal retention over the original flurochromes, 
making them an ideal addition to the flow-FISH assay. This meant the original 
fluorochrome panel could be expanded from three colours to five or more colours 
(based on a BD LSRI) as summarised in table 4.1:   
 
Original Flow-FISH Panel New Flow-FISH Panel 
FITC Q565 
Cy3 FITC 
Cy5 Q605 
 Q800 
 Cy5 
 
Table 4-1. Original vs. New Flow-FISH set-up on the BD LSR I 
 
4.3.4 Telomere lengths within CD8+ T cell subpopulations 
 
4.3.4.1 Telomere lengths within CD8+ T cell subpopulations 
In section 4.3.2, it was shown that CD8+ T cells were most affected by age associated 
telomere loss, and CMV positivity increased this rate of attrition. Since CMV may cause 
the accumulation of late differentiated CD8+ T cells which have shorter telomeres, the 
expanded flow-FISH protocol was used to analyse telomere lengths within CD8+ T cell 
subpopulations and stratify according to donor age and CMV serostatus. Previously 
fresh blood was needed and sorted prior to telomere analysis of populations requiring 
more than 2 colour stain, however, using Qdots in the flow-FISH protocol it was now 
possible to use frozen PBMCs for direct determination of telomere length analysis. It 
total, 26 frozen donor PBMCs were analysed in this way as shown in figure 4.8.  
 
  
123 
 
 (A) 
 
 
 
(B) 
 
 
 
 
 
 
 
Figure 4-8.  Using Qdots to investigate telomere lengths within CD8
+
 T cell subpopulations 
(A) Representative FACs plot analysis showing 4-colour flow-FISH using two Qdots (565, 605) and two 
regular flurochromes (Cy5 and FITC) in combination. (B) Pooled data of CD8
+
 T cell subpopulation 
telomere lengths. 26 donors shown. Significant differences displayed by * values. 
*<0.05;**<0.005;***<0.0005. 
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Figure 4.8A shows a representative example of the implemented of Qdots CD8-Q565 
and CD45RA-Q605 in the flow-FISH protocol to analyse telomere lengths in CD8+ T cell 
subpopulations. Figure 4.8B shows total CD8+ T cell subpopulation telomere lengths in 
26 donors. Telomere lengths were observed to shorten significantly, traversing from 
CD8+ TN to TCM (p<0.0001) then from TCM to TEM (p<0.0001) but then increase in length 
from TEM to CD8
+ TEMRA cells (p=0.018). This implied that CD8
+ TEMRA cells are not the 
most prone to telomere-dependent senescence of the memory subpopulations.  
 
4.3.4.2 Impact of CMV on CD8+ T cell subpopulation telomere lengths 
Data was further stratified on the basis of age or CMV serostatus (Figure 4.9). When 
telomere lengths are stratified according to age (figure 4.9A) those in the older age 
group had significantly shorter telomeres in each subpopulation compared with the 
young (TN Y vs. O p=0.040; TCM Y vs. O p=0.006; TEM Y vs. O p=0.008; TEMRA Y vs. O 
p=0.028;). When telomere lengths are stratified according to CMV serostatus (figure 
4.9B) although telomere lengths are shorter in CMV positive individuals, only the CD8+ 
TEMRA subpopulation is significantly shorter in CMV positive compared with CMV 
negative individuals (p=0.011). Results show the compounding effect of age and CMV on 
CD8+ T cell subpopulation telomere lengths. This indicates the accumulation of highly 
differentiated CD8+ T cells may contribute to the overall lowering of telomere length in 
total CD8+ T cells, but also shows that within these subpopulations there is also 
significant shortening by age. 
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Figure 4-9. Telomere lengths of CD8
+
 T cell subpopulations grouped by age and CMV status 
(A) Pooled data showing CD8
+
 T cell subpopulation telomere lengths by age group. 16 young and 7 old 
donors shown. (B) Pooled data showing CD8
+
 T cell subpopulation telomere lengths by CMV status. 10 
CMV negative and 11 CMV positive shown. Significant differences displayed by * values. 
*<0.05;**<0.005;***<0.0005. 
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4.3.5 Telomere lengths within CMV-specific CD8+ T cells 
 
4.3.5.1 Telomere lengths within CMV-specific CD8+ T cells 
With such large CMV-specific TCEs appearing with ageing, the telomere lengths of this 
population need to be investigated. Previously it has been problematic to determine 
telomere lengths of virus-specific CD8+ T cells using tetramers in flow-FISH, as the 
fluorochromes with which tetramers are engineered can be denatured during the heat 
hybridisation step. Sorting CMV-specific populations is theoretically possible, but 
difficult, as the populations can be small, especially in younger donors.  To overcome 
this problem, Qdot streptavidin conjugates were tested in combination with unlabelled 
biotinylated pentamer (supplied by Proimmune) in the flow-FISH assay. Pentamers were 
chosen over of tetramers purely for practical reasons: pentamers were available fully 
formed and unlabelled, whereas tetramers were tagged with PE as part of their 
tetramerisation step with streptavidin-PE and therefore Qdot streptavidin conjugates 
could not be used. A representative example of how Qdots and pentamers were used to 
identify CMV-specific CD8+ T cell telomere lengths is shown in figure 4.10A. FACs plot 
analysis illustrates staining before (top) and after (bottom) the telomere probe heat 
hybridisation step. The CMV-specific population of 0.96% of CD8+ T cells was 
successfully retained following the hybridisation step (0.9%) and telomere lengths 
successfully determined, as depicted by the relevant histograms. This was extended to a 
5 colour flow-FISH assay using CD8-Q565, Pentamer (NLV) – Q800, CD45RA-Q605 and 
CD45RO-APC and telomere probe-Cy5 to determine telomere lengths in total CD8, total 
CMV-specific and CD45RA+ and CD45RO+ CMV-specific populations (figure 4.10B). 
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Figure 4-10. Determining telomere lengths of CMV-specific CD8
+
 T cell subpopulations 
(A) Stability of tetramer staining before and after heat hybridisation step of the flow-FISH protocol as 
illustrated by FACs plot analysis. (B) The implementation of Qdots to perform 5 colour flow-FISH to 
determine telomere lengths within CMV-specific CD45RA and CD45RO memory populations. Values 
within histograms represent telomere length MFI of the relevant population. 
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Two subpopulations, CD45RA and CD45RO, as opposed to the four CD45RA/CD27 
subpopulations, were investigated to maximise the total number of CD45RA re-
expressing memory CMV-specific CD8+ T cells. This was predominately due to young 
individuals in particular often showing smaller CMV-specific TCEs. Furthermore, as the 
CMV-specific compartment was shown to become increasingly dominated by CD8+ TEMRA 
and ‘TN’ cells during ageing, the aim was to measure telomere lengths in all CD45RA re-
expressing memory versus all the CD45RO expressing memory CMVpp65-specific CD8+ T 
cells. This was to determine if CD45RA re-expression on CD8+ CMV-specific T cells was 
accompanied by shorter telomeres, commensurate with their accumulation.  
 
Figure 4.11 shows an analysis conducted on 6 young and 6 old HLA matched individuals. 
Significant longer telomere lengths were found in the CD45RA versus CD45RO 
CMVpp65-specific memory CD8+ T cells in both young and old age groups (both p=0.03). 
Furthermore, the telomere lengths in total CMVpp65-specific CD8+ T cell populations 
were significantly shorter in older subjects than in younger individuals (p=0.008). Results 
show that both CD8+ TEMRA cells and CMV-specific CD8
+ CD45RA+ T cells do not have the 
shortest telomeres of all memory subpopulations. This also indicates they are not the 
most prone to telomere-dependent senescence and may attribute to their persistence, 
potentially being maintained in a telomere-independent manner. However, CD8+ TEMRA 
cell telomeres are still relatively short and likely to contribute to the impact of CMV on 
shortening telomeres through their accumulation within the CD8 compartment of CMV 
positive individuals. 
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Figure 4-11.  Telomere lengths of CD8
+
 CMVpp65-specific CD45RA and CD45RO memory subpopulations 
Total CMVpp65-specific and CMVpp65-specific CD45RA or CD45RO memory telomere lengths within 
young or old age groups. 6 young and 6 old donors shown. Significant differences displayed by *values. 
*<0.05;**<0.005;***<0.0005. 
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4.4 Discussion 
Mounting evidence highlights the detrimental association between relatively short 
telomeres and disease, as discussed in the introduction of this chapter. However, the 
effect of antigenic burden upon telomere lengths during healthy ageing is less well 
documented. Such a study has been presented in this chapter, concluding that CMV can 
significantly impact telomere lengths in healthy individuals.  
 
The results showed age-related telomere attrition to be most prominent in T cells, in 
particular CD8+ T cells, but not CD4-CD8- (mainly B cell) subsets. Furthermore, CMV 
positivity significantly affected the rate of telomere shortening, by increasing the 
average rate of base pair attrition per year and being associated with shorter telomere 
lengths in CMV positive old versus CMV negative old individuals. These findings fit to 
some degree with a recent study of patients with coronary heart disease (Spyridopoulos 
et al., 2009) which showed that CMV positive patients had significantly shorter CD8+ T 
cell telomeres than CMV negative patients, while no other cell type was affected by 
CMV status. But the present study serves to highlight how healthy individuals may also 
be affected by common persistent viral infections such as CMV. 
 
Indeed, the fact that CMV can lower an individual’s telomere length may negatively 
impact their predisposition to death by infection and a variety of diseases (Samani et al., 
2001, Calado and Young, 2009, Brouilette et al., 2007, Brouilette et al., 2003, Cawthon 
et al., 2003). The loss of virus-specific T cells through telomere-dependent senescence 
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could also compromise the individual’s immunity to that virus. This is further highlighted 
by low telomerase activity, the enzyme which adds back telomere repeats, being found 
in T cells specific for CMV and other chronic viral infections such as HIV, HCV and HBV 
(Bestilny et al., 2000, Fletcher et al., 2005, Satra et al., 2005). This suggests a common 
mechanism whereby persistent antigenic stimulation results in increased T cell turnover 
and telomere shortening within virus-specific T cells. 
 
An increase in CD8+ TEMRA cells with age and CMV was shown in the previous chapter; 
however results show these cells did not show the shortest telomere lengths of the 
memory subpopulations. This was especially prominent in the CMV-specific CD8+ 
compartment, wherein the CD45RA+ memory population had significantly longer 
telomeres than the CD45RO+ memory subpopulation. Indeed, this fits with similar 
observations seen with EBV-specific CD45RA re-expressing memory CD8+ T cells, which 
were shown to have longer telomeres than their CD45RO+ counterparts (Dunne et al., 
2002). This suggests that the effect of CMV infection in accelerating telomere attrition 
and reducing overall CD8 T cell telomere length may largely be due to the CD45RO+ 
subpopulations. However, it must be noted that all memory populations have shorter 
telomere lengths compared with naive so any increase in memory CD8+ T cells at the 
cost of naive CD8+ T cells will serve to shorten the overall telomere length. We have 
since published this in collaboration with another group, showing highly differentiated T 
cells correlate with shorter telomeres (van de Berg et al., 2010). This is further 
highlighted by the fact that despite TEMRA cells accumulating in the old CMV-specific 
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compartment, the CMV-specific compartment overall showed significantly shorter 
telomere lengths than in the young CMV-specific compartment, suggesting this 
population is driven closer to senescence during ageing.  
 
The next chapter will focus on how TEMRA cells may be generated in-vivo. To address this, 
the proliferative potential and telomerase activity of the CD8+ T cells subpopulations will 
be compared in-vitro. Furthermore, whether TEMRA cells can be maintained 
homeostatically by cytokine will also be investigated. 
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5 The generation of CMV-specific CD8+ T cell expansions 
during ageing 
 
5.1 Introduction 
In the present study CD8+ TEMRA cells have been shown to accumulate during ageing and 
are present at a significantly higher frequency in CMV positive individuals. This is despite 
CD8+ TEMRA cells being highly differentiated and showing signs of low turnover and high 
susceptibility to apoptosis when analysed directly ex-vivo which suggests they may be 
close to senescence. However, it has also been shown that CD8+ TEMRA cells have 
relatively long telomeres for a memory CD8+ T cell subpopulation, indicating they have 
residual capacity for replication which may explain their persistence and accumulation 
within the CD8+ T cell compartment. It is therefore possible that CD8+ TEMRA cells may be 
close to senescence through telomere-independent pathways. Indeed, cellular 
senescence can occur by telomere-independent mechanisms as the result of DNA 
damage caused by reactive oxygen species, ionizing radiation, chromatin perturbation 
and activation of p53 and stress pathways (Campisi and d'Adda di Fagagna, 2007, Passos 
and Von Zglinicki, 2006). This initiates a DNA damage response similar to telomere-
dependent senescence (d'Adda di Fagagna, 2008). 
 
It is also unclear whether CMV-specific CD8+ TEMRA cells are maintained by periodic CMV 
reactivation or generated in the absence of antigen by homeostatic signals. Indeed, the 
two are not mutually exclusive, as TEMRA cells could be generated from previously 
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antigen driven memory subpopulations which later undergo homeostatic CD45RA re-
expression. Evidence to support this hypothesis comes from studies with IL-15, a 
cytokine that is essential for CD8+ T cell memory survival (Tough et al., 2000). IL-15 was 
shown to generate CD8+ TEMRA cells from CD8
+ TCM cells (Geginat et al., 2003) and also 
cause CD45RA re-expression on CD45RO+ EBV-specific CD8+ memory T cells (Dunne et 
al., 2005) in the absence of antigen in-vitro.  
 
As TEMRA cells are found predominately in older individuals and are also increased in 
those who are CMV positive, this suggests ageing and/or chronic CMV infection may 
cause changes in the cytokine milieu which favours their generation. Indeed, there is 
evidence to support this hypothesis. Previous data has shown that CMV stimulated 
plasmacytoid dendritic cells can produce high levels of IFN-α, which can lead to down-
regulation of co-stimulatory molecules and inhibition of telomerase activity in activated 
CD4+ T cells (Fletcher et al., 2005). This is significant as the antiviral effects of IFN-α can 
also lead to the secondary production of cytokines such as IL-2 and IL-15 (Tough et al., 
1996). In fact, acute viral infections i.e. HBV, Dengue virus, and Influenza virus were 
shown to trigger bystander activation and expansion of CMV-specific CD8+ T cells 
through IL-15 (Sandalova et al., 2010). Furthermore, elevated levels of pro-inflammatory 
cytokines including IFN-α and IL-15 have been reported during ageing (Gangemi et al., 
2005, Zhang et al., 2002, De Martinis et al., 2005, Franceschi et al., 2007). Therefore, 
chronic inflammation during ageing may lead to increased circulating IL-15 levels which 
drive the appearance of CD8+ TEMRA cells. 
  
135 
 
5.2 Aims 
The aim of this chapter is to determine how CD8+ TEMRA cells are generated. Low 
proliferative and low anti-apoptotic levels coupled with relatively long telomeres for a 
memory subpopulation suggests they could be approaching senescence by telomere-
independent pathways. To address this, the potential of CD8+ TEMRA cells to proliferate 
efficiently in response to activation will be investigated. Specifically, the level of 
proliferation and telomerase activity exhibited following activation will be determined in 
CD8+ TEMRA cells and compared with the other CD8
+ T cell subpopulations. Senescence-
related DNA damage, whether resulting from telomere dependent or telomere 
independent DNA damage can be identified by molecules such as the histone protein 
γH2AX (Passos et al., 2010). Therefore the levels of γH2AX within CD8+ T cell 
subpopulations will also be determined.  
 
As discussed earlier, evidence suggests a role for IL-15 cytokine in the generation of 
CD8+ TEMRA cells. Therefore the proliferative and phenotypic changes of CMV-specific 
CD8+ T cells in response to IL-15 will be investigated. Additionally, whether CMV can 
cause increased IL-15 levels in-vitro will be assessed in order to question the mechanism 
whereby chronic CMV infection may influence the appearance of more CD8+ TEMRA cells 
through bystander proliferation in-vivo. 
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5.3 Results 
 
5.3.1 Proliferative responses of CD8+ T cell subpopulations to stimulus 
In chapter 3, CMV-specific CD8+ TEMRA cells showed low levels of proliferation on the 
basis of Ki-67 expression compared with other memory CD8+ T cell subpopulations when 
sampled directly ex-vivo. One possibility for the low proliferative capacity may be that 
CD8+ TEMRA cells are resting memory T cells that have not seen antigen recently. 
Alternatively, this may indicate CD8+ TEMRA cells are a senescent population that are un-
responsive to antigen. The first step therefore was to investigate if CD8+ TEMRA cells can 
proliferate efficiently when reactivated.  
5.3.1.1 CD8+ TEMRA cells show poor proliferative responses 
The proliferative responses of CD8+ T cell subpopulations to a broad stimulus were 
investigated. Donor PBMCs were first negatively selected for CD8+ T cells then further 
sorted by CD45RA and CD27 to give the four CD8+ T cell subpopulations of interest. Each 
subpopulation was then separately seeded at 100,000 cells and stimulated with anti-
CD3 by placing in OKT3 coated wells for a period of 4 days. The proliferative response 
(Ki-67 positivity) on day 4 was recorded for each CD8+ T cell subpopulation (figure 5.1A) 
as determined by the mean responses of 7 donors tested. CD8+ TEMRA cells showed 
significantly lower Ki-67 levels (with a mean of 21%) compared with other CD8+ T cell 
subpopulations (means all above 50%) indicating CD8+ TEMRA cells have poor proliferative 
responses to a broad activation in-vitro.   
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5.3.1.2 CMV-specific CD8+ TEMRA cells show poor proliferative responses 
Next, the proliferative responses of CD8+ CMVpp65-specific T cell subpopulations to 
CMVpp65 peptide were investigated. Donor PBMCs from a CMV positive individual were 
first selected for CD8+ T cells by negative magnetic bead selection and then further 
sorted on the basis of CD45RA and CD27 to give the four CD8+ T cell subpopulations of 
interest. Each subpopulation was then separately seeded at 100,000 cells per well and 
stimulated with CMVpp65 peptide for 4 days. The proliferative response (Ki-67 
positivity) was subsequently recorded for each CD8+ T cell subpopulation (figure 5.1B) as 
based on the mean responses of 5 individuals tested. CMV-specific CD8+ TN cells showed 
the highest Ki-67 levels (mean of 24%) with TCM showing the second highest response 
(mean of 13%) and both TEM and TEMRA subpopulations showing the lowest responses 
(mean of 10%). Results showed CMV-specific CD8+ T cells have a relatively poor 
response to CMVpp65-specific activation in-vitro, with CMV-specific CD8+ TEMRA cells 
showing among the lowest Ki-67 levels in response to activation of all subpopulations. 
 
Overall results showed that CD8+ and CMV-specific CD8+ TEMRA cells show poor 
proliferative responses to activation. This is consistent with Ki-67 positivity observed 
directly ex-vivo in chapter 3 and provides further support that CD8+ TEMRA cells may be 
close to senescence. 
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Figure 5-1. Proliferative responses of sorted CD8
+
 and CMV-specific CD8
+
 T cell subpopulations to 
stimulation 
CD8
+
 T cell subpopulations were sorted at >98% purity then stimulated separately in (A) OKT3 coated 
wells for 4 days at which Ki67 levels were recorded (mean of 7 experiments) or in (B) CMVpp65 peptide 
containing medium for 4 days at which Ki67 levels were recorded (mean of 5 experiments). Significant 
differences displayed by *values. *<0.05;**<0.005;***<0.0005. 
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5.3.2 Telomerase activity of CD8+ and CMV-specific CD8+ T cells 
The attrition of telomere length can be suppressed by the enzyme telomerase, which 
adds back telomeric repeats (Akbar and Vukmanovic-Stejic, 2007). However, it has been 
shown that repeated stimulation can eventually lead to the loss of telomerase activity in 
highly differentiated CD8+CD27-CD28- memory T cells (Plunkett et al., 2007, Henson et 
al., 2009). In the previous chapter CD8+ TEMRA cells and CMV-specific CD8
+ CD45RA+ 
memory cells were shown to have significantly longer telomeres than CD8+ TEM cells or 
CMV-specific CD8+ CD45RO+ memory T cells respectively. This may indicate CD8+ TEMRA 
cells have relatively high telomerase activity that maintains the telomere length within 
these cells. Therefore, the activity of telomerase was compared in CD8+ and CMV-
specific CD8+ T cell subpopulations. 
 
5.3.2.1 Measuring telomerase activity using the TRAP assay 
The analysis of telomerase activity was conducted using the telomeric repeat 
amplification protocol (TRAP) assay, as described in materials and methods (section 
2.4.3). Briefly, cell extracts from stimulated cells were isolated and PCR was performed 
with samples adjusted to 500 Ki67+ T cells per reaction (Reed et al., 2004). Telomeric 
elongation was performed using a *γ-P32] ATP-end-labelled telomerase substrate (TS) 
primer and samples amplified by PCR. The PCR products were then run on a 
polyacrylamide gel which was subsequently exposed to an autoradiography film. 
Telomerase activity was then calculated as a ratio between the mean optical densities of 
the telomeric repeat bands and the internal standard control band.   
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5.3.2.2 CD8+ TEMRA cells show low level  telomerase activity 
Telomerase activity was measured in sorted CD8+ T cell subpopulations following 
stimulation with anti-CD3 and irradiated autologous APCs. A representative example of 
relative telomerase activity in one donor is shown by the autoradiography of a TRAP 
assay acrylamide gel (figure 5.2A). CD8+ TEMRA cells were found to have the lowest levels 
of telomerase activity of all CD8+ T cell subpopulations. Telomerase activity was 
calculated as mean telomerase activity per subpopulation from the consolidation of 5 
experiments (figure 5.2B).  
5.3.2.3 CMV-specific CD8+ TEMRA cells show low level  telomerase activity 
Telomerase activity was measured in sorted CD8+ T cell subpopulations from CMV 
positive individuals following stimulation with CMVpp65 peptide (2pg/ml) plus 
irradiated autologous APCs. A representative example of relative telomerase activity in 
one donor is illustrated by the autoradiography of a TRAP assay acrylamide gel in figure 
5.2C. CMV-specific CD8+ TEMRA cells were found to have the lowest levels of telomerase 
activity of all CD8+ T cell subpopulations, as highlighted by the mean telomerase activity 
per subpopulation determined from 3 experiments (figure 5.2D).  
 
Results showed that telomerase activity in both CD8+ and CMVpp65-specific CD8+ TEMRA 
cells were the lowest of all subpopulations, equating to a restriction in their ability to be 
maintained through subsequent division and indicative of a senescent subpopulation. 
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Figure 5-2.  Telomerase levels in CD8
+
 and CMV-specific CD8
+
 T cell subpopulations  
Telomerase activity was determined using the TRAP assay. (A) Sorted CD8
+
 T cell subpopulations were 
stimulated with OKT3 and irradiated APCs for 4 days. Autoradiography of a TRAP assay 12% acrylamide gel 
from a representative example is shown. (B) Bar chart shows mean relative telomerase levels from five 
experiments. (C) Sorted CD8
+
 T cell subpopulations from CMV positive individuals were stimulated with 
CMVpp65 peptide and irradiated APCs for 4 days. Autoradiography of a TRAP assay 12% acrylamide gel 
from a representative example is shown. (D) Bar chart shows mean relative telomerase levels from three 
experiments. 
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5.3.2.4 CD8+ TEMRA cells show evidence of high DNA damage  
The low levels of telomerase activity found in CD8+ and CMV-specific CD8+ TEMRA cells 
indicate they are highly differentiated cells which have undergone repeated cellular 
proliferation and are close to senescence (Fletcher et al., 2005, Weng et al., 1996, 
Plunkett et al., 2007). However, the previous chapter showed CD8+ TEMRA cells exhibit 
relatively long telomere lengths for a memory subpopulation and most significantly 
CMV-specific CD8+ CD45RA+ memory T cells have significantly longer telomeres than 
CMV-specific CD8+ CD45RO+ memory T cells. This dichotomy suggests that rather than 
being lost through repeated stimulation, telomerase may be shut off or inhibited in CD8+ 
TEMRA cells. As discussed in the introduction of this chapter, cellular senescence can also 
occur by telomere-independent mechanisms as the result of DNA damage. One such 
indicator of DNA damage is γ-H2AX (Passos et al., 2010).  
 
The levels of γ-H2AX were analysed in the four CD8+ T cell subpopulations directly ex-
vivo (figure 5.3). CD8+ TEMRA cells exhibited significantly higher levels of γ-H2AX 
compared with the other subpopulations. This supports the hypothesis that CD8+ TEMRA 
cells may be close to telomere-independent senescence through the accumulation of 
DNA damage. These are preliminary results and are not sufficient in numbers to 
determine the influence of age or CMV serostatus as independent factors. Furthermore, 
γ-H2AX levels on CMV-specific CD8+ T cell subpopulations require investigation.  
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Figure 5-3. DNA damage levels as indicated by γ-H2AX expression on CD8+ T cell subpopulations 
(A) Representative histograms showing γ-H2AX levels in each subpopulation. Filled blue histogram 
represents sample and empty histogram IgG1-488 isotype control. (B) Pooled data from 8 individuals 
showing γ-H2AX levels of CD8
+
 T cell subpopulations. Standard error bars shown. 8 young individuals 
tested (4 CMV+/4 CMV-). *<0.05;**<0.005;***<0.0005. 
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5.3.3 Proliferative and phenotypic responses to IL-15 cytokine 
It has been shown previously that IL-15 can cause CD45RA re-expression on CD45RA 
negative CD8+ T cell memory populations in the absence of antigenic stimulation in-vitro 
(Dunne et al., 2005, Geginat et al., 2003). This suggests a mechanism by which CD8+ 
TEMRA cells may be generated in-vivo.  
 
The potential of IL-15 to cause CD45RA re-expression on CD45RA negative CD8+ and 
CMV-specific CD8+ T cells was therefore investigated. Figure 5.4 outlines the two 
experimental approaches used to investigate this. In the first experiment (figure 5.4A) 
the proliferative and phenotypic responses of the four CD8+ T cell subpopulations, as 
identified by CD45RA and CD27 expression, were sorted then cultured individually with 
one shot of 10U IL-15 cytokine. In the second experiment (figure 5.4B) the CD45RA 
negative fraction only was sorted from CD8+ T cells taken from a CMV positive individual 
then cultured with one shot of 10U IL-15 cytokine. In the second experiment the CMV-
specific population was identified by tetramer to analyse CMV-specific CD8+ T cell 
proliferation and CD45RA re-expression during IL-15 treatment.  
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                                      (A)                                                                            (B) 
 
 
Figure 5-4. Schematic of IL-15 reversion experiments  
IL-15 reversion experiments were conducted in one of two ways; as depicted by (A) for the four CD8
+
 T 
cell subpopulations and (B) for one CD45RA negative subpopulation.  
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5.3.3.1 IL-15 maintains the survival and proliferation of CD8+ T cells  
The ability of IL-15 to maintain the survival of memory CD8+ T subpopulations in the 
absence of antigen was tested. The four CD8+ T cell subpopulations were sorted and 
individually cultured with IL-15. The number of cells recovered at time-points indicated 
were recorded and expressed as a percentage of the initial seeded numbers (figure 
5.5A). CD8+ TCM and TEM cells proliferated efficiently in response to IL-15 treatment, 
reaching close to 350% of the original seeded cell numbers. Although CD8+ TEMRA cells 
initially proliferated slowly, by day 21 cell numbers were relatively high, at approx 260% 
of seeded numbers. CD8+ TN cells were less responsive to IL-15 and numbers by day 21 
were comparably lower than the other subpopulations. When not treated with IL-15, 
cell death was observed to occur within 4 days (not shown). Results confirm that IL-15 
can maintain the proliferation of memory CD8+ T cells in the absence of antigen. 
 
5.3.3.2 IL-15 causes CD45RA re-expression 
The expression of CD45RA and CD27 was also determined during IL-15 treatment. 
Samples of cells were taken at days 0, 1, 9, 14, and 21 then stained with antibodies to 
CD8, CD45RA and CD27. CD45RA re-expression was found to increase commensurate 
with days of IL-15 treatment on both CD8+ TCM and CD8
+ TEM cells, resulting in 
approximately 60% and 45% CD45RA+ re-expression on these subpopulations 
respectively (figure 5.5B).  
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Figure 5-5. Proliferative and phenotypic responses of CD8
+
 T cell subpopulations to IL-15 treatment 
CD8
+
 T cell subpopulations were sorted on the basis of CD45RA and CD27 then cultured individually with 
IL-15 (10U). (A) The percentage survival of CD8
+
 T cell subpopulation nubers with time (in days) post IL-15 
treatment as determined by viable cell counting on days 0, 1, 9, 14 and 21. Percentage cell survival 
calculated based on original seeded numbers at day 0 (set to 100%). (B) FACs plot analysis showing 
CD45RA/CD27 phenotype of each CD8
+
 T cell subpopulation on days 0, 1, 9, 14 and 21. Numbers in 
quadrants represent percentages of total live cells. Experiment shown is representative of two. 
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5.3.3.3 IL-15 causes CMV-specific T cells to proliferate 
Next, the response of CMV-specific CD8+ T cell responses to IL-15 was investigated. 
Sorted CD45RA negative CD8+ T cells were obtained from CMV positive individuals who 
were HLA matched for analysis of the CMVpp65-specific CD8+ T cell population. CD45RA 
negative CD8+ T cells were seeded at 100,000 cells per well and cultured over 14 days 
with 10U of IL-15. At time-points 0, 1, 4 and 14 one well was harvested, viable cell 
numbers counted and total cells stained with CMVpp65-specific tetramer together with 
CD8, CD45RA and CD45RO antibodies. IL-15 was shown to cause the expansion of this 
CD45RA negative subpopulation to approximately 250% of its original seeded number 
by day 14 (figure 5.6A). This indicated that IL-15 can drive the expansion of CMV-specific 
CD8+ T cells efficiently in the absence of antigen. 
 
5.3.3.4 IL-15 causes CMV-specific T cell CD45RA re-expression 
Commensurate with the expansion of this population was the re-expression of CD45RA 
on CD45RA negative CMVpp65-specific CD8+ T cells. This is shown in the representative 
example FACs plot analysis of one individual (figure 5.6B). Here, the percentage of 
CD45RA re-expression is displayed in the relevant quadrant of total CD8+ T cells (top 
panel) and CMV-specific CD8+ T cells (bottom panel). Both of these populations showed 
increased expression of CD45RA by day 14 compared with initial levels at day 0, 
equating to 47% and 39% CD45RA positive population on total CD45RA negative CD8+ 
and CMV-specific CD8+ T cells respectively. Results of three experiments confirm 
CD45RA re-expression in response to IL-15 treatment in-vitro. 
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Figure 5-6. Homeostatic proliferation and CD45RA re-expression on CD8
+
 and CMVpp65-specific CD8
+
 
CD45RA negative T cells during IL-15 treatment 
(A) The percentage recovery of CD8
+
 CD45RA- T cells with time (in days) during IL-15 treatment, as 
determined using viable cell count from 100% at day 0 then subsequently at days 1, 4, and 14. (B) FACs 
plot analysis showing CD45RA re-expression on the sorted CD45RA negative population at days 0 to 14. 
Numbers represent percentages in quadrants. Experiment shown is representative of three. 
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5.3.3.5 CMV lysate and IFN-α increases production of IL-15 
Previous data has shown that CMV lysate stimulated plasmacytoid dendritic cells 
(pAPCs) can produce high levels of IFN-α (Fletcher et al., 2005). IFN-α may also cause the 
secondary production of IL-15 (Tough et al., 1996), which has been implicated in the 
generation of CD45RA re-expressing memory subpopulations, as shown in the previous 
section and elsewhere (Dunne et al., 2005, Geginat et al., 2003, Sandalova et al., 2010).  
 
Therefore, the potential of CMV to cause the production of IL-15 was investigated. IL-15 
mRNA levels were measured by RT-PCR in total PBMCs from CMV positive individuals, 
following the treatment of cells with either IFN-α or CMV lysate. In each case two 
experiments were conducted. For the first experiment, treating PBMCs with IFN-α for 4, 
24 and 48 hours (figure 5.7A) showed a 4 hour treatment yielded maximal production of 
IL-15 mRNA, with a 4.8 fold increase at a concentration of 500U/ml compared with no 
IFN-α treatment. This 4 hour treatment was then repeated on a different donor (figure 
5.7B) and a 3 fold increase in IL-15 mRNA was observed at a peak concentration of 
1000U/ml. Both results demonstrated that treatment with IFN-α resulted in increased 
production of IL-15 mRNA from baseline levels (i.e. no IFN-α treatment). When PBMCs 
were treated with CMV lysate for 24, 48 and 72hrs (figure 5.7C) a 24hr treatment 
yielded maximal production of IL-15 mRNA, with a 2 fold increase compared with no 
CMV lysate treatment.  This 24 hour treatment was then repeated on a different donor 
(figure 5.7D) and a 3.5 fold increase in IL-15 mRNA levels was observed. Results showed 
that CMV lysate can lead to increased levels of IL-15 mRNA in total PBMCs. 
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Figure 5-7.  IL-15 production following the stimulation of total PBMCs with either IFN-α or CMV lysate 
The production of IL-15 mRNA was determined by RT-PCR following the treatment of total PBMCs with 
either IFN-α (A&B) or CMV lysate (C&D) for times and concentrations indicated.  
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5.4 Discussion 
The aim of this chapter was to investigate how CD8+ TEMRA cells may be generated. In 
conclusion, results suggest that this subpopulation may be accumulating through 
homeostatic-driven proliferation from previously generated CD8+ TCM or CD8
+ TEM 
subpopulations. This is based on the low level proliferative responses and low 
telomerase activity exhibited by CD8+ TEMRA cells upon stimulation, and observations IL-
15 caused CD45RA re-expression on CD45RA negative CD8+ and CMV-specific CD8+ T 
cells. 
 
Low levels of telomerase activity found in CD8+ and CMV-specific CD8+ TEMRA cells 
indicates they are highly differentiated cells which have undergone repeated cellular 
proliferation, and are close to senescence (Fletcher et al., 2005, Weng et al., 1996, 
Plunkett et al., 2007). Indeed, this is consistent with findings of low Ki-67 and Bcl-2 
levels in CD8+ and CMV-specific CD8+ TEMRA cells directly ex-vivo (chapter 3). 
Furthermore, despite having relatively long telomeres for a memory subpopulation, 
CD8+ TEMRA cells showed high levels of DNA damage in the form of γ-H2AX histone 
protein expression. Overall, results suggest that CD8+ TEMRA cells may be close to 
senescence through telomere-independent mechanisms. Indeed, ongoing work is 
investigating p38, a mitogen activated protein kinase involved in stress related 
responses which can trigger apoptosis. Preliminary work (not shown) indicates that the 
inhibition of p38 through BIRB 796, an inhibitor of p38 signaling (Bagley et al., 2007) can 
enhance telomerase activity. 
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Work presented in this chapter also showed IL-15 can maintain the homeostatic 
proliferation of CMV-specific CD8+ memory T cells. This is in-line with reports that 
CD27/CD28 negative memory cells can be maintained efficiently by IL-15 cytokine (Chiu 
et al., 2006). Most importantly, IL-15 caused CD45RA re-expression on CMV-specific 
CD45RO+ CD8+ T cells, supporting similar findings with EBV-specific CD8+ T cells (Dunne 
et al., 2005) and total CD8+ TCM cells (Geginat et al., 2003). This identifies a key role for 
IL-15 in the generation of CD8+ TEMRA cells. 
 
It is possible the persistence of CMV and other viruses may lead to increased levels of IL-
15 in-vivo and subsequently drive the generation of CD8+ TEMRA cells. IL-15 is produced 
by dendritic cells, monocytes and endothelial cells during and following viral infections 
(Oppenheimer-Marks et al., 1998, Waldmann, 2006). Furthermore, acute viral infections 
i.e. HBV, Dengue virus, and Influenza virus have been shown to trigger bystander 
activation and expansion of CMV-specific and EBV-specific CD8+ T cells through IL-15 
(Sandalova et al., 2010). It must also be remembered that CD8+ TEMRA cells are not just 
seen in CMV positive individuals but also in CMV negative individuals, but at significantly 
lower numbers. CMV negative individuals will be infected with other chronic viruses; on 
average a healthy individual is infected with 8-12 chronic viruses (Virgin et al., 2009). 
Therefore, it is possible that other viruses may also be causing bystander proliferation 
and generation of CD8+ TEMRA cells through IL-15 or related cytokines. Previous work has 
shown that CMV lysate can produce high levels of IFN-α through plasmacytoid dendritic 
cells (Fletcher et al., 2005). Results presented in this chapter show CMV lysate can also 
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increase IL-15 production in-vitro, although the main source is yet to be determined, as 
total PBMCs were stimulated and individual cell types not separated. However, taken 
together, evidence suggests that chronic infection may lead to increased IL-15 levels. 
 
Another possibility is that CMV-specific CD8+ T cells are more amenable to the effects of 
IL-15, and therefore more likely to undergo CD45RA reversion. One possibility is that 
CMV-specific CD8+ T cells have increased IL-15 receptor expression levels. The IL-15 
receptor is part of the common cytokine-receptor γ-chain family, sharing the γ-chain 
(CD132) with IL-2, IL-4, IL-7, IL-9 and IL-21, but is distinguished separately by the 
expression of IL-15Rα and IL-15Rβ (Waldmann, 2006, Khaled and Durum, 2002). The 
mechanism of signalling through IL-15 is still poorly understood however, as IL-15Rα can 
be found both directly on T cells or trans-presented to T cells by DCs or monocytes 
(Khaled and Durum, 2002, Ma et al., 2006, Waldmann, 2006, Geginat et al., 2003, Sauce 
et al., 2006). Therefore, T cells expressing higher levels of IL-15Rα or other constituents 
of the receptor (e.g. IL-15Rβ or CD132) may confer a higher affinity for soluble IL-15. 
Indeed, IL-15 is a limiting factor, and can determine the number of each type of 
lymphocyte with competitors dying through neglect (Khaled and Durum, 2002). 
Therefore, determining expression of IL-15R may be important in this context. 
Interestingly, age-related CD8+ T cell clonal expansions in mice show higher IL-15Rα 
compared with other CD8+ T cells (Messaoudi et al., 2006). In humans, CMV-specific 
CD8+ T cells retain high IL-15Rα expression following acute infection compared with 
EBV-specific CD8+ T cells following acute infection (Sauce et al., 2006). With such 
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complex mechanism of action, measuring IL-15Rα levels on T cells has proved difficult 
and variable, with reports of very low or absent expression on T cells (Geginat et al., 
2003, Sauce et al., 2006). Furthermore, attempts to determine IL-15Rα levels on CD8+ 
and CMV-specific CD8+ T cell subpopulations in this study have unfortunately been 
unsuccessful. 
 
The key findings of this chapter therefore are that CD8+ TEMRA cells may be generated 
from the previously proliferating memory subpopulations. CMV also has the potential to 
increase IL-15 in-vitro which may point to a role in the generation of CD8+ TEMRA cells in-
vivo. Longer telomeres coupled with low proliferative capability, low telomerase activity 
and low Bcl-2 levels indicates they may be a population which is close to senescence 
through telomere-independent mechanisms. The next chapter will therefore investigate 
if CD8+ TEMRA cells are also close to exhaustion i.e. whether or not they can exhibit 
efficient functional responses upon activation. 
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6 The functional quality of CMV-specific CD8+ T cells during 
ageing 
 
6.1 Introduction  
Dealing with a chronic viral infection presents a unique challenge to T cells, as they must 
control the infection over one’s lifetime in the face of possible T cell exhaustion. 
Therefore the importance of maintaining a quality immune response during a persistent 
infection is becoming increasingly recognised: bad prognoses with chronic infections 
such as Hepatitis C and HIV are associated with exhausted virus-specific T cells whereas 
favourable prognoses are associated with virus-specific T cells exhibiting broad 
polyfunctional responses upon activation (Betts et al., 2006, Effros, 2004, Golden-Mason 
et al., 2008, Jones et al., 2008, Kaufmann and Walker, 2008, Cellerai et al., 2011). 
Indeed, it is considered the more effector functions that constitute a T cell response the 
more protective the response will be (Makedonas and Betts, 2006, Seder et al., 2008). In 
the context of vaccination, poor polyfunctional responses to flu vaccine equate with 
poor protection, a problem frequently encountered when vaccinating the old (Kovaiou 
et al., 2007, McElhaney and Dutz, 2008, Seder et al., 2008, Weinberger et al., 2008).  
 
In addition to a broad polyfunctional response, the avidity of a virus-specific CD8+ T cell 
for antigen is also becoming increasingly recognised as an important factor in the 
control of infection. However whether high or low avidity T cells are most beneficial 
during a chronic infection is debateable. To highlight this, two studies investigating the 
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relationship between avidity of CD8+ T cells and disease progression in HIV (Almeida et 
al., 2007, Harari et al., 2007) both found a broad polyfunctional response was a 
signature of virus-specific CD8+ T cells in HIV non-progressors but one group identified 
these ‘superior’ cells as highly avid (Almeida et al., 2007) whereas the other group 
identified them as low avidity cells (Harari et al., 2007). Indeed, the hypothesis is 
plausible either way, as high avidity T cells will recognise viral antigen more efficiently 
than low avidity T cells but the former may become functionally exhausted as a result of 
more frequent activation during chronic infection. 
 
Does the accumulation of CMV-specific TCEs with ageing suggest a lack of control of 
chronic CMV infection later in life? The large numbers of CMV-specific CD8+ T cells in the 
old have been reported as being dysfunctional when compared with those in the young 
(Almanzar et al., 2005, Ouyang et al., 2003b) however there is little evidence of CMV 
reactivation in the old suggesting the virus is kept under control. One hypothesis is that 
CD8+ T cells that are most optimal against CMV but become exhausted, while the less 
optimal CD8+ T cells are consequently recruited, albeit in greater numbers, to control 
CMV. Evidence supporting this comes from observations of how healthy individuals 
control symptomatic primary CMV infections. In one study (Lidehall et al., 2005), by 
relating the number of CMV-specific CD8+ T cells found within donors to their total IFN-γ 
production recorded upon CMV stimulation, results showed individuals controlled 
infection by either mounting small highly efficient clones or compensating less efficient 
clones with increased cell numbers. In another study, by comparing CMV and EBV 
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responses in-vitro it was also shown that older individuals (>60) produced significantly 
lower IFNγ/virus-specific T cell ratios than those in the 40-60 age group (Khan et al., 
2004).  
6.2 Aims  
It has been proposed that CD8+ TEMRA cells may be an end-stage population as they show 
a high level of differentiation (Appay et al., 2002) and exhibit poor proliferative potential 
upon stimulation (Geginat et al., 2003). Indeed, previous chapters have confirmed that 
CD8+ TEMRA cells show low proliferation directly ex-vivo and in response to activation. 
Furthermore, results have shown that CD8+ TEMRA cells may be close to telomere-
independent senescence as they show a high susceptibility to apoptosis, low telomerase 
activity and high level DNA damage in the form of γH2AX expression.  
 
The aim of this chapter therefore was to question whether these accumulating CMV-
specific CD8+ TEMRA cells are also close to exhaustion, representing a less efficient 
population controlling CMV infection by a means of quantity over quality, or if they have 
maintained an ability to respond functionally upon activation. In order to address this 
question, the polyfunctional responses of CD8+ TEMRA cells to activation were compared 
with other CD8+ T cell subpopulations in both the global CD8+ and CMV-specific CD8+ T 
cell compartments. Furthermore, the avidity for antigen was investigated to determine 
whether this may impact the functional quality of the CD8+ T cell response and also 
whether donor age or CD8+ T cell phenotype influences this response. 
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6.3 Results  
 
6.3.1 CD8+ T cell subpopulation functional responses to activation 
Multiple functional markers are currently being used to identify quality T cells i.e. 
polyfunctional T cells which confer enhanced viral control (Casazza et al., 2006, Kirchner 
et al., 2008, Betts et al., 2006). It was therefore the aim to investigate the polyfunctional 
responses exhibited by CD8+ T cell subpopulations upon activation. 
 
6.3.1.1 CD8+ TEMRA cells show low frequency responses to activation 
Polyfunctional responses were measured by recording the simultaneous production of 
CD40L, IFN-γ, IL-2, and TNF-α of CD8+ T cell subpopulations following an anti-CD3 
stimulus. PBMCs from 27 young (18 CMV positive) and 12 old (9 CMV positive) donors 
were used for analysis. The frequency of responding cells i.e. cells responding with at 
least one cytokine was recorded for all cells as a percentage of the total subpopulation 
(figure 6.1A). CD8+ TEMRA cells had significantly lower numbers of responding cells 
compared with CD8+ TEM cells (p<0.0001) and CD8
+ TCM cells (p=0.01). However, when 
analysing the polyfunctional profile of those responding cells (figure 6.1B) no significant 
difference in polyfunctionality was uncovered between the CD8+ T cell subpopulations. 
Furthermore, when data was divided on the basis of age and CMV seropositivity (not 
shown) no further significant differences were uncovered on the basis of their 
polyfunctional responses to activation. 
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(A) 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
Figure 6-1.  Analysing polyfunctional responses of CD8
+
 T cell subpopulations to activation  
Total PBMCs were stimulated by OKT3 and functional outputs determined by CD8
+
 T cell subpopulation. 
(A) Responding cells determined by production of at least one function by subpopulation. (B) 
Corresponding polyfunctional profile of responding cells represented by CD40L, IL-2, IFN-γ, and TNF-α 
readouts in any combinations of 4, 3, 2, or 1 function expressed. Numbers shown are the mean 
percentages from 27 young (18 CMV positive) and 12 old (9 CMV positive) donors. Significant correlations 
represented by asterisks; *<0.01;**<0.001;***<0.0001. 
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6.3.2 CMV-specific CD45RA vs. CD45RO functional responses  
In the previous section, CD8+ TEMRA cells showed low frequency responses to α-CD3 
stimulus compared with CD8+ TCM and TEM cells. Next, the CMV-specific response to 
activation was compared between CMV-specific CD45RA vs. CMV-specific CD45RO 
memory CD8+ T cells. IFN-γ production following CMVpp65 peptide pulsed APCs 
stimulation was used to determine the percentage of CMV reacting cells, as IFN-γ has 
been shown to be the best indicator of activation (Kirchner et al., 2008). The outline for 
this experiment is shown in figure 6.2. 
 
 
 
 
Figure 6-2. Outline for CMV-specific CD45RA vs. CD45RO CD8
+
 T cell activation experiments 
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6.3.2.1 CMV-specific CD45RA+ T cells show low frequency responses 
CD8+CD45RA+ and CD8+CD45RO+ pure populations were sorted from HLA-matched 
individuals with identifiable CD45RA and CD45RO CMVpp65-specific subpopulations 
(representative example figure 6.3A). These subpopulations were then separately 
stimulated with either non-pulsed or CMVpp65-pulsed irradiated autologous APCs at 
various cell to cell ratios. An un-stimulated control containing medium only was also 
included. Focusing on the response of a representative individual (figure 6.3B); 
stimulation by non-specific APCs resulted in no IFN-γ production by either CMV-specific 
CD45RA+ or CD45RO+ CD8+ T cell subpopulation when compared to the un-stimulated 
control. When stimulated with CMVpp65-pulsed APCs, IFN-γ was produced in a dose-
responsive manner commensurate with increased APCs cell numbers added. The 
response of CMV-specific CD45RO+ cells peaked at ≈30% IFN-γ+ at a ratio of 1:2 cells to 
CMV-specific APCs, with no additive effect at a ratio of 1:4. In comparison, CMV-specific 
CD45RA+ cells in the same individual showed lower IFN-γ production under the same 
conditions peaking at just ≈13% IFN-γ+ at the highest ratio of 1:4 cells.  
 
The results suggest the CMV-specific CD8+ CD45RA+ memory T cells show a lower 
functional response to activation with cognate CMV peptide compared with CD8+ CMV-
specific CD45RO+ memory T cells. 
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(A) 
 
 
 
 
 
(B) 
 
 
 
 
Figure 6-3.  Functional response of CMV-specific CD45RA vs. CD45RO memory CD8
+
 T cell populations 
(A) FACs plots illustrating CMV-specific CD45RA
+
 and CD45RO
+
 CD8
+
 T cell memory populations post 
sorting via FACs Aria. (B) These CMV-specific CD45RA
+
 and CD45RO
+
 CD8
+
 T cell memory populations  
were stimulated separately with un-pulsed APCs or increasing ratios of NLV-pulsed APCs and IFN-γ 
response recorded. U.S. represents the un-stimulated control (containing no APCs). This is a 
representative of two experiments. 
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6.3.3 Investigating CMV-specific CD8+ T cell avidity for antigen 
Lower functional responses to activation may be related to T cell avidity. The Virus-
specific T cell population consists a heterogeneous mixture of T cells bearing high or low 
affinity TCR for peptide (Villacres et al., 2003). As discussed in the introduction of this 
chapter, it is unclear whether high or low avidity T cells are most optimal at controlling 
chronic infection. Therefore, the identification of high avidity CD8+ T cells within the 
CMV-specific population was investigated on the basis of donor age and phenotype. 
 
6.3.3.1 Using mutated ‘CD8null’ tetramers to identify high avidity T cells 
As discussed in chapter 1 (section 1.2.6), high avidity virus-specific CD8+ T cells can be 
identified using mutated (CD8null) tetramers.  A high avidity population can therefore 
be identified and compared to the normal population binding regular un-mutated 
tetramer, as illustrated when staining using these two tetramers within the same donor 
(figure 6.4).  
 
 
Figure 6-4. Staining with normal versus mutated (CD8 Null) tetramers 
Representative FACs plot analysis showing PBMCs from one individual stained with either the normal 
(left) or CD8 null mutated (right) tetramers, which identify a normal or high affinity CD8
+
 T cell population 
respectively. Numbers shown represent total percentage of CD8
+
 T cells identified by relevant tetramer. 
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6.3.4 CMV-specific CD8+ T cell avidity and ageing 
The next step was to determine any influence of donor age on the avidity of the 
CMVpp65-specific CD8+ T cell population. If indeed ‘quantity over quality’ is a hallmark 
of the CD8+ T cell response to CMV in older individuals, those subjects with larger 
CMVpp65-specific CD8+ TCEs may have a smaller percentage of high avidity T cells 
compared with younger individuals, with smaller CMVpp65-specific CD8+ TCEs. This was 
therefore investigated.  
6.3.4.1 Low avidity NLV-specific CD8+ T cell populations in the old 
All donors who were an HLA-A*02 or HLA-B*07 match were stained with both normal 
and CD8null tetramers specific for NLV- or TPR-specific CMVpp65 peptide respectively, 
and the size of these populations recorded (figures 6.5A & 6.5B). The population binding 
CD8null tetramer was a fraction of that binding normal tetramer (0-100%), which varied 
between individuals. When dividing this data into young or old age groups and by NLV- 
or TPR-specific populations (figure 6.5C & 6.5D); the normal NLV population and CD8null 
NLV population was comparable in the young, whereas in the old, the CD8null NLV 
population was significantly lower (<0.01) than the normal NLV population. This pattern 
was not seen for the TPR population. Results suggest the NLV-specific CD8+ T cell 
population in old HLA-A*02+ individuals is of lower avidity than in the young.  
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 (A)                                                                                    (B) 
 
 
(C)                                                                      (D) 
 
 
 
Figure 6-5.  Frequency of normal and CD8null binding populations within donors 
Bar chart comparing normal and CD8null tetramer binding populations identified within donors. (A) total 
NLV-specific normal and high CD8null populations from 30 donors. (B) TPR-specific normal and CD8null 
populations from 20 donors. (C) NLV-specific normal and CD8null populations by age: 10 young and 16 old 
donors. (D) TPR-specific normal and CD8null populations by age: 4 young and 10 old donors. Significant 
differences represented by asterisks; *<0.01;**<0.001;***<0.0001. 
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6.3.5 The relationship between avidity and CD45RA re-expression 
The next step was to investigate any association between CD45RA re-expression and 
avidity within CMVpp65-specific CD8+ T cell populations.  
6.3.5.1 CD45RA expression is associated with low avidity 
Expression of CD45RA/CD45RO in the normal and high avidity CMVpp65-specific 
populations was compared within the same individuals. In the representative example 
of figure 6.6A; the characteristic CD45RA/CD45RO spread in the total normal CMVpp65-
specific population can be seen, with a predominately CD45RA+ (i.e. 73%) 
subpopulation. However, within the same individual, the high avidity CMVpp65-specific 
population is just 15% CD45RA+; the dominant subpopulation being CD45RO+ (i.e. 66%). 
When data on 40 individuals were pooled (figure 6.6B), a highly significant negative 
correlation was found between the percentage of the CD45RA+ memory subpopulation 
within the total CMVpp65-specific population and the percentage of the CMVpp65-
specific population being high avidity i.e. binding the null tetramer (p=0.0002, R2=0.30). 
The reverse was also true, i.e. a positive correlation when plotting the percentage of 
CD45RO+ memory in the total CMVpp65-specific population, against the percentage of 
CMVpp65-specific population being high avidity (not shown). Furthermore, when the 
data was divided into NLV or TPR specific CMVpp65 populations, it was NLV-specific 
response that seemed to drive this highly significant relationship (p<0.0001 R2=0.53, 
Figure 6.6C) and not the TPR-specific response (p=0.2727, R2=0.09, Figure 6.6D). 
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(A) 
 
 (B) 
 
 
(C)                                                                                 (D) 
 
 
Figure 6-6.  CD45RA
+
 memory CMVpp65-specific CD8
+
 T cells are associated with low avidity. 
(A) Representative example of staining in one individual with either the Normal or High affinity NLV-
specific tetramer with CD45RA and CD45RO. (B) Pooled data showing relationship between percentages 
CD45RA
+
 within total (NLV- or TPR-specific populations); 45 donors shown. (C) Pooled data showing 
relationship between percentages CD45RA
+
 within NLV-specific populations; 29 donors shown. (D) Pooled 
data showing relationship between percentages CD45RA
+
 within TPR-specific populations; 16 donors 
shown. Significant correlations represented by asterisks; *<0.01;**<0.001;***<0.0001. 
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Although the association between CD45RA expression and T cell avidity was seen in 
HLA-A*02 individuals, the correlation was not significant in HLA-B*07 individuals. 
However, some HLA-B*07 individuals had two separate populations upon staining with 
the normal tetramer (figure 6.7). When comparing the CD45RA/CD45RO phenotype of 
these two populations, the higher MFI population showed a predominately CD45RO+ 
phenotype and the lower MFI showed a predominately CD45RA+ phenotype. This 
suggests that these individuals may also have CD45RA re-expressing CMV-specific T cells 
that are associated with lower affinity on the basis of less binding of the tetramer 
equating to lower MFI. 
 
 
 
 
Figure 6-7.  Dual populations identified with TPR-specific tetramer show alternate phenotypes 
Representative example of staining in one individual with TPR-specific tetramer. From left to right, 
CD45RA/CD45RO expression is shown on each population of total TPR-specific, high MFI TPR-specific, and 
low MFI TPR-specific populations. Representative of at least 3 individuals.  
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6.3.6 Co-receptor availability on CD8+ and CMV-specific CD8+ T cells 
In order for CD8+ T cells to become activated, peptide must be presented to its TCR via 
the MHC class I molecules on the surface of the APC. To stabilise this interaction it is 
imperative there is adequate CD8 co-receptor availability on the T cell (Daniels and 
Jameson, 2000, Villacres et al., 2003). To investigate if CD8 co-receptor availability may 
determine T cell binding to the mutated (CD8null) tetramer observed by CD45RA+ 
subpopulations, the surface expression levels of CD8 co-receptor was analysed on both 
CD8+ and CMV-specific CD8+ T cell subpopulations (figures 6.8A & 6.8B respectively). No 
difference in CD8 levels was found between the memory subpopulations, indicating no 
subpopulation exhibited greater CD8 availability which may account for enhanced 
binding to the null tetramer.  
 
 
(A)                                                                               (B) 
 
Figure 6-8.  CD8 co-receptor expression in global CD8
+
 and CMV-specific CD8
+
 T cell subpopulations 
(A) CD8 levels within the CD8
+
 T cell subpopulations relative to total CD8 levels (set to 100%) from 10 
individuals. (B) Relative levels of CD8 in CD45RA
+
 and CD45RO
+
 CMV-specific populations relative to total 
CMV-specific CD8 levels (set to 100%) from 6 individuals. 
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6.3.6.1 CD8null tetramers identify T cells with superior polyfunctionality 
Polyfunctional responses by CMV-specific CD8+ T cells have been correlated with control 
of CMV viremia during organ transplantation (Gratama et al., 2001, Kirchner et al., 2008, 
Nebbia et al., 2008). Although CMV reactivation in healthy individuals is rare, older 
individuals have been associated with dysfunctional responses to CMV (Almanzar et al., 
2005, Ouyang et al., 2003b, Khan et al., 2004). Null tetramers identify a population of T 
cells with high affinity for antigen, however it is unclear whether this population also 
exhibits a superior functional response upon activation. It has been shown previously 
that CD8+ T cells recognising very low antigen concentrations i.e. high-avidity CD8+ T 
cells, are the most efficient at eliminating viruses (Alexander-Miller et al. 1996; Almeida 
et al. 2007; Derby et al. 2001). However, one study has shown that low-avidity CD8+ T 
cells may be more beneficial in controlling chronic infections (Harari et al. 2007).  
 
Whether high or low avidity CMV-specific CD8+ T cells show the superior functional 
responses were therefore investigated, as the association of T cell avidity between age 
and phenotype found in the last section may have functional consequences. The 
functional responses of normal and high avidity CMVpp65-specific populations to 
CMVpp65 peptide were compared to investigate this. IFN-γ, CD107a and TNF-α were 
used as functional indicators of their response to activation. The outline of this 
experiment is summarised in figure 6.9.  
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Figure 6-9. Normal vs. high avidity polyfunctionality comparison experiment 
Schematic summarising the experiment used to compare the polyfunctional read-out of CMV-specific high 
avidity versus total normal population. 
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Results comparing the polyfunctional responses of the normal vs. high avidity 
populations are shown in figure 6.10. A representative example of one donor response 
(figure 6.10A), shows with stimulation at the low CMVpp65 peptide concentration of 
0.001μg; the high avidity population (identified by CD8null tetramer) responded with 
greater production of all functional markers, relative to the normal population 
(identified by non-mutated tetramer), as depicted in the relevant histograms. When 
comparing functional responses over a peptide titration, the high avidity population 
produced elevated levels of each functional marker relative to the normal population at 
all concentrations tested (figure 6.10B). 
 
Despite inter-individual variations in responses, findings were consistent in three 
different donors. When comparing responses to stimulation with 0.1μg CMVpp65 
peptide, the high avidity population showed significantly higher expression of all 
functional markers (figure 6.10C). Results suggest that the high avidity population also 
exhibits superior polyfunctionality over the total normal population. Therefore, the use 
of CD8null tetramers gave a novel and efficient way of identifying CMVpp65-specific 
CD8+ T cells exhibiting high polyfunctionality within a given CMVpp65-specific CD8+ T cell 
population. 
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 (A) 
 
(B) 
 
(C) 
 
Figure 6-10.  CMVpp65-specific CD8
+
 T cell functional responses identified by avidity tetramers 
(A) Representative staining of one donor identifying the normal (top) or high avidity (bottom) 
CMVpp65specific populations by regular tetramer and CD8 Null tetramer respectively. Relative expression 
of IFNγ, CD107a and TNFα following stimulation with 0.001μg CMVpp65peptide is shown for each 
population by relevant histograms, as percentage positivity vs. isotype control. (B) Full titration showing 
functional readouts following the stimulation of normal or high affinity populations with CMVpp65 
peptide concentrations at 0μg, 0.001μg, 0.01μg, 0.1, and 1μg/ml. (C) Example comparison of functional 
output by either population following stimulation with 0.1μg CMVpp65 peptide for 3 donors. One-tailed 
paired T test used. Significant correlations represented by asterisks; *<0.01;**<0.001;***<0.0001. 
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6.4 Discussion 
The aim of this chapter was to investigate if CD8+ TEMRA cells represented an exhausted 
subpopulation within the CD8+ T cell compartment. The purpose was to specifically 
address whether CD8+ TEMRA cells can respond functionally upon activation. In 
conclusion, results showed both CD8+ and CMVpp65-specific TEMRA cells can exhibit a 
broad polyfunctional profile upon activation. However, they do so only when given a 
greater stimulus. Furthermore, evidence suggests it is a low avidity for antigen that may 
explain their higher requirement for activation. Therefore CMVpp65-specific TEMRA cells 
are associated with lower functional avidity. 
 
CD8+ TEMRA cells were found to react less efficiently to a broad antigenic stimulus relative 
to the other memory CD8+ T cells in terms of percentage of responding cells. This was 
further illustrated by the fact that CMV-specific CD45RA+ memory CD8+ T cells 
responded to CMV antigen less efficiently than CMV-specific CD45RO+ memory CD8+ T 
cells based on IFN-γ production. Work presented in this chapter showed that this is 
likely due to an association between CD45RA re-expression and low affinity TCR for 
antigen within this CMVpp65-specific CD8+ T cell subpopulation. It has been shown 
previously that some memory CD8+ T cells require greater CD8 help for activation than 
others (Price et al., 2005, Khan et al., 2010). However, CD8 co-receptor levels in the 
present study were found to be similar across all CD8+ and CMV-specific CD8+ T cell 
memory subpopulations regardless of CD45RA expression, suggesting this is not the 
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reason for the difference in activation in this instance. However CD8 antibody blocking 
experiments will be needed to confirm this. 
 
As discussed in the introduction of this chapter, debate surrounds whether a high or low 
avidity T cell response is most beneficial during a chronic viral infection (Almeida et al., 
2007, Harari et al., 2007). In the present study it was found that high avidity CD8+ T cells 
(as identified by binding CD8null tetramer) displayed the superior functional responses 
to CMV peptide. These observations are consistent with findings showing CMV-specific 
CD8+ T cells with high avidity express all effector functions upon activation ex-vivo 
compared with low avidity CD8+ T cells, which exhibited no ex-vivo cytotoxicity, secreted 
minimal IFN-γ, and did not recognise autologous infected targets (Villacres et al., 2003).  
 
So how do CD45RA re-expressing memory T cells accumulate if they show lower 
functional avidity? Usually during an immune response CD8+ T-cell clones that initially 
expand bear TCRs with a broad range of avidities for the same antigen and this is 
subsequently followed by a strong contraction of those T cells expressing low avidity 
TCR (Zehn et al). However, chronic CMV infection may lead to the exhaustion of CMV-
specific CD8+ T cells, as has been observed in older individuals (Ouyang et al., 2003b). 
Studies into antigen avidity during persistent CMV infection has found CD8 clonotypes 
exhibiting high antigen avidity were preferentially driven towards terminal 
differentiation compared with those of low antigen avidity (Price et al., 2005). 
Interestingly, the same authors also found low avidity clonotypes could co-exist 
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competitively with their high avidity counterparts. In the context of animal studies, it 
has been shown that mice receiving repeated challenges with Listeria monocytogenes 
(L.m.) can lead to L.m-specific CD8+ TEM cells becoming ablated and impaired while L.m-
specific CD8+ TCM cells remain unaffected (Huster et al., 2009). This further highlights 
how one CD8+ T cell memory subpopulation may be outlived by another during chronic 
infection. In this respect, CMV-specific cells with high functional avidity may be lost and 
replaced by CMV-specific cells with low functional avidity. Indeed, there is a finite 
‘immune space’ and this may result in competition between such T cells (Akbar and 
Fletcher, 2005, Franceschi et al., 2000, Pawelec et al., 2005, Vasto et al., 2007, Ku et al., 
2001).  
 
The functional avidity of CMVpp65-specific CD8+ TCEs was also analysed on the basis of 
donor age. Old HLA-A*02+ individuals showed a lower frequency of cells with high 
functional avidity compared with younger individuals. Furthermore, the percentage of 
CMVpp65-specific CD45RA+ memory cells was associated with a significantly lower 
functional avidity population within these individuals. Furthermore, on retrospective 
analysis, the old individual with a large CD8null binding NLV-specific population of 11.5% 
(figure 6.5C) was subsequently found to be 82% CD45RO+, which was consistent with 
the association of CD45RO expression and high affinity. However, the highly significant 
correlation between functional avidity and CD45RA expression was due to individuals 
who were HLA-A*02+ (targeting NLV peptide) although there was evidence for a similar 
association for those who were HLA-B*07+ (targeting TPR peptide) in certain individuals. 
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Such individuals showed dual staining with tetramer that led to the identification of two 
distinct populations exhibiting different CD45RA/CD45RO phenotype. Indeed, the 
identification of dual populations with tetramer has been shown elsewhere, and may 
represent populations with different TCR affinities (Moss and Khan, 2004).  
 
These results suggest different HLA-types may equate with different T cell functional 
avidity for antigen. Indeed, there are similar reports associating HLA type with T cell 
functional avidity during chronic viral infection (Almeida et al., 2007, Harari et al., 2007). 
Furthermore, it is known that susceptibility to various diseases can be dependent on 
HLA type (Blackwell et al., 2009, Burgner et al., 2006). Although CMV disease is rare in 
immune-competent individuals, HLA type can still influence the T cell response of these 
individuals (Hollsberg, 2002, Lacey et al., 2003). Indeed, a minimal number of CD8+ 
CMVpp65-specific T cells have been estimated to be needed for protection against CMV 
reactivation during organ transplantations (Aubert et al., 2001, Cwynarski et al., 2001). 
Interestingly, these numbers seem to differ on the basis of one’s HLA type (Giest et al., 
2010, Koehl et al., 2008). For example, HLA-B*3501/pp65-specific CD8+ T cells confer 
protection from CMV reactivation with significantly lower cell numbers than HLA-
A*0201/pp65-specific CD8+ T cells (Giest et al., 2010).  
 
Furthermore, individuals having both HLA-A*02 and HLA-B*07 alleles show preferential 
and dominant T cell numbers specific for the TPR epitope of CMVpp65 over the NLV 
epitope (Lacey et al., 2003)and our observations). In addition, while not tested in the 
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present study, these HLA-A*02/B*07 positive individuals show TPR-specific T cell 
responses with higher cytokine production and preferential expansion over their NLV-
specific T cell responses (Lacey et al., 2003). Interestingly, when stimulating with NLV 
peptide only (instead of overlapping pp65 peptide pool which would contain TPR 
peptide), NLV responses are comparable to those of HLA-A*02 single positive individuals 
(Lacey et al., 2003). This suggests, in the absence of immunodominant TPR stimulus, the 
NLV response can compensate. This is consistent with findings in this chapter, as it was 
shown TPR-specific T cells were uniformly high avidity T cells, which showed the greater 
production of cytokine compared with the total population. Immunodominance of HLA-
B*07+ restricted epitopes over HLA-A*02+ restricted epitopes has also been reported in 
EBV immune responses (Hollsberg, 2002). One possible mechanism for this 
immunodominance is enhanced peptide-MHC association and processing. Evidence 
supporting this shows different HLA-B44 subtypes processing the same epitope do so 
with different speeds of epitope assembly and transportation (Khanna et al., 1997).  
 
In conclusion, this chapter shows that CD8+ TEMRA cells retain polyfunctionality upon 
activation, suggesting they are not an exhausted population. However, it seems they 
require a higher degree of activation to display these functional properties, and whether 
CMV-specific CD45RA+ memory CD8+ T cells can reach the levels displayed by CMV-
specific CD45RO+ memory CD8+ T cells is questionable, and requires further 
investigation. Significantly, it seems that a lower avidity for antigen may be instrumental 
in this association.  
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7 General Discussion 
 
This thesis aimed to address the impact of one proposed driver of senescence, CMV 
infection, on age-related changes seen within the CD8+ T cell compartment. The results 
of this investigation will now be discussed in the light of current evidence to formulate a 
hypothesis on how CMV may impact immune senescence. 
7.1 CMV and the Immune Risk Phenotype 
The OCTO and NONA longitudinal studies (Wikby et al., 2005) identified CMV 
seropositivity as a significant factor within the immune risk phenotype (IRP), a cluster of 
immune parameters associated with a 2-4 year decreased survival rate. The expansion 
of highly differentiated CMV-specific CD8+ T cell memory populations may provide the 
link between CMV and the IRP (Pawelec et al., 2006a). Therefore, data presented here 
showing that the age-related accumulation of highly differentiated CD8+ TEMRA cells 
within the CD8+ T cell compartment is accelerated in CMV positive individuals is 
important. Indeed, some old individuals had >50% of their global CD8+ T cell population 
consisting of these CD8+ TEMRA cells, all of which were CMV positive. Furthermore, 
results have shown that CMV-specific CD8+ TEMRA cells dominate within CMV-specific 
CD8+ TCEs of older individuals. This is consistent with similar findings that CMVpp65-
specific CD8+ T cells in the elderly were predominantly CD45RA+ but in the young they 
were mostly CD45RO+ (Colonna-Romano et al., 2007). The increase in this highly 
differentiated CD8+ T cell population may serve to impact the CD4:CD8 ratio and lower 
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CD27/CD28 expression of the CD8+ T cell compartment, both of which are significant 
factors defining the IRP.  
 
The association between CMV seropositivity, the IRP and premature mortality is 
currently being disputed through the large Leiden longevity study (Maier et al. 
unpublished observations). Furthermore, one study showed a group of long-lived 
individuals with a 30% decreased mortality risk appeared to be more resistant to CMV 
infection, and even after CMV infection were less susceptible to the CMV related 
immune changes (Derhovanessian et al., 2010). Interestingly, this long-lived population 
did not show the age-related accumulation of CD45RA re-expressing memory T cells 
(Derhovanessian et al., 2010). Therefore, the impact of CMV may require further 
definition. Are some individuals more susceptible to CMV related changes? When 
considering the significance of CMV seropositivity on the IRP, it must be remembered 
that seroprevalence varies considerably depending on racial group and socioeconomic 
status (Dowd et al., 2009). Therefore, CMV seropositivity may be a restrictive biomarker, 
identifying only those who are more likely to have encountered other infections or 
complications, or even those who have less competent immune responses generally. 
This could this explain why CMV seropositivity is associated with increased incidences of 
cardiovascular disease, frailty, cognitive decline, depression, stress and anxiety (Simanek 
et al., 2011, Schmaltz et al., 2005, Strandberg et al., 2004, Phillips et al., 2008) but is 
negatively associated with wealth, education, and longevity (Dowd et al., 2009, Cannon 
et al., 2010, Bate et al., 2010).  
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One proposed mechanism for the detrimental impact of CMV infection during ageing is 
that large CMV-specific CD8+ TCEs may compete for survival niches that lead to the loss 
of T cells of other specificities (Akbar and Fletcher 2005; Moss and Khan 2004). The 
analysis of CMV-specific TCEs within individuals may therefore yield more appropriate 
information than just CMV seropositivity alone. Indeed, there has been much work 
characterising these CMV-specific TCEs (Gillespie et al., 2000, Kern et al., 1999, Khan et 
al., 2004, Moss and Khan, 2004, Nebbia et al., 2008, Ouyang et al., 2003a, Ouyang et al., 
2004, Pita-Lopez et al., 2009, Wills et al., 1996, Wills et al., 1999, Ouyang et al., 2003b). 
One key question is whether these represent senescent or exhausted T cells and if these 
fill up the immune space requiring a large share of survival signals. Indeed, CMV-specific 
T cells in older individuals show lower IFN-γ responses (Hadrup et al., 2006, Ouyang et 
al., 2002, Ouyang et al., 2004, Khan et al., 2004) indicative of exhaustion and higher 
KLRG-1 (Ouyang et al., 2003a) indicative of senescence.  
7.2 Senescence vs. exhaustion in TEMRA cells 
Results in this study showed CD8+ TEMRA cells are relatively prone to apoptosis through 
low Bcl-2 levels, and exhibit low proliferation both directly ex-vivo and in response to 
stimulation. In addition, low telomerase levels and high DNA damage through γH2AX 
expression was also found in this subpopulation. This collectively suggests CD8+ TEMRA 
cells are a senescent population. Similar results have also been observed with CD4+ 
TEMRA cells, which show low ki67, low Bcl-2 and low telomerase activity (Libri et al., 
2011). Relatively long telomere lengths for a memory population however, indicate they 
may be approaching senescence through a telomere-independent mechanism, having 
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undergone less rounds of cell division. Indeed, turnover studies using in-vivo deuterated 
glucose labelling, suggests CMV-specific CD8+ CD45RA+ memory T cells may persist 
through an extended lifespan rather than through an increase in proliferation (Wallace 
et al., 2004). In doing so, have they accumulated greater DNA damage? The high γH2AX 
expression found in results presented here suggests they have, although γH2AX 
expression in CMV-specific CD8+ T cells needs to be investigated also in or order to 
address this.  
 
p38 MAP kinase is one of the key molecules that regulates both telomere-dependent 
and telomere-independent senescence (Iwasa et al., 2003, Ono and Han, 2000). 
Recently in our group, it has been shown that CD4+ TEMRA cells express high levels of 
total and phosphorylated forms of p38 (Dimitri et al., submitted). Furthermore, the 
addition of BIRB 796, an inhibitor of p38 signaling (Bagley et al., 2007), resulted in 
enhanced cell recovery, reduced apoptosis and enhanced telomerase activity by up to 4 
fold (Dimitri et al., submitted). This suggests p38 regulates senescence-associated 
defects in T cells, specifically in CD4+ TEMRA cells. Preliminary results suggest similar 
findings in CD8+ TEMRA cells also, and work is ongoing. 
 
Evidence indicates CD8+ TEMRA cells are a senescent population, but are they exhausted? 
Exhaustion is defined by the progressive loss of T cell function, leading to the deletion of 
the exhausted cell. This develops when there is a high antigenic load and non-functional 
antigen-specific CD8+ T cells have been observed during HIV (Day et al., 2006), hepatitis 
  
184 
 
B virus (HBV) (Das et al., 2008) and hepatitis C virus (HCV) (Urbani et al., 2006, 
Nakamoto et al., 2009) infections. Exhausted T cells are subject to negative regulation 
by signaling through multiple inhibitory receptors that inhibit functional and 
proliferative responses (Blackburn et al., 2009). Exhaustion therefore is different from 
senescence in that it is initiated by signaling events and not through DNA damage 
responses as is found in senescent T cells (Akbar and Henson, 2011). Programmed cell 
death 1 (PD-1) has been shown to be the most highly expressed cell and best studied 
surface inhibitory receptor that regulates exhaustion in CD8+ T cells  (Day et al., 2006, 
Petrovas et al., 2006, Trautmann et al., 2006, Barber et al., 2006, Blackburn et al., 2009). 
PD-1 is expressed highly on highly differentiated T cells (Appay et al., 2008, Sauce et al., 
2007, Shen et al., 2010, Henson et al., 2008) and the expression of PD-1 on both CD4+ 
and CD8+ T cells has been associated with CMV disease and reactivation during 
transplantation (Gallez-Hawkins et al., 2009). Also during transplantation, PD-1 
expression on CMV-specific T cells was associated with poor functional responses and 
viremia in patients (Sester et al., 2008). Interestingly, expression of PD-1 is lower on 
CD8+ TEMRA cells compared with TEM cells (Appay et al., 2008, Sauce et al., 2007, Shen et 
al., 2010) suggesting CD8+ TEMRA cells are not the most exhausted of the memory CD8
+ T 
cell populations according to this pathway. Indeed, high avidity CD45RO+ T cells could be 
induced to undergo apoptosis through more frequent antigenic stimulation, which 
would be reflected by higher PD-1 levels compared to TEMRA cells (Alexander-Miller et 
al., 1996). 
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Indeed, results presented here have shown that CD8+ and CMV-specific CD8+ TEMRA cells 
are capable of exhibiting broad polyfunctional responses, including IFN-γ, CD107a, and 
TNF-α, supporting evidence that they are not an exhausted population. CD4+ TEMRA cells, 
despite showing signs of senescence, have also been shown to retain polyfunctionality 
(Libri et al., 2011). However, results from this thesis showed the polyfunctional 
responses to activation were marked by a lower percentage of CD8+ TEMRA cells 
responding compared to the other memory CD8+ T cell subpopulations. Furthermore, 
the CMV-specific IFN-γ response to activation was significantly greater in CD45RO+ 
versus CD45RA+ CMV-specific CD8+ T cells.  
 
Work using mutated avidity tetramers also revealed that despite CMV-specific CD8+ T 
cells being able to mount polyfunctional responses, the high avidity population 
exhibited significantly greater numbers producing each functional marker compared 
with the low avidity population. This is important as CD45RA re-expression on CMV-
specific CD8+ T cells was associated with lower functional avidity. Therefore, evidence 
collectively suggests CMV-specific CD8+ TEMRA cells may be responding less efficiently 
than the CMV-specific population as a whole. This may explain how the accumulation of 
TEMRA cells within the CMV-specific compartment of old individuals could lead to an 
overall reduction (dysfunctional responses and senescence) of the CMV-specific 
compartment as a whole, compared with that in the young (Hadrup et al., 2006, Ouyang 
et al., 2003a, Ouyang et al., 2004, Khan et al., 2004). 
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7.3 Generation of TEMRA cells 
There is debate whether TEMRA cells are driven to proliferate by antigen or are 
homeostatically maintained by cytokine. Initial evidence suggesting they are driven by 
antigen came from TCR vβ repertoire screening, which showed TEMRA cells differed 
significantly from un-primed naive CD8+ T cells and often contained large clonal 
expansions (Hamann et al., 1999a). CD8+ TEMRA cells also have shorter telomere lengths 
than un-primed naive T cells (Faint et al., 2001, Hamann et al., 1999a), exhibit low 
expression of CD27/CD28, and display various effector type properties (Wills et al., 
2002, van Leeuwen et al., 2002), collectively indicating they have undergone repeated 
antigenic stimulation. However, the appearance of CMV-specific CD8+ TEMRA cells 
coincides with the resolution of primary CMV infection (Miles et al., 2007, Wills et al., 
1999, van de Berg et al., 2008) and also correlate with clearance of CMV from the blood 
of pregnant women with primary CMV infection (Lilleri et al., 2008). Interestingly, lower 
CMV-specific CD8+ TEMRA cell numbers in the few months post infection, also correlated 
with higher chances of transmission to the new born (Lilleri et al., 2008) suggesting 
active CMV infection was still occurring at this point. Altogether, this suggests that TEMRA 
cells may appear in the absence of active CMV infection. 
 
Data presented here shows TEMRA cells dominate the CMV-specific CD8
+ T cell 
compartment later in life, which suggests they appear more frequently later in infection. 
The argument against cytokine driven, rather than antigen driven, proliferation of TEMRA 
cells is the prediction that cytokine would cause the expansion of all memory T cells 
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equally; however TCR screening of EBV-specific and CMV-specific CD8+ TCEs reveals 
preferentially expansion of certain clones (Iancu et al., 2009, Trautmann et al., 2005). 
Therefore, it is possible that TEMRA cells are generated from previously proliferating 
memory cells which are subsequently maintained by cytokine. In support of this 
hypothesis, IL-15 plus IL-7 was shown to cause the reversion of CD8+ T cells from a 
CD45RO+CCR7+ (TCM) to CD45RA
+CCR7- (TEMRA) phenotype (Geginat et al., 2001) and IL-15 
treatment alone caused EBV-specific CD8+CD45RO+ T cells to revert back to a CD45RA+ 
phenotype in-vitro (Dunne et al., 2002). Further confirmation comes from data in the 
present study, showing CMV-specific CD8+CD45RO+ T cells can re-express CD45RA 
during IL-15 treatment.   
 
Older humans have increased serum levels of pro-inflammatory cytokines such as IL-6 
and TNF-α, which correlate with increased frailty and reduced life expectancy 
(Franceschi et al. 2007). Previous studies have shown that TNF-α can accelerate T cell 
differentiation in-vitro (Bryl et al. 2005) and inhibit telomerase activity in human CD8+ T 
cells (Parish et al. 2009). It has also been shown that CMV can lead to increased IFN-α 
levels, causing T cell differentiation and telomerase down-regulation in CD4+ T cells 
(Fletcher et al., 2005). Acute viral infections also have the potential to drive the 
bystander activation and proliferation of CMV and EBV specific CD8+ T cells  (Sandalova 
et al., 2010). Evidence therefore suggests the involvement of pro-inflammatory 
cytokines in the generation and activation of TEMRA cells. Indirect evidence for this is that 
anti-TNF-α therapy in patients with rheumatoid arthritis depletes CD8+ TEMRA cells (Bruns 
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et al. 2009). Furthermore, supporting the hypothesis that an inflammatory cytokine 
environment may lead to the accumulation of TEMRA cells come from results in this 
thesis, showing that both IFN-α and CMV lysate treatment can increase IL-15 mRNA 
levels in-vitro. Therefore a hypothesis for the generation of CMV-specific CD8+ TEMRA 
cells is proposed (figure 7.1). Based on results from this thesis and the evidence 
discussed so far, it is hypothesised that both CMV and ageing act synergistically to 
create an environment favouring the generation of CMV-specific CD8+ TEMRA cells from 
low avidity memory CD8+ T cell populations. 
 
 
 
Figure 7-1. Hypothesis for the generation of CMV-specific TEMRA cells during ageing 
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7.4 Mechanism and purpose for reversion 
 
What purpose does CD45RA re-expression serve? Differential expression of CD45 
isoforms have been reported to influence biological function and cell signalling events, 
however, experiments with CD45-defective cells show the addition of chimeric 
molecules containing only the intracellular CD45 PTPase domain was sufficient to 
restore TCR-CD3 mediated cell signalling (Volarevic et al., 1993). This questions the role 
of the CD45 glycoprotein extracellular domain. The immune synapse formed between a 
T cell and its APC allows sustained MHC-TCR interaction with subsequent downstream 
signalling for complete activation, the large size of CD45R relative to other participants 
of the IS led to proposals that it is excluded from the immune synapse (Penninger et al., 
2001). In support of this, CD45R was reportedly absent from membrane lipid rafts 
involved with signalling (Rodgers and Rose, 1996). However reversion to the larger 
CD45RA+ glycoprotein-rich isoform could still theoretically influence activation by APCs 
at the immune synapse, by creating a glycoprotein barrier absent during communication 
of CD45RO+ isoform expressing T cells with APC. Such a model compares the CD45RA 
isoform to a break or rheostat on the cell surface, preventing surplus activation. In fact, 
there is experimental evidence to support this in the form of the kinetic-segregation 
model (Choudhuri et al., 2005). In this respect TEMRA cells may be a ‘pseudo-naive’ 
population, requiring greater and/or longer stimulation for activation than required by 
the traditional memory cells. The association between CD45RA re-expression and low 
functional avidity on CMV-specific CD8+ T cells may reflect this. However, whether it is 
CD8+ T cells expressing low avidity that are preferentially re-expressing CD45RA or 
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whether the process of CD45RA re-expression mechanically causes lower avidity needs 
further investigation. However, experiments using mouse models have shown that a 
single cell can differentiate into either high or low avidity CD8+ T cells (Kroger and 
Alexander-Miller, 2007).  
7.5 The impact of CMV on telomere length 
The benefit of having longer telomere lengths in blood leukocytes is associated with 
better health (Terry et al., 2008) and more years of life (Njajou et al., 2009). The 
consequence of having short lymphocyte telomeres on the other hand is associated 
with an 8-fold increase in death from infectious diseases and a greater risk of heart 
disease (Cawthon et al., 2003, Spyridopoulos et al., 2009). Therefore, the finding that 
CMV infection in healthy individuals is associated with shorter telomeres is important 
and we have recently published this (van de Berg et al., 2010). The age-related attrition 
of telomeres was most prominent in CD8+ T cells and CMV positivity was shown to 
significantly increase the rate of telomere attrition in CD8+ T cells. Furthermore, the 
effect of CMV infection upon telomere length is less marked in the young age group, but 
highly significant in the old age group, suggesting both the decrease in naive cells 
(having relative long telomeres) and accumulation of memory cells (having relatively 
shorter telomeres) may be the root cause. Indeed, telomere lengths were longest in 
CD8+ TN cells and shorter in the memory populations, which was consistent with 
previous observations (Akbar and Vukmanovic-Stejic, 2007). However CD8+ TEMRA cell 
telomere lengths were not the shortest of the memory subpopulations but actually 
significantly longer than the CD8+ TEM cells, which is consistent with another report 
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(Plunkett et al., 2005). Furthermore CMV-specific TEMRA cells showed significantly longer 
telomeres than CMV-specific CD8+CD45RO+ T cells. Despite this, these populations 
represent T cells with significantly shorter telomere lengths compared with naive T cells, 
and these highly differentiated  cells correlate with shorter telomere lengths (van de 
Berg et al., 2010). Therefore, their accumulation contributes to lowering overall 
telomere length. 
7.6 Clinical relevance of the study 
The effective control of CMV in a clinical setting gives an insight into how CMV may be 
optimally controlled in healthy ageing individuals. In one study the absolute number of 
responding CMV-specific CD8+ T cells was inversely correlated to the amount of pre-
emptive ganciclovir treatment required following hematopoietic stem cell 
transplantation (Gratama et al., 2001), which suggests a minimal number of cells is 
required to confer protection. Indeed, evidence suggests a minimal number of CD8+ 
CMVpp65-specific T cells are needed for protection against CMV reactivation during 
organ transplantations (Aubert et al., 2001, Cwynarski et al., 2001) and these numbers 
have been found to differ on the basis of an individual’s HLA type (Giest et al., 2010, 
Koehl et al., 2008). However an adequate functional response also seems to be key in 
the control of CMV replication: In one study a significantly lower frequency of IFN-γ/IL-2 
multi-cytokine producing CD4+ and CD8+ T cells were found in liver transplant recipients 
experiencing CMV DNAemia compared to those not having CMV DNAemia (Nebbia et 
al., 2008). Furthermore, in a study of renal transplant recipients, poor control of CMV 
replication was linked to impairments in IFN-γ production by CMV-specific CD8+ T cells 
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which was associated with a 14-fold increased risk of progression to high level CMV 
replication (Mattes et al., 2008). Additionally, the authors highlighted a possible age-
associated decline in function as patients >40 years of age were more likely to progress 
to high level CMV infection.  CMV reactivation as defined by symptomatic CMV disease 
has also been associated with quality T cells showing high IFN-γ production versus those 
with symptomatic CMV reactivation which showed poor IFN-γ responses (Crough et al., 
2007).  
 
Therefore the identification of optimal CMV-specific CD8+ T cells with high functional 
avidity presents an opportunity for the selection of those T cells in a therapeutic 
scenario. Recently, what started as small scale trials using adoptive transfer of CMV-
specific CD4+ and CD8+ T cells for patients undergoing transplantation has spread due to 
promising preliminary results conferring protection from CMV reactivation (Feuchtinger 
et al., 2010, Kotton, 2010, Peggs et al., 2003, Schmitt et al., 2011, Emery et al., 2011). 
The engineering of TCRs specific for viral epitopes also presents a possible avenue for 
adoptive transfer of functionally optimal T cells (Perro et al., 2010).  The benefits of 
which have been shown in Hepatitis B virus (HBV) infection wherein polyfunctional HBV-
specific CD8+ T cells can be generated (Gehring et al., 2010); this offers the possibility of 
reconstituting the immune response which is found to be dysfunctional in some patients 
with chronic HBV infection. In a previous report high avidity CD8+ T cells were shown to 
express all effector functions upon activation ex-vivo compared with low avidity CD8+ T 
cells which exhibited no ex-vivo cytotoxicity, secreted minimal IFNγ and did not 
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recognise autologous infected targets (Villacres et al., 2003). This is confirmed in the 
present study, as the high avidity population also showed better activation and 
polyfunctional potential. Therefore, in addition to the polyfunctionality of a T cell, the 
functional avidity of a T cell may prove a defining attribute when selecting the most 
optimal T cells. 
 
Such criteria could also be applied to tackling the large CMV-specific TCEs found in older 
individuals. Indeed, the purging of large CMV-specific CD8+ TCEs from older individuals 
to ‘free up space’ has been proposed (Koch et al., 2006, Pawelec et al., 2006b). Many of 
the CD8+ T cells in the old have been reported as being dysfunctional when compared 
with those in the young (Almanzar et al., 2005, Ouyang et al., 2003b) and are believed to 
be disposable due to the lack of unique clonotypes contained within them (Weinberger 
et al., 2009). Furthermore CMV-specific CD8+ TCEs often express KLRG-1, a marker 
identifying cells unable to undergo further division (Ouyang et al., 2003a, Voehringer et 
al., 2002) and senescence marker CD57 (Kern et al., 1996). Therefore purging CMV-
specific CD8+ TCEs on the basis of KLRG-1/CD57 co-expression could be an option, while 
retaining a core of polyfunctional, long-lived CMV-specific memory T cells. The latter 
could be evaluated therefore on the basis of their functional avidity for antigen 
 
In addition, the senescent or exhausted cells may be reinvigorated through the blocking 
of markers including p38 (senescence) as well as PD-1 (exhaustion) in highly 
differentiated T cells (Henson et al., 2008, Akbar and Henson, 2011). An important 
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observation is that PD-1 signalling blockade can restore antigen-specific T cell responses 
(both proliferation and cytokine secretion) in LCMV-infected mice (Barber et al., 2006) 
and in humans with chronic viral infections (Day et al., 2006, Petrovas et al., 2006, 
Trautmann et al., 2006),  
 
Telomerase can slow senescence in cells through telomere elongation and therefore 
represents another possible target for intervention. Gene transduction with the catalytic 
component of telomerase (hTERT) was shown to result in telomere length stabilization 
and reduced expression of cyclin-dependent kinase inhibitors in in-vitro cell cultures 
(Effros et al., 2005). Furthermore telomerase reactivation has been successful in 
reversing the age-associated damage observed in aged mice (Jaskelioff et al., 2011). 
CMV-specific T cells with low telomerase levels could therefore benefit from such 
methods, however the risk of malignancy is ever present and like all potential therapies 
the benefits must outweigh the risks. Several diseases that are manifested by 
telomerase deficiencies may benefit from such therapy e.g. DKC, but the treatment of 
healthy individuals may be less justified. Although there are ongoing trials of a natural 
telomerase activator being used as part of a supplementary diet (Harley et al., 2011). 
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7.7 Future studies 
 
7.7.1 Generation of high vs. low avidity T cell populations 
Do low avidity CMV-specific CD8+ T cells preferentially revert to a CD45RA re-expressing 
phenotype in response to IL-15? This may be investigated by combining the use of 
mutated avidity tetramers and the IL-15 treatment experiments demonstrated in this 
thesis. 
 
7.7.2 Investigating other CMV antigens 
Work presented here has focused on CMVpp65-specific T cell responses, as CMVpp65 
has consistently been shown to illicit large T cell clonal expansions. However, T cell 
immune responses to CMV peptide pools has revealed a broad response, with CD8+ T 
cells targeting many different CMV peptides (Gandhi and Khanna, 2004). Therefore, 
extending analysis to include different CMV antigens may reveal more on the 
relationship between T cell functional avidity and phenotype. IE-1 in particular has been 
shown to elicit large T cell numbers, which can often exceed T cell numbers specific for 
pp65 (Khan et al., 2002a, Kern et al., 2000). Furthermore, IE-1-specific T cell responses 
correlate with protection from CMV infection (Bunde et al., 2005, Nickel et al., 2009). 
The question is, whether IE-1-specific T cells or T cells specific for other CMV antigens 
share the characteristics of pp65-specific CD8+ T cells, and if this is influenced by size of 
the population or donor age. 
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7.7.3 Alternate senescence pathways 
Are TEMRA cells undergoing a different form of senescence? Preliminary data suggests 
TEMRA cells show high levels of DNA damage and inhibiting these pathways can up-
regulate telomerase. Work will focus on investigating the CMV-specific compartment 
and what mechanisms may be involved and manipulated. 
 
7.7.4 Telomere length analysis using quantum dots.  
The application of quantum dots in the analysis of telomere lengths is currently being 
continued in lab. Future experiments aim to identify if CMV-specific CD8+ T cells that 
have critically short telomere lengths are also associated with loss of function or 
senescence.  Further characterisation of telomere lengths on the basis of avidity will 
also be addressed.  
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